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Febrile neutropenia (FN) is a serious and common complication among cancer 
patients receiving myelosuppressive chemotherapy. FN is associated with 
substantial clinical burden and economic burden on patients. The overall aim of 
this thesis is to optimize FN management among cancer patients in Singapore, 
so that the disease burden of FN can be reduced. Specifically, three directions 
for optimizing FN management were investigated in this thesis, which included 
(i) encouraging appropriate use of granulocyte colony-stimulating factor (G-
CSF) by using economic evaluations, (ii) using biomarker to guide rational 
antibiotic usage, and (iii) improving risk assessment for identifying patients 
with FN who are at low risk of developing serious complications by patient-
reported outcome. 
 
Before conducting economic evaluations on the G-CSF usage for FN, it is 
necessary to understand the economic burden of FN in Singapore. Therefore, 
we first conducted a systematic review on the existing cost-of-illness studies of 
FN, and identified main cost components of FN management. Subsequently, we 
evaluated the direct cost associated with the management of FN in Singapore. 
After that, two cost-effectiveness analysis studies were performed to evaluate 
the use of G-CSF for FN as prophylaxis and treatment, respectively. In addition, 
we studied the effectiveness of using procalcitonin (PCT) to differentiate 
between infectious fever and non-infectious fever (NIF) among cancer patients. 
 ix 
Finally, we evaluated the psychometric properties of a neutropenia-specific 
health-related quality of life instrument, the Functional Assessment of Cancer 
Therapy-Neutropenia (FACT-N) questionnaire, among Singapore population, 
followed by the development and validation of a prognostic model, by 
integrating the FACT-N elements with the Multinational Association for 
Supportive Care in Cancer (MASCC) risk index, for identifying low risk 
patients with FN. 
 
The studies performed in this thesis have revealed the following findings: 
 First, routine primary prophylaxis with G-CSF is identified as cost-effective 
when compared to other strategies, which included the secondary 
prophylaxis and no prophylaxis. In addition, the cost-effectiveness of 
adding G-CSF to antibiotics as a treatment for FN was demonstrated.  
 Second, we identified that two separate PCT measurements can improve the 
accuracy on discriminating between infectious fever and NIF, when 
compared to a single PCT measure.  
 Third, the psychometric properties and the measurement equivalence 
between the English and Chinese versions of FACT-N were established for 
most of the domain and total scores in our study. Further, we developed and 
validated a prognostic model by incorporating the malaise subscale in 
FACT-N and the MASCC risk index, which has shown a better performance 
on identifying low risk patients with FN for developing serious 
complications when compared to the MASCC risk index.  
 x 
In conclusion, this thesis has contributed new knowledge in the management of 
FN, and promoted the optimization of FN management among Asian cancer 
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1.1 An overview on febrile neutropenia (FN) 
FN is defined by the Infectious Disease Society of America (IDSA) as a single 
oral temperature of ≥38.3°C or a temperature of ≥38.0°C sustained over 1 hour, 
together with an absolute neutrophil count (ANC) of < 500/mm3, or an ANC of 
< 1000/mm3 with an expected decrease below 500/mm3 within the next 48 hours 
[1]. This definition has been well accepted by other medical organizations [2-
5], with only some minor variations.  
 
FN is well recognized as a serious and common complication among cancer 
patients receiving myelosuppressive chemotherapy. This problem is clinically 
relevant in Singapore. One recent study in Singapore revealed that despite 
prescribing appropriate granulocyte colony stimulating factors (G-CSF) 
prophylaxis support, up to 16% of cancer patients would experience at least one 
FN episode during their chemotherapy [6]. FN can lead to life-threatening 
complications, and the overall 30-day mortality among solid tumors and 
lymphomas patients with FN was reported as 6.6% by an audit study in 
Singapore [7]. Aside from the clinical burden, FN can also lead to significant 
economic burden on patients, payers, and general society. In Singapore, one 
recent study reported that the mean cost of FN inpatient management among 
patients with hematological diseases was around 15,298 United States dollars 
(US$) per FN episode [8]. It has been identified that the ward charges 
constituted the largest component of the cost (44.1%), followed by the 
laboratory charges (27.3%) and medication charges (18.7%) [8]. 
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Considering the substantial clinical and economic burden of FN, it is imperative 
to stratify patient’s risk of developing FN and identify those who are at high 
risk for FN, so that interventions could be implemented to appropriately manage 
their FN risk. The National Comprehensive Cancer Network (NCCN) guideline 
has classified patients into three risk groups for developing FN: high risk 
(>20%), intermediate risk (10%-20%), and low risk (<10%) [2]. The overall 
risk of developing FN depends on chemotherapy regimens received and patient-
related risk factors [2]. One recent systematic review revealed that patient-
related risk factors associated with an increased FN risk included older age, poor 
performance status, advanced disease, presence of comorbidities, low baseline 
blood cell counts, and low body surface area/body mass index [9]. In addition, 
once an episode of FN occurs, the risk of developing FN increases in subsequent 
chemotherapy cycles [2]. 
 
1.2 Prevention of FN 
1.2.1 Antibiotic prophylaxis 
To prevent the occurrence of FN, both the American Society of Clinical 
Oncology (ASCO) [4] and IDSA [1] guidelines recommend that antibacterial 
prophylaxis with fluoroquinolone should be considered for high risk patients 
who have received chemotherapy and were expected to have prolonged 
neutropenia over 7 days. A Cochrane review included one hundred and nine 
trials with 13,579 cancer patients who developed chemotherapy-induced 
neutropenia (CIN), and has demonstrated that antibiotic prophylaxis could 
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significantly reduce the all-cause mortality (relative risk (RR) = 0.66; 95% 
confidence interval (CI): 0.55 to 0.79) and infection-related mortality (RR = 
0.61; 95% CI: 0.48 to 0.77), when compared with placebo or no intervention 
group [10]. It was also shown that antibiotic prophylaxis could significantly 
reduce the incidence of fever (RR = 0.80; 95% CI: 0.74 to 0.87), clinically 
documented infections (RR = 0.65; 95% CI: 0.56 to 0.76), and 
microbiologically documented infections (RR = 0.51; 95% CI: 0.42 to 0.62) 
[10]. However, as bacterial resistance continues to remain as a public health 
issue [11-13], the concern on the emergence of resistant bacteria has restricted 
the routine use of prophylactic antibiotics, and the IDSA guideline suggests not 
to provide routine antibiotic prophylaxis to those patients who are at low risk 
for prolonged neutropenia [1]. 
 
1.2.2 G-CSF prophylaxis 
Numerous studies and meta-analysis suggested that prophylactic use of G-CSF 
can reduce the incidence of FN, infection related mortality, and all-cause 
mortality [14-16]. The IDSA [1] and NCCN [2] guidelines suggest primary 
prophylaxis (PP) with G-CSF throughout all cycles of chemotherapy among 
high risk patients for FN (>20%), while among low risk patients for FN (<10%), 
routine use of prophylactic G-CSF is not advocated. If patients experienced one 
episode of FN from a prior cycle of chemotherapy, the ASCO guideline 
recommends to initiate a secondary prophylaxis (SP) with G-CSF (for those 
who did not receive primary G-CSF prophylaxis) [17]. Due to the high cost of 
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G-CSF and its potential for overuse, many studies have been conducted in 
recent years to investigate the appropriate G-CSF prophylaxis strategy [18-20]. 
One study in United Kingdom has compared the cost-effectiveness of PP, SP, 
and no prophylaxis (NP) with G-CSF, and indicated that the most cost-effective 
strategy mainly depended on patient’s risk of developing FN [20]. In addition, 
novel strategies including minimizing the number of G-CSF injections have 
also been explored, and it was identified that prophylactic use of G-CSF during 
just the first two cycles of chemotherapy was associated with lower cost 
(€17,168 vs. €20,658) but a higher risk of FN (36% vs. 10%), when compared 
to PP with G-CSF throughout all cycles of chemotherapy [19]. If a patient’s FN 
risk is over 20%, the ASCO guideline suggests that G-CSF prophylaxis should 
be used based on clinical considerations rather than by cost [17]. However, if 
patients are at intermediate risk of developing FN (10%-20%), appropriate G-
CSF prophylaxis strategy remains uncertain, and the decision normally depends 
on clinician’s preference. In this case, the cost-effectiveness analysis can be 
useful to guide appropriate G-CSF prophylaxis strategy.  
 
Over the last decade, several biosimilar G-CSF products have been approved 
and entered the market [21,22]. In addition, some studies have shown that 
biosimilar G-CSF is as good as its originator product in reducing the incidence 
of FN [23-26]. Hence, current guidelines, including the ASCO [17], NCCN [2], 
and European Society for Medical Oncology (ESMO) [3], have recommended 
the use of biosimilar G-CSF as a prophylactic agent for FN. Further, the ASCO 
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suggests that the choice of prophylactic agent between the biosimilar G-CSF 
and the originator G-CSF should depend on a number of factors, such as the 
cost, convenience, and clinical situation [17].  
 
1.3 Treatment of FN 
1.3.1 Initial clinical and laboratory evaluation 
For patients who developed FN after receiving chemotherapy, initial assessment 
and investigations should be performed before applying empirical broad-
spectrum antimicrobial therapy. A comprehensive history should be taken, 
which include information with the nature of administered chemotherapy, prior 
antimicrobial prophylaxis, concomitant steroid use, recent surgical procedures, 
presence of allergies, infection exposures, prior documented infections or 
pathogen colonization, co-existence of noninfectious causes of fever, and 
underlying co-morbidities [1,2]. After that, physical examination, blood tests, 
microbiologic cultures, and radiographic tests should be further investigated 
[1,2]. Based on the IDSA guideline, tests on complete blood cell counts, serum 
creatinine levels, and urea nitrogen levels are recommended to be performed at 
least every 3 days during the antibiotic therapy, in order to monitor and manage 
possible drug toxicity [1].  
 
In recent years, a number of studies have investigated the use of biomarkers for 
infections, such as C-reactive protein (CRP), interleukins-6 (IL-6), and 
procalcitonin (PCT) among cancer patients with FN [27-29]. One meta-analysis 
 7 
investigated the performance of CRP, IL-6, and PCT as biomarkers for bacterial 
infections, and identified that the positive likelihood ratio for CRP, IL-6, and 
PCT were 1.82 (95%CI: 1.42 to 2.33), 3.68 (95%CI: 2.41 to 5.60), and 5.49 
(95%CI: 4.04 to 7.45), respectively, suggesting that PCT had the best 
performance on predicting for bacterial infections [27]. In addition, one recent 
review has indicated that serial PCT evaluations can be more accurate at the 
diagnostic stage for infections, and the use of PCT in combination with other 
clinical and laboratory tests is promising to identify early infectious 
complications among FN patients and guide the antibiotic usage [30]. 
 
1.3.2 Risk assessment for serious complications 
Patients with FN are at varied risk of developing serious medical complications. 
Classification of patients with FN into low-risk or high-risk for serious 
complications can guide the subsequent management decision-making, such as 
the necessity for inpatient admission, antibiotic usage, and length of stay in 
hospital [1]. Currently, the most widely used risk assessment tool is the 
Multinational Association for Supportive Care in Cancer (MASCC) risk index 
which allows the identification of low risk patients with FN for serious medical 
complications [31]. Existing guidelines, such as the ESMO [3], European 
Organization for Research and Treatment of Cancer [5], ASCO [4], NCCN [32], 
and IDSA [1], have also advocated the implementation of MASCC risk index 
in clinical practice to identify low risk patients with FN for serious 
complications. The MASCC risk index is consisted of a number of weighted 
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factors, which include elderly patient (age  60 years); outpatient or inpatient 
status; burden of illness; presence of hypotension; presence of chronic 
obstructive pulmonary disease; presence of dehydration; and presence of solid 
tumor or, among patients with hematological malignancies, the absence of 
previous fungal infection (Table 1) [31]. Patients with a cumulative MASCC 
risk index  21 points are defined as low risk for experiencing serious 
complications [31]. For those low risk patients with FN, a simpler and cost-
effective management option can be considered, such as oral antibiotics, 
outpatient management, and early discharge [1]. However, there are some 
inherited limitations with the MASCC risk index. For example, there is a lack 
of clear definition on how one defines the burden of illness, hence the severity 
of the disease burden is normally subjected to a clinician’s judgment which may 
lead to confusion and inconsistence in the application of MASCC risk index 
[1,33]. Furthermore, the specificity of MASCC risk index still needs to be 
improved [34]. 
 
Table 1. MASCC scoring system 
Characteristic  Weight  
 Burden of illness: no or mild symptoms 5 
 No hypotension 5  
 No chronic obstructive pulmonary disease 4  
 Solid tumor or no previous fungal infection 4  
 No dehydration 3  
 Burden of illness: moderate symptoms 3  
 Outpatient status  3  
 Age < 60 years 2  
Points attributed to the variable “burden of illness” are not cumulative. The 
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maximum theoretical risk index is 26. MASCC = Multinational Association for 
Supportive Care in Cancer 
 
1.3.3 Antibiotics treatment for FN 
FN is treated as a medical emergency, as infections among patients diagnosed 
with FN can rapidly progress and lead to life-threatening complications, 
particularly when empirical antibiotics are not promptly initiated [1]. The 
antibiotics treatment should normally be given to FN patients immediately after 
the collection of blood culture and before the completion of any other 
investigations [35]. Delay in the antibiotics treatment can result in increased 
mortality [36] and prolonged hospitalization [37]. Based on the IDSA guideline, 
for high-risk patients with FN, hospitalization with intravenous antibiotics 
treatment is needed, and initial antibiotics should cover P. aeruginosa and other 
severe gram-negative pathogens [1]. The IDSA guideline also recommends to 
use monotherapy with an anti-pseudomonal β-lactam agent (cefepime, 
piperacillin-tazobactam), or a carbapenem (imipenem or meropenem) as the 
first-line treatment [1]. In addition, the monotherapy with β-lactam agent was 
found superior than a combination therapy of β-lactam agent plus 
aminoglycoside, due to lower infection-related mortality, fewer adverse events, 
and fewer fungal super-infections [38]. Vancomycin is not recommended as 
first-line treatment for FN, however, it should be considered if patients are 
suspected for catheter-related infection, skin or soft-tissue infection, 
hemodynamic instability, or pneumonia [1]. 
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For patients who manifest FN and are at low risk for complications, outpatient 
management with oral antibiotics treatment can be considered among carefully 
selected patients [3]. A combination therapy of fluoroquinolones (ciprofloxacin 
or levofloxacin) plus amoxicillin-clavulanate is proposed as the oral empirical 
treatment [1,4,32]. If the low risk patients with FN have presented documented 
infections, especially for the cases of infection by bacteria resistant to 
fluoroquinolones and β-lactam, the IDSA [1] and ASCO [4] recommend 
inpatient management, so that intravenous antibiotics, such as meropenem or 
piperacillin-tazobactam, can be administered. 
 
1.3.4 Therapeutic use of G-CSF 
The benefit of using therapeutic G-CSF as adjunctive treatment for established 
FN remains controversial. One recent meta-analysis evaluated the safety and 
efficacy of adding therapeutic G-CSF to antibiotics treatment for FN [39], and 
identified that the addition of G-CSF has no significant impact on overall 
mortality (G-CSF plus antibiotics vs. antibiotics alone: hazard ratio (HR) = 
0.74; 95% CI: 0.47 to 1.16; P = 0.19) and infection-related mortality (HR = 
0.75; 95% CI: 0.47 to 1.20; P = 0.23). However, the use of therapeutic G-CSF 
for established FN has been demonstrated to reduce a patient’s likelihood for 
prolonged hospitalization over 10 days (RR = 0.65; 95% CI: 0.44 to 0.95; P = 
0.03), duration of antibiotic usage (standardized mean difference (SMD) = -1.50 
days; 95% CI: -2.83 to -0.18; P = 0.03), and duration of neutropenia (SMD = -
1.70 days; 95% CI: -2.65 to -0.76; P = 0.0004) [39]. Although these benefits are 
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statistically significant, the IDSA guideline considers the benefit is too minimal 
to be clinically important [1]. After taking into account the high cost of G-CSF 
at that time and its possible associated adverse effects, therapeutic use of G-
CSF is not generally recommended by the IDSA guideline [1]. However, it 
should be noted that this recommendation is highly based on the economical 
factor concerning about the high cost of G-CSF (the IDSA guideline was last 
updated in 2010). With the availability of less expensive biosimilar G-CSF in 
recent years, it is necessary to reconsider whether the therapeutic use of G-CSF 
should be advocated. In fact, the recent updated NCCN guideline has 
recommended that therapeutic G-CSF can be considered in certain 
circumstances during the treatment of FN [2]: (i) if patients received short-
acting G-CSF (such as filgrastim) as prophylaxis but developed FN, the short-
acting G-CSF should be continued during the treatment of FN; (ii) if patients 
did not receive any G-CSF as prophylaxis and developed FN, for those patients 
who presented risk factors for serious complications, therapeutic G-CSF should 
be considered. The risk factors for developing FN associated serious 
complications include the presence of sepsis syndrome, age over 65 years, ANC 
lower than 100 cells/mm3, neutropenia duration expected to be over 10 days, 
presence of pneumonia or other clinically documented infections, presence of 
invasive fungal infection, inpatient fever, and prior episode of FN [2]. 
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1.4 Potential directions for optimizing FN management  
1.4.1 Encouraging appropriate use of G-CSF by economic evaluation 
FN management, especially in the inpatient setting, can be associated with 
substantial economic burden [40]. One recent review reported that the estimated 
cost of FN varied from US$ 6,396 to US$ 34,756 per episode, and the 
medication cost was a main factor associated with higher FN management cost 
[41]. Therefore, health economics should play an essential role with regards to 
the rational medication usage for managing FN, especially to those high cost 
medication such as G-CSF.  
 
With the availability of biosimilar G-CSF in the market, the price of the 
originator product of G-CSF has been gradually decreased in recent years [42]. 
The substantial decrease in the drug cost has certainly increased the economic 
attractiveness of using G-CSF as prophylaxis in managing FN. In particular, 
economic evaluations such as cost-effectiveness analysis and cost-utility 
analysis, can provide important evidence to decision-makers on whether 
prophylactic use of G-CSF would be value for money for the payers or the 
societies in general. In fact, one review on the economic evaluation studies of 
G-CSF in the prevention and treatment of FN has illustrated the cost-saving 
potential of G-CSF [43]. Although this result is limited by a small number of 
studies, it has already revealed a need for some rigorously designed economic 
evaluation studies in guiding the appropriate G-CSF usage in the prevention and 
treatment of FN [43].  
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In addition, economic evaluation can be useful to select appropriate G-CSF 
agent and encourage its diffusion within the healthcare system. For example, as 
prophylactic growth factor agent to prevent FN, numerous types are available 
in the market, such as pegfilgrastim, filgrastim, and biosimilar G-CSF. 
Economic evaluation can inform the policy makers about which type of G-CSF 
is the most cost-effective choice for preventing FN, so that they can consider 
including potentially the most cost-effective agent into the institution 
formulary, national formulary or provide government subsidy on it [44], and 
broaden its usage. 
 
1.4.2 Biomarker-guided rational antibiotic usage 
For all patients with FN, it is still strongly recommended to administer empiric 
therapy with antibiotics, in order to prevent any rapid progress of infections [1]. 
However, empiric antibiotics treatment for most infections is likely to be 
inappropriately long, which may lead to the serious complications including 
antibiotic resistance [45]. The risk of infections with resistant gram-positive and 
gram-negative bacteria has emerged over the past few years [46-48]. The 
emerging antibiotic resistant pathogens are associated with a high mortality rate 
in cancer patients [49-51]. In addition, for those with persistent fever and 
manifesting non-severe infections, the early discontinuation of antibiotics 
treatment is also needed, in order to control the antibiotic resistance. Although 
blood cultures (BC) remain the gold standard for the diagnosis of bacterial 
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infection and to guide antibiotic therapy, prolonged turn around time of blood 
culture results may possibly delay the initiation of appropriate antibiotics. In 
contrast, a number of serum biomarkers, including CRP, PCT, IL-6, and 
lipopolysaccharide-binding protein, have demonstrated their potential to 
differentiate between infectious fever and non-infectious fever (NIF), and 
recognize severe infections [52]. Specifically, PCT has been most widely 
studied as a marker of infection and was demonstrated to possess the best 
performance on predicting for bacterial infections [27-29]. In addition, PCT can 
be detected within several hours since fever onset [53], and has the advantage 
of providing immediate and meaningful information to guide appropriate 
antibiotic usage. Several studies have revealed that there was a significant 
reduction on the antibiotic consumption among those patients who were treated 
based on PCT-guided approach, when compared to those who were treated with 
conventional approach [54-58]. Therefore, it is valuable to further explore the 
use of biomarker, such as PCT, in differentiating the sources of fever, which 
can help to guide appropriate antibiotic usage among FN patients. 
 
1.4.3 Improving risk assessment by incorporating patient-reported 
outcome (PRO) into screening measures 
Clinical profiles of patients manifesting FN are generally heterogeneous, with 
subsets of patients possessing varying risks of developing serious medical 
complications. Identifying those who are low risk for complications can 
promote the application of simpler and cost-effective management approaches, 
 15 
such as the early discharge from hospital and outpatient management [34]. To 
serve as the purpose of identifying low-risk patients with FN, the MASCC risk 
index was developed and published in 2000 [31], and has been well accepted 
by the existing guidelines [1,3,32]. However, it was revealed that the MASCC 
risk index has a weak specificity, and an improved model for safely predicting 
patients with an acceptably low risk of developing serious complications is still 
expected [34]. In addition, one study observed that among those low risk 
patients with FN defined by the MASCC risk index who are eligible for early 
discharge and outpatient management, a proportion of them were still managed 
inpatient due to patient’s reluctance for early discharge [59]. This implies that 
the current MASCC risk index did not capture factors from patient’s perception 
on their health status.  
 
PRO describes the impact of health conditions and treatments on patient lives 
from the perspective of patients. PRO measure allows patients to report how 
they feel, function, and perceive their health-related quality of life (HRQoL) 
directly, without interpretation by another individual including the healthcare 
professional [60]. The Functional Assessment of Cancer Therapy-Neutropenia 
(FACT-N) is a profile-based instrument to provide a targeted assessment of 
HRQoL among patients with neutropenia based on their self-report, and has 
been validated in United States [61]. Several studies have reported that PRO 
can provide unique prognostic information for patient’s outcomes [62,63]. 
Considering the prognostic value of PRO, it is of interest to explore the 
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possibility to use PRO elements from neutropenia-specific instrument, such as 
the FACT-N, as adjunctive to the MASCC risk index for identifying low-risk 
patients with FN. In this way, patient’s engagement in the FN management can 
be promoted and this may possibly improve patients’ satisfaction in the 
treatment of FN. 
 
1.5 Research objectives 
The overall aim of this thesis is to support the optimization of FN management 
among Asian cancer patients in Singapore. With this aim in mind, it is aimed to 
develop strategies to reduce the disease burden and economic burden of FN in 
local settings. Specifically, the following research questions were proposed, 
which were in line with the points mentioned in Section 1.4:  
 
(1) What is the most cost-effective strategy to use G-CSF as prophylaxis and 
treatment for FN? Before conducting economic evaluations on the current FN 
management strategies, it is necessary to first understand the economic burden 
of FN in Singapore, because the cost of FN can vary tremendously among 
different countries due to different healthcare systems. A systematic review on 
the cost components of FN was presented in Chapter 2. Subsequently, Chapter 
3 evaluated the direct cost associated with the management of FN in Singapore. 
In the preventive phase, there are many alternatives on the prophylactic use of 
G-CSF for FN, which include different administration regimens of G-CSF and 
the choice on different types of G-CSF agents. Chapter 4 identified the most 
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cost-effective G-CSF prophylaxis strategy for FN. In addition, there is 
uncertainty on the benefit of using G-CSF as a treatment for FN. Chapter 5 
demonstrated the cost-effectiveness of therapeutic use of G-CSF and provided 
evidence to support its routine use for treating FN.  
 
(2) Is biomarker useful in guiding antibiotics usage among patients diagnosed 
with FN? Empiric therapy with antibiotics is strongly recommended to treat FN. 
However, inappropriate use of antibiotics, especially among those patients with 
NIF, can result in serious problem, such as antibiotic resistance. In Chapter 6, 
the use of PCT, a biomarker for infection, was evaluated to differentiate 
between infection fever and NIF, which can provide evidence to support rational 
use of antibiotics among patients with FN. 
 
(3) Can we integrate the PRO into risk assessment tool and improve the 
prognostic performance on identifying patients with FN who are at low risk of 
developing serious complications? The inpatient management of patients with 
FN can be costly. For those low risk patients with FN, simpler and cost-effective 
treatment can be considered. The MASCC risk index can still be improved, and 
it is of interest to incorporate the PRO into the risk assessment tool, due to its 
prognostic value for disease deterioration. In Chapter 7, we validated the FACT-
N questionnaire, which is an HRQoL instrument specifically developed for 
patients with neutropenia, among Singapore population. After that, Chapter 8 
investigated the use of FACT-N together with the MASCC risk index in 
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identifying low risk patients with FN for serious complications, and developed 
a new prognostic model. 
 
In addition, National Cancer Centre Singapore (NCCS) was the clinical site for 
the research projects in this thesis, which treats mostly solid tumors and 
lymphomas patients in Singapore. Therefore, the study population in this thesis 




















Chapter 2. Economic burden of chemotherapy-induced 












Cost-of-illness (COI) studies estimate the resources consumed as a result of a 
particular disease [64]. COI studies are conducted with an aim to improve 
understanding of the economic burden that a specific disease may have on an 
individual, a healthcare system, or society in general [65,66]. Furthermore, COI 
studies can provide key data inputs to some economic evaluation studies, such 
as cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis 
[67].  
 
2.1.1 Direct cost and indirect cost 
In general, there could be two components estimated within a COI study: direct 
costs (medical and non-medical) and indirect costs [66]. Direct costs estimate 
the opportunity costs of all kinds of resources used to treat FN [65], and it can 
be further separated into direct medical costs and non-medical costs. Direct 
medical costs include ward costs, laboratory test costs, radiography costs, 
transfusion costs, medication costs, emergency room visit costs, physician visit 
costs, and home nursing visit costs [65]. Direct non-medical costs represent the 
costs incurred by patients or their family members which are directly associated 
with FN, but not of medical nature, such as transportation charges [65]. Indirect 
costs refer to the productivity losses due to morbidity or mortality [65]. 
Productivity loss is the forgone productivity caused by work absences, which is 




The perspective taken is an important consideration in COI studies. Based on 
different perspectives chosen, the cost estimation can vary. The perspective 
could be from the patient, the employers, the insurance company, the healthcare 
providers, the government, or the society. The societal perspective is the most 
comprehensive approach in the COI studies. This approach avoids cost 
underestimation that may occur when a narrower perspective is taken [66]. 
However, in practice, considering the funding and time constraints, it could be 
challenging to collect comprehensive data for the societal perspective. 
 
2.1.3 Approaches for cost estimation 
In the literature, three methods are commonly employed to estimate the direct 
costs: econometric (EC), bottom-up and top-down approach [66]. Indirect costs 
can also be estimated in three different ways: the human capital approach, the 
friction cost approach and the willingness-to-pay (WTP) approach [66]. The 
human capital approach is the most commonly used method, as it considers the 
forgone income of the patient and their caregivers and takes into account 
premature mortality and disability [66].  
 
To date, the only available systematic review that revealed the economic burden 
of FN was published in 2007 [40]. However, in that review, only the overall FN 
cost was reported, which made it challenging to investigate the main cost 
component in the economic burden of FN. In addition, the study methods used 
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by the included COI studies including the perspectives, time horizon, and cost 
estimation method were not revealed in detail. In view of these limitations, we 
have conducted a systematic review to determine the main cost component in 
the economic burden of FN. The secondary objective of this review was to 
identify the parameters associated with higher FN cost. This review aimed to 
provide a greater insight for the development of future COI studies in estimating 
the economic burden of FN. This review focused on patients with lymphoma 
because these patients often receive highly myelosuppressive chemotherapy, 
which can lead to a high risk of developing FN [5]. 
 
2.2 Methods 
An electronic bibliography search was conducted through Pubmed, Scopus and 
Web of Science to identify COI studies on FN published up to 2013, which 
estimated the economic burden of FN related to lymphoma patients. The 
following search terms were used: (“cancer”) AND (“febrile neutropenia” OR 
“neutropenic fever”) AND (“costs” OR “economics”). It should be noted that 
those studies reporting the economic burden of a variety of cancer types but 
provided information on the subgroup of lymphoma patients would also be 
eligible for inclusion. Therefore, a broader search term “cancer” was used, 
instead of “lymphoma”. Studies were limited to the English language and all 
adults aged 18 and above. COI studies that described different cost components 
in FN cost and provided sufficient cost breakdown were included. Editorials, 
case reports, and reviews were excluded from this review. Cost studies on FN 
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in paediatric and children lymphoma patients, and studies exploring the costs 
for patients undergoing bone marrow or stem cell transplant were excluded to 
limit the possible variability in costs as a result of different standards of care.  
 
2.2.1 General characteristics of included studies 
The included studies were outlined in terms of its study design, country, data 
source and perspectives used. Perspectives that were not revealed by the studies 
were subjected to interpretation by two investigators of this study, and if there 
were different opinions, the two investigators would make decisions by 
discussion. Studies were also summarized for the characteristics of their study 
population and the inclusion/exclusion criteria in order to provide a 
comprehensive understanding of the included studies.  
 
2.2.2 Data analysis of included studies 
In order to allow cost estimates from COI studies of different countries to be 
more comparable, figures were converted to 2013 US$. Cost data were first 
inflated to 2013 currency value using that country’s Consumer Price Index 
(CPI). Figures were then changed to 2013 US$ using currency exchange rates 
on 20 December 2013 [68]: 1 Australian dollar (AU$) = 0.89 US$, 1 Canadian 
dollar (CAN$) = 0.93 US$, 1 British Pound (₤) = 1.64 US$, 1 Euro (€) = 1.37 
US$. If there was no indication of the year of cost data in the study, it was 
assumed to be the year of paper submitted or accepted. The economic burden 
of FN was calculated by summing up the costs from the inpatient care and 
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outpatient care. The studies also indicated the time horizon in which these costs 
were incurred. A “per episode” time horizon would indicate the time taken for 
managing each episode of FN, from the diagnosis of FN to the resolution of the 
illness or mortality of the patient. 
 
The overall cost was disaggregated into their specific resources used in the 
inpatient and outpatient settings. The resource components were extracted from 
the included COI studies and categorized into a checklist format [8,69] to 
facilitate the comparison of the types of resources included by the COI studies 
in estimating the cost. The categorization of ‘resources used’ were reviewed by 
two investigators. Different cost components were compared within the COI 
study and between the studies to evaluate the main cost component associated 
with the economic burden of FN.  
 
2.2.3 Parameters associated with higher FN cost 
Parameters associated with higher cost of FN were identified among the 
included studies. To be included, those parameters must be reported as 
statistically significant (p ˂ 0.05) associated with a higher FN cost in those cost 
studies among patients with lymphoma. Those parameters would enable the 
identification of patients who were at greater risk for higher economic burden 
of FN.  
 
2.2.4 Quality assessment of included COI studies 
 25 
A quality assessment checklist developed by Larg and Moss (2011) [70] was 
adopted to evaluate the included COI studies. In this review, each study was 
summarized as percentages of fulfilled criteria within the checklist [71]. 
Additionally, the results for each criterion in the checklist were summed in 
percentages to reveal the degree of fulfilment of each criterion in the checklist. 
Studies that fulfilled (Y) the criterion were awarded a score of 1; studies that 
partially fulfilled (P) the criterion were awarded a score of 0.5, while those that 
did not fulfil were given a score of 0. Those criteria that were not applicable 
(NA) to the particular study were removed from the calculation, leaving the 
remaining studies to be considered in the total percentage. Each criterion was 
assumed to be equally weighed. The purpose was not to create a hierarchy in 
the criteria by assigning them different weights, but to use these criteria to 
evaluate included COI studies. 
 
2.3 Results 
2.3.1 Search results 
The search identified 3,296 articles from Scopus, Pubmed and Web of Science. 
After screening the title and abstract, 3,141 articles were excluded based on 
inclusion and exclusion criteria. 155 studies remained for full article review. Of 
those, another 145 articles did not fulfil the inclusion criteria. At last, 10 papers 
were identified in this review (Figure 1). These included studies estimated the 
cost of FN either from lymphoma patients or have lymphoma patients as part of 




Figure 1. Flowchart for screening articles in Scopus, Pubmed and Web of 
Science 
 
2.3.2 General characteristics 
In Table 2, the studies reviewed showed results from the following regions: 
United States (n=5), Australia (n=1), Singapore (n=1), Canada (n=1), Spain 
(n=1), and Europe and Australia (n=1). The majority of the studies employed a 
healthcare provider perspective [8,72-75]. Four other studies [76-79] used a 
societal perspective. Two studies [76,77] accounted for indirect costs. Six 
studies used a retrospective cohort design analysis [73-75,78-80]. The source of 
cost data for most of the studies was from claims databases and hospital records. 
 27 
There was one study [79] focused specifically on the lymphoma patients as its 
study population, while other cost studies included lymphoma and various other 




Table 2. General characteristics of included COI studies a (n = 10) 
Study 
Country 
Perspective Study design Sample size Cost data source 
Cost components 













outpatient care for FN 
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and billing records. 
Room and board costs, 
ICU and non-ICU 
costs, laboratory costs, 
pharmacy costs, 
central supply and 
surgery supply costs 
NA 
USA [77] Societal b 
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cohort study 
71 pts; 32% 
lymphoma 
Medicare Physician 
Fee Schedule, US 
Census Bureau 
Medication, physician 
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lymphoma 
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lymphoma 
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and other medication 
cost, laboratory and 

















medical - nonsurgical, 
pathology, allied 


































2010 Unit Costs of 
Health and Social 
Care Report from 
the Personal Social 
Services Research 




FN inpatient care, 
outpatient encounter, 
















charges, and surgical 
charges 
NA 
a All the studies employed Incidence-based approach; b The perspective indicated is subjected to the interpretation of the reviewer 
as it is not specified in the study; ICU = intensive care unit; COI = cost-of-illness; NA = not available; pts = patients; G-CSF = 
Granulocyte colony-stimulating factor; FN = febrile neutropenia 
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2.3.3 Data analysis 
In Table 3, there was a large variation in the cost estimation on FN cost. Among 
the studies that were conducted in the US, the estimated cost ranged from 
$16,054 to $34,756 (2013 US$) [73,76-78,80]. Among the studies conducted 
out of the US, the estimated cost ranged from $6,396 to $13,823 (2013 US$) 
[8,72,74,75,79]. It should be noted that although similar approaches were 
employed for estimating FN cost (healthcare provider’s perspective, only direct 
medical cost were include, and a time horizon of per FN episode), the cost 
estimation varied greatly across different countries [8, 72-75]. This 
demonstrated that different health care systems from different countries might 
affect the cost estimates substantially. The study conducted by Bennett and 
Calhoun (2007) [77] considered a comprehensive set of cost components in its 
direct and indirect costs from a societal perspective, hence yielded the highest 
estimated cost of FN. The costs estimates of other studies were not as 
comprehensive in terms of their direct and indirect costs. Three studies [78-80] 
estimated their direct costs in an EC approach, while the other studies [8,72-77] 
estimated their direct costs in a bottom-up approach. Two studies [76,77] 
estimated the indirect costs via the human-capital method (HCM), in which the 





Table 3. Summary of the economic burden of FN in lymphoma patients 
Study Country Yeare Perspective Time Horizon  






Mean (95%CI) / 
Median (IQR) 
Adjusted 
(US$ 2013) a 
[77] USA 2007 Societal d per episode f US$ 28,506 
(23,786-33,226) 
34,756 BUM HCM 
[73] USA 2010 Healthcare 
provider d 
per episode f US$ 24,218 
(23,328-25,109) 
26,686 BUM NA 
[76] USA 2008 Societal d per episode f US$ 16,341 
(14,354-18,327) 
19,212 BUM HCM 
[78] USA 2009 Societal d 17.5 months US$ 19,701 
(11,543-27,287) b, c 
22,450 EC NA 
[80] USA 2007 Third party 
payer 
Chemotherapy 








[8] Singapore 2013 Healthcare 
provider 
per episode f US$ 13,823 
(11,647-15,999) 
13,823 BUM NA 
[74] Australia 2007 Healthcare 
provider 
per episode f AUS$ 5,640 c 
(2,525-13,183) 




2010 Societal d per episode f ₤ 5,776  
(4,928-6,713) 
9,543 EC NA 
[72]  Canada 2007 Healthcare 
provider 
per episode f CAN$ 6,324  
(5,135-7,735) 
6,396 BUM NA 
[75] Spain 2005 Healthcare 
provider 
per episode f € 4,514  
(3,805-5,223) 
6,661 BUM NA 
a 1AU$ = 0.89 US$, 1CAN$ = 0.93US$, 1₤ = 1.64 US$, 1€ = 1.37 US$ (20 December 2013); b Cost were discounted at 3% 
per year; c Median cost (Interquartile Range); d Perspective was not indicated by the study and was interpreted by two 
reviewers; e The year of conducting the study; f A “per episode” time horizon would indicate the time taken from the 
diagnosis of FN to the resolution of FN or mortality of the patient; BUM = bottom-up method; EC = econometric; HCM = 
human-capital method; CI = confidence interval; IQR = interquartile range; NA = not available 
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One study conducted by Michels et al (2012) [78] estimated a relatively long-
term cost of FN with a mean follow-up time of 17.5 months, and applied a 
discounting rate of 3% per annum to account for the future cost since the study 
extended beyond a year. Another study conducted by Weycker et al (2007) [80] 
measured the cost of FN from the beginning of initial hospitalization for FN 
through the end of chemotherapy course, in which the mean duration was 153 
(±97) days, and as such, yielded a lower FN cost.  
 
Table 4 revealed that numerous cost components from inpatient and outpatient 
care were included in the COI studies. All the studies included inpatient care in 
their cost components, but only six studies [8,72-76] revealed the breakdown of 
resources used in their inpatient care cost. Among the COI studies that evaluated 
direct medical cost, all of them considered ward and medication cost in their 
cost components. Hendricks et al [76] considered the direct non-medical cost 
aspect as part of its inpatient care component. In terms of indirect costs, only 
two studies [76,77] included loss of productivity by the patients, and out-of-
pocket costs to caregivers as their cost components. For outpatient care costs, 
five studies [76-80] have incorporated it in their cost estimation of FN. 
Medication costs were considered in most of the outpatient cost, followed by 






Table 4. Checklist of resource use a 
Resource Category [79] [78] [80] [77] [76] [8] [74] [72] [75] [73] 
Inpatient care x x x x x x x x x x 
 Direct cost           
Direct Medical cost           
  Ward     x x x x x x 
  Laboratory     x x x  x 
  Radiography     x x x  x  
  Transfusion        x x  
  Medication    x x x x x x x 
     Antibiotics      x  x x x 
     G-CSF        x x  
Direct Non-medical cost           
  Transportation     x      
 Indirect Cost           
 Lost productivity    x       





Outpatient care x x x x x      
 Direct cost           
  Laboratory     x      
  Radiography     x      
  Medication  x x  x      
    Antibiotics  x x        
    G-CSF  x         
  ER visit   x         
  Physician visit  x  x x      
  Home nursing visit     x      
 Indirect cost           
  Lost productivity    x       
  Out-of-pocket cost    x x      
a Checkmark indicates that cost figure is provided; ER = emergency room; G-CSF =  granulocyte colony-stimulating factor 
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2.3.3.1 Comparison of inpatient and outpatient cost 
Costs from the inpatient and outpatient care were compared against each other 
(Figure 2). Inpatient care was the greatest contributor to the economic burden 
of FN with an average of 79%. In the study conducted by Hendricks et al [76], 
in which a multicentre trial was performed to compare the costs between 
outpatient home treatment and inpatient treatment, the outpatient care cost was 
lower than the inpatient care cost (43% vs. 57%). The outpatient care cost 
included hospital costs in the patients treated in outpatient home treatment 
setting that were admitted in hospital, which accounted for 60% of their 
outpatient care costs. If the hospitalization cost was isolated and considered 
fully under inpatient care, the main cost component in the economic burden of 
FN could be inpatient care.  
 
 
Figure 2. Comparison of cost from inpatient and outpatient care 
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2.3.3.2 Comparison of direct and indirect costs within inpatient care 
Within the inpatient care setting, direct costs were compared against indirect 
costs from the studies. Bennett and Calhoun (2007) [77] only considered the 
loss of productivity in terms of wages paid to caregiver and out-of-pocket costs 
as part of its indirect costs, and reported the direct costs and indirect costs in 
inpatient setting for lymphoma patients as $17,869 and $3,732, respectively. 
Hendricks et al (2011) [76] considered the time loss from work as well as 
informal caregiving time but did not place a monetary value on them. As such, 
the value of indirect cost was underestimated. Moreover, long term costs due to 
mortality and morbidity were not accounted for as well [66], since the time 
horizon for both studies [76,77] did not extend beyond the episode of FN.  
 
2.3.3.3 Incidence of cost component among direct cost in inpatient care 
Since direct cost was the main contributor for the inpatient care, the cost 
components which comprised ward stay, medication, diagnostics, and 
laboratory were compared with each other to investigate the main cost driver. 
Among those components, ward stay was the greatest cost driver for the direct 
inpatient care costs for the treatment of FN, averaging 70% of the total direct 




Figure 3. Direct cost components of inpatient care in the treatment of FN 
 
2.3.3.4 Incidence of cost components among direct cost in outpatient care 
Most of the studies [76-78,80] which estimated direct costs within outpatient 
care revealed that medication cost is the cost component with highest incidence. 
Contrastingly, the study conducted by Weycker et al [80] showed physician 
office visit component to be the major cost component in estimating the cost of 
FN in outpatient care. However, this study included other aspects such as 
emergency room encounters, all office and visit within that component itself, 
and thus overestimated the physician office visit cost. 
 
2.3.4 Parameters associated with higher FN cost 
Six COI studies [8,73,74,76-78] revealed the factors associated with higher cost 
of FN (Table 5). The study conducted by Dulisse et al [73] showed that specific 
co-morbidities and infections were associated with longer length of stay, higher 
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mortality risk and larger cost in non-Hodgkin lymphoma (NHL) patients. Apart 
from individual co-morbidities, this study also revealed that the higher the 
number of co-morbidities cancer patients had, the larger the cost of FN. Other 
factors associated with higher FN cost included inpatient management, 
discharge dead, males, longer duration of neutropenia, therapeutic use of G-
CSF, longer length of stay in the hospital, lower ANC nadir, and longer duration 
of antibiotics use. 
 
Table 5. Parameters associated with higher FN cost 
Studies Parameters  Category 








 Discharge dead 
 Males 






[76]   Inpatient management 
 Longer duration of neutropenia 
 Use of therapeutic growth factor  
Management Location 
Duration of low ANC 
Therapeutic use of G-CSF 
[74]  Longer length of stay Length of stay 
[78]  Inpatient management 
 Discharge dead 
Management Location 
Discharge status 
[8]  Longer duration of antibiotics use 
 Lower ANC nadir 




Comorbidity & Infection 
FN = febrile neutropenia; ANC = absolute neutrophil count; G-CSF = 




2.3.5 Quality assessment of included COI studies  
All the included studies were assessed for quality. The COI studies fulfilled 
44% to 84% of the listed criteria in the checklist (Table 6). The study conducted 
by Hendricks et al [76] fulfilled the most number of criteria (84%), while 






Table 6. Checklist for the evaluation of COI studies 
Checklist [79] [78] [80] [8] [74] [72] [75] [73] [77] [76] 
1. Analytical Framework           
a. Is there a defined perspective of the study?        
 N N Y N Y Y Y N N N 
b. Was the appropriate epidemiologic approach taken?       
 Y Y Y Y Y Y Y Y Y Y 
c. Was the study question well specified?         
 P P P P P P P P P P 
2. Methodology and data           
a. Was the appropriate method(s) of resource quantification used?      
 P Y P P P P P P P Y 
b. Was the resource quantification method(s) valid?        
 N Y P Y Y P Y Y P Y 
c. Were there appropriate valuation of healthcare resources?      
 N Y N Y N Y Y Y Y Y 
d. Was the approach for valuing indirect costs justified and assumptions valid?     
 N N N NA N NA N N Y Y 
e. Was there appropriate inclusion of intangible costs?       








3. Analysis and reporting 
a. Was the study question addressed in the analysis?        
 Y Y Y Y Y Y Y Y Y Y 
b. Was there a range of cost estimates presented?        
 Y Y Y Y Y Y Y Y Y Y 
c. Were the main uncertainties identified?         
 Y Y Y Y Y Y Y Y Y Y 
d. Were sensitivity analyses performed on important parameter estimates, key assumptions and point estimates? 
 N Y Y N N Y N N N Y 
e. Was sufficient documentation and justification made for cost components, data and sources, assumptions and methods? 
 N Y N Y Y Y Y Y N Y 
f. Was uncertainty of the estimates and its implications sufficiently discussed?     
 Y Y Y Y Y Y Y Y Y Y 
g. Were limitations of the analysis discussed regarding its cost components, data, assumptions and methods?  
 Y Y Y Y Y Y Y Y Y Y 
h. Was there an appropriate degree of detail in the results presented to answer the study question? 
 N Y N Y Y Y N Y N Y 
 





















* Percentage of criteria each study fulfilled; Y = fulfilled the criterion; P = partially fulfilled the criterion; N = failed to fulfil 





In this review, we have found that there was a large variation in the cost 
estimates among the COI studies in lymphoma patients with FN. The main 
component of the economic burden of FN was identified as the direct medical 
cost in the inpatient care. Specifically, the ward cost was the greatest cost driver 
for the direct inpatient care costs. Parameters associated with higher FN cost 
included inpatient management, male gender, discharged dead, and comorbidity 
and infection.  
 
Many potential factors could lead to the large variation in estimating the cost of 
FN, which included the year of pricing (due to different number of years used 
for discounting), the perspective employed, and the cost estimation approach 
used. In this study, we have identified that different healthcare system could be 
the main contributor for the cost variation. It was observed that despite using 
CPI to standardize the cost estimates, the cost of FN still varied largely among 
different countries. The studies conducted by Dulisse et al [73], Zhou et al [8] 
and Mayordomo et al [75] employed the same perspective of a healthcare 
provider, had the same time horizon, and used bottom-up method to estimate its 
cost. However, the overall cost varied greatly of US$26,686, US$13,823 and 
US$6,661 respectively. Upon closer examination, all these studies were 
conducted in different countries, elucidating that the large variation in the cost 
of FN was because these studies were conducted in different countries. The 
public healthcare system is unique for each country, with different standards of 
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care as well as different costing of health care resources [81]. For instance, when 
drug prices (selling price to the patient) were compared between the US and 
Canada, the price was 69% higher in the US than in Canada [82]. The drug price 
(selling price to the patient) is also 7% higher in the UK than Canada [82].  The 
highest cost of FN was documented in the US, followed by Europe, and Canada 
could be due to the higher cost of health care resources and services provided. 
Therefore, in order to have an accurate estimate on the economic burden of FN 
in Singapore, it is necessary to conduct a COI study to reflect the specific 
resource use in local settings. In addition, it should be noted that variations on 
the proportion of patients with different cancer types included in each study 
could also lead to the large variation on the cost of FN. 
 
It is noted that the indirect costs aspects were often overlooked in the included 
COI studies. A study by Cosler et al (2004) [83] indicated that indirect costs 
comprise a major proportion of the healthcare costs, up to 70% of overall cancer 
care, but such was not the case in our included studies. The studies [76,77] 
considered a HCM to evaluate the indirect costs [65]. Since FN is an acute 
condition, and typically produces temporary complete disability, the cost 
involved from the patient time lost from work may not be significant [76]. Our 
review has shown that direct costs were over four-fold of indirect costs in the 
inpatient settings for lymphoma patients [77]. Therefore, it was shown that 
direct costs served as the major component in the economic burden of FN.  
However, future COI studies should also consider exploring indirect costs of 
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FN, since this review showed that limited studies evaluated the indirect cost of 
FN. 
 
In addition, it is observed that none of the cost-of-illness studies identified in 
this review have employed patient’s perspective. As there has been increasing 
attention directed towards understanding the impact of financial toxicity to 
patients, future study investigating the specific economic burden of FN from 
patient’s perspective is needed. 
 
There were several limitations associated with this review. Firstly, there were 
relatively limited COI studies that were dedicated to review the cost of FN in 
lymphoma patients. Among the ten studies identified, only one study [79] 
estimated their costs specifically for lymphoma patient population, while the 
rest of the studies estimated cost of FN from their study population, which 
consisted of lymphoma patients among other types of cancer patients. Due to 
these challenges, no definite inference was possible to provide the average cost 
of FN related to lymphoma patients. Secondly, only papers written in English 
were included, which restricted the number of studies screened and may 
potentially introduce selection bias. However, we expected these included 
studies to be of higher methodological quality since most of the high quality 
studies would be published in English. In addition, we are uncertain whether 
the primary studies adhere to any specific guidelines for the management of FN. 
However, considering that different management pathways may affect the 
 47 
estimation of economic burden of FN, it should be noted that such variation 
might limit the interpretability of the findings in this review.  
 
2.5 Conclusion 
Our review has demonstrated that there was a large variation in the cost 
estimates among the COI studies, which could be due to different cost 
estimation approach and different healthcare systems. It is necessary to conduct 
a local COI study to have an accurate estimation on the economic burden of FN 
in Singapore. Besides, the main component of the economic burden of FN was 
identified as the direct medical cost in the inpatient care.  
 
2.6 After-note 
An electronic bibliography search was updated to identify the publications from 
18 December 2013 to 13 December 2016 by using the same searching strategy 
mentioned in Section 2.2. For the included COI studies, the same methodology 
was employed for data analysis as in Section 2.2. The cost estimates from 
included COI studies were converted into 2016 US$. Costs were first inflated 
into 2016 currency value using the general CPI. The currency exchange rate on 
15 December 2016 was used to standardize the cost into US$: 1 € = 1.05 US$. 
 
The updated search identified a total of 513 articles from Scopus, Pubmed and 
Web of Science. After screening the title and abstract, 502 articles were 
excluded based on inclusion and exclusion criteria. Eleven studies remained for 
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full article review. Of those, another 9 articles did not fulfil the inclusion 
criteria. At last, two new papers were identified (Figure 4). 
 
 
Figure 4. Flowchart for screening articles in Scopus, Pubmed and Web of 
Science from December 2013 to December 2016 
 
The newly identified studies are from Singapore (n=1) and Ireland (n=1) [Note: 
the newly identified study from Singapore [84] is the same as the study that will 
be introduced in Chapter 3]. Both of these two studies employed healthcare 
provider’s perspective, and only accounted for the direct medical cost 
associated with the inpatient management of FN (Table 7).  The source of cost 






Table 7. General characteristics of newly included COI studies (n = 2) 




Study design Retrospective Retrospective 
Sample size 367 pts; 21.5% 
lymphoma 
32 pts; 19% lymphoma 









Hospital bed stay, laboratory 
tests, microbiology 
investigations, radiological 






COI = cost-of-illness; NA = not available; pts = patients 
 
The adjusted cost estimates for FN reported in Singapore study and Ireland 
study were US$ 4,288 and US$ 9,330, respectively. Although both two studies 
employed similar approaches for estimating the cost of FN, there was still a 












Table 8. Summary of the cost of FN from newly included COI studies 
Study Country Singapore [84] Ireland [85] 
Year a 2012 2013 
Perspective  Healthcare provider Healthcare provider 




Mean (95% CI)  US$ 4,193  
(3,779-4,607) 




US$ 4,288 US$ 9,330 
Direct cost approach BUM BUM 
Indirect cost approach NA NA 
a The year of conducting the study; b A “per episode” time horizon would 
indicate the time taken from the diagnosis of FN to the resolution of FN or 
mortality of the patient; BUM = bottom-up method; CI = confidence interval; 
COI = cost-of-illness; NA = not available 
 
Both the Singapore study and Ireland study included the inpatient care in their 
cost components and revealed the breakdown of the resources used in their 
inpatient care cost (Table 9). However, neither has included direct non-medical 
cost and indirect cost into the cost estimations for FN. The Ireland study 
revealed that the ward cost was the main cost driver for the inpatient care of FN, 
contributing to 76.8% of the total cost of inpatient management [85]. The 
Singapore study did not show the percentage of each cost component in total 
inpatient cost for FN, however, it indicated that longer inpatient stay was 
associated with a higher FN cost [84]. Other parameters associated with a higher 
total inpatient cost were reported as severe sepsis and lymphoma as underlying 
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cancer [84]. The Ireland study did not investigate the parameters associated with 
higher FN cost [85]. 
 
Table 9. Checklist of resource use in the newly included COI studies a 
a Checkmark indicates that cost figure is provided; G-CSF = granulocyte 
colony-stimulating factor; COI = cost-of-illness 
 
Overall, after including the newly published studies between 18 December 2013 
and 13 December 2016, the major findings remained consistent with the 




Resource Category Singapore [84] Ireland [85] 
Inpatient care x x 
 Direct cost   
Direct Medical cost   
  Ward x x 
  Laboratory x x 
  Radiography x x 
  Transfusion  x 
  Medication x x 
     Antibiotics  x 
     G-CSF   
Direct Non-medical cost   
  Transportation   
 Indirect Cost   
 Lost productivity   










Chapter 3. Direct cost associated with the management 
of febrile neutropenia among solid tumor and 










FN has a substantial economic effect, particularly in the inpatient setting [40]. 
Three U.S. studies [73,78,86] estimated that the average costs of FN inpatient 
management ranged from US$18,880 to US$22,086. The direct costs for 
outpatient management were considerably lower than inpatient care, at US$985 
per episode [78]. Similar trends with a different cost burden degree were 
observed in Europe. A German prospective study [87] analyzed the influence 
of FN on the use of health resources and costs for patients with both solid tumors 
and lymphoma and found that the estimated mean direct cost per FN episode 
requiring hospital care was €3,950. A Spanish study [75] employed healthcare 
provider’s perspective to estimate the inpatient management cost of FN and 
found a mean direct cost per episode attributable to FN of €3,841 in a similar 
patient population. In a recent study conducted in Ireland [85] which estimated 
the inpatient management cost for FN patients from healthcare provider’s 
perspective, the mean cost per FN episode in the inpatient setting was estimated 
to be €8,915. The cost of FN therefore varies greatly across different countries 
and health care systems.  
 
In Singapore, limited data have been reported on the cost of the management of 
FN on cancer patients. Cost studies are therefore needed to make accurate 
estimates on the cost of FN among patients with various types of cancers. The 
primary objective of this study was to describe the total direct inpatient costs 
among the solid tumor and lymphoma patients who received inpatient 
 54 
management for chemotherapy-induced FN and the factors that were associated 
with higher direct cost. The secondary objective was to describe the out-of-
pocket patient payments and the factors that were associated with the higher 
out-of-pocket patient payments. We expected this study to provide an accurate 
estimate on the cost of FN, reflecting the local management in Singapore. This 
study is a fundamental requirement for the development of further economic 
evaluations on the current FN management strategies and for reducing the cost 
of FN among cancer patients in Singapore  
 
3.2 Methods 
3.2.1 Study design and setting 
This was a secondary analysis of a prospective study [88] conducted at the 
NCCS in 2014. In the original study, the clinical efficacy of the adjunctive G-
CSF among cancer patients with FN was evaluated. Clinical data 
(demographics, medical history, medication history, and treatment outcomes) 
were prospectively obtained from patients as well as hospital information 
support system and the pharmacy prescription database. The complete methods 
for the data collection are described in detail elsewhere [88]. The National 
Healthcare Group Domain Specific Review Board approved the study and 
waived the requirement for patient consent (DSRB E/2009/00340). The NCCS 
is an ambulatory cancer centre that treats approximately 70% of all of the solid 
tumor and lymphoma cases in Singapore [89]. At the NCCS, the majority of the 
patients who develop FN are hospitalized for treatment until they recover from 
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their low ANC and fever [7]. The inpatient management of FN follows the 
guideline from the IDSA [1].  
 
In Singapore, inpatient care is classified into private ward (Class A and Class 
B1) and subsidized ward (Class B2 and Class C) patients. The Class A (single 
bed) ward is not subsidized by the government. Different levels of government 
subsidy are available for the Class B1 (four beds), Class B2 (six beds), and Class 
C (open ward) wards for Singapore citizens and permanent residents [90,91]. 
The government subsidizes 0% to 20% of the total hospital bill for Singapore 
citizens and permanent residents in the Class B1 wards. In contrast, citizens and 
permanent residents in the Class B2 and Class C wards can receive subsidy of 
up to 80% of their total bill [91]. The Goods and Services Tax is absorbed for 
those who are eligible for subsided treatment, related services and/or who are 
staying in the Class B2 and C wards [90]. 
 
3.2.2 Patient population 
All of the adult cancer patients (aged 18 years and above) who received 
chemotherapy for the treatment of solid tumors or lymphoma at the NCCS and 
were hospitalized for FN between 2009 and 2012 were included in this study. 
The definition of FN was based on the IDSA guideline [1]. The cancer type was 
determined using the ninth revision of the International Classification of 
Diseases – Clinical Modification. Patients who were hospitalized more than two 
days before their FN episode were excluded. If a patient required 10 days or 
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more of hospitalization after recovering from fever and low ANC, the patient 
was also excluded from this analysis. In patients who had experienced multiple 
FN-related hospitalizations during the study period, the first hospitalization was 
selected for analysis. 
 
3.2.3 Cost data 
The cost data were estimated from billing data obtained via the financial 
electronic databases of the NCCS and the Singapore General Hospital (SGH), 
which included the total hospital cost, the reimbursement bill, the out-of-pocket 
patient payments (Medisave funds included), and the cost breakdown of out-of-
pocket patient payments (consisted of ward charges, laboratory charges, 
radiology charges, prescription charges, surgical charges, and other charges). A 
hospital’s perspective was taken in this study. The FN-related costs included all 
of the costs incurred from the day of hospitalization until the discharge date. 
These medical costs were expressed as the total hospital cost and the out-of-
pocket patient payments (adjusted by the government subsidy). The resource 
and costs associated with the treatment of the underlying cancer were not 
included. All of the cost data were adjusted to 2012 Singapore dollar (SG$) 
using the Singapore CPI [92]. The cost data were then converted to 2012 US$ 
using purchasing power parity (PPP) conversion rate obtained from the World 
Bank (2012; 1 SG$ = 0.7157 US$).  The out-of-pocket patient payments was 
broken down into its individual cost components [8]. The information on 
disaggregated cost of total hospital cost was not available. 
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3.2.4 Study outcomes and definitions 
The primary outcomes of this analysis were the total hospital cost and the out-
of-pocket patient payments per FN episode. Univariate and multivariate 
analyses were performed to identify the clinical factors which had significant 
associations with a higher total hospital cost or out-of-pocket patient payments 
per FN episode. We evaluated the patient demographics (age, gender, and 
ethnicity), major cancer diagnoses (breast cancer, lymphoma, gastrointestinal 
cancer, head and neck cancer, lung cancer, sarcoma, genitourinary cancer, 
gynecologic cancer, and others), length of stay, treatment with therapeutic G-
CSF, admission source (emergency department, clinic, and inpatient referral), 
MASCC risk index, ward class (Class A, Class B1, Class B2, and Class C), 
severity of sepsis, duration of antibiotics, and the ANC at presentation and 
nadir.  
 
3.2.5 Statistical analysis 
The clinical and demographic characteristics were reported for each patient 
based on a single admission per patient. We evaluated all of the admissions 
associated with FN. Descriptive analyses were used to summarize the primary 
study outcomes of this study (total hospital cost and out-of-pocket patient 
payments). The means, median, and 95% CI were reported. For the univariate 
and multivariate analyses, the total hospital cost and the out-of-pocket patient 
payments per FN episode were transformed on the natural logarithmic scale 
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because an exploratory analysis revealed that the two dependent variables were 
not normally distributed. Group comparisons of natural logarithmic transformed 
cost data were conducted using Student t-test or analysis of variance (ANOVA). 
Scheffe's Test was performed if there was a statistically significant finding 
through the ANOVA test. This step was performed to identify the variables of 
interest which may affect the outcomes (total hospital cost and out-of-pocket 
patient payments) in this study. Pearson’s correlation coefficient analysis was 
conducted to identify the variables significantly associated with a higher total 
hospital cost or out-of-pocket patient payments. After identifying the variables 
which were significantly associated with higher costs, multiple linear regression 
models were conducted to estimate the total hospital cost and out-of-pocket 




3.3.1 Patient population 
Three hundred and sixty seven adult cancer patients were documented with FN-
related hospitalizations between 2009 and 2012. The average patient age was 
54.8 years (range, 18-79), 37.9% of the patients were male, and 77.1% were of 
Chinese ethnicity. The most common primary cancer types were breast cancer 
(36.8%), followed by lymphoma (21.5%), gastrointestinal cancer (10.6%), head 
and neck cancer (9.3%), and lung cancer (8.5%) (Table 10). G-CSF was used 
as a therapeutic treatment (86.9%) in the majority of the FN episodes. The 
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majority of the patients (90.5%) were Singapore citizens or permanent 
residents. 
 
Table 10. Clinical and demographic characteristics of the subjects 
Baseline characteristics Number of patients (n=367) 
Age in years  
Mean (SD) 54.8 (12.2) 
18-40 (%) 41 (11.2%) 
41-60 (%) 202 (55.0%) 
61-80 (%) 124 (33.8%) 
Gender  
Male (%) 139 (37.9%) 
Female (%) 228 (62.1%) 
Ethnicity  
Chinese (%) 283 (77.1%) 
Malay (%) 38 (10.4%) 
Indian (%) 20 (5.4%) 
Other (%) 26 (7.1%) 
Cancer Type  
Breast CA (%) 135 (36.8%) 
Lymphoma (%) 79 (21.5%) 
Gastrointestinal CA (%) 39 (10.6%) 
Head and Neck CA (%) 34 (9.3%) 
Lung CA (%) 31 (8.5%) 
Sarcoma (%) 16 (4.4%) 
Genitourinary CA (%) 15 (4.1%) 
Gynecologic CA (%) 13 (3.5%) 
Other/Unknown CA (%) 5 (1.4%) 
MASCC Risk Index  
≥ 21 (%) 300 (81.7%) 
< 21 (%) 67 (18.3%) 
Outcome  
Death (%) 14 (3.8%) 
Recover (%) 353 (96.2%) 
Length of Stay (days), Mean (SD) 5.8 (3.7) 
SD = standard deviation; CA = cancer; MASCC = Multinational 




3.3.2 Total hospital cost 
The mean and median total hospital cost per FN episode for all of the 
hospitalizations were US$4,193 (95% CI: US$3,779-4,607) and US$2,837, 
respectively. A subgroup analysis by cancer type showed that the patients with 
lymphoma had the highest mean total hospital cost of US$6,560 (95% CI: 
US$5,198-7,922), followed by patients with genitourinary cancer (US$4,898, 
95% CI: US$2,095-7,701), and gynecologic cancer (US$4,615, 95% CI: 
US$3,133-6,097). Breast cancer patients had the lowest mean total hospital cost 
(US$2,898, 95% CI: US$2,529-3,267) of the identified cancer types (Table 11).  
 
FN episodes that manifested with severe sepsis had a considerably higher mean 
cost (US$7,879, 95% CI: US$6,135-9,623) than those without sepsis 
(US$3,590, 95% CI: US$3,240-3,940). Other factors associated with a higher 
mean total hospital cost were inpatient referrals (US$7,238, 95%CI: US$5,637-
8,839) and a low MASCC risk index (US$5,998, 95% CI: US$4,749-7,247).  
 
3.3.3 Out-of-pocket patient payments 
The mean and median out-of-pocket patient payments per FN episode were 
US$2,230 (95% CI: US$1,976-2,484) and US$1,405, respectively. A subgroup 
analysis by cancer type revealed that the patients with lymphoma had the 
highest mean out-of-pocket patient payments of US$3,389 (95% CI: US$2,562-
4,216), followed by patients with gynecologic cancer (US$2,877, 95% CI: 
US$1,560-4,194), and genitourinary cancer (US$2,629, 95% CI: US$1,131-
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4,127). Breast cancer patients had the lowest mean out-of-pocket patient 
payments (US$1,567, 95% CI: US$1,318-1,816) of the known cancer types 







Table 11. Descriptive analysis of the total hospital cost and the out-of-pocket patient payments (n=367) 
Variables No. (%) 
Total hospital cost  Out-of-pocket patient payments 
per episode, 2012 US$  per episode, 2012 US$ 
Mean  
(± 95% CI) 




(± 95% CI)  
p Value * 
Median 
(IQR)  









Age in years 
        
  
    




























      
    
    





















      
    
    
Breast CA 135 (36.8%) 2,898 (± 369) 




1,567 (± 249) 








































































Therapeutic G-CSF   
    
    
    



















Admission Source   
    
    
    
ED  195 (53.1%) 3,721 (± 503) 


























Severe Sepsis   
    
    




No 315 (85.8%) 3,590 (± 350) 




2,044 (± 264) 













MASCC Risk Index   
    
    
    
≥ 21 300 (81.7%) 3,790 (± 412) 



















Ward Class   
    
    
    





5,245 (± 1,889) 































ED = emergency department; NCCS = National Cancer Centre Singapore; CI = confidence interval; MASCC = Multinational 
Association of Supportive Care in Cancer; CA = cancer; IQR = interquartile range; @ p value from ANOVA test; # p value 
from two sample t-test, assumed equal variance; * ANOVA test and two-sample t-test were conducted on natural logarithmic 









The mean out-of-pocket patient payments of FN episodes with severe sepsis 
(US$3,358, 95% CI: US$2,586-4,130) was higher than without sepsis 
(US$2,044, 95% CI: US$1,780-2,308). Higher FN out-of-pocket patient 
payments were associated with the use of therapeutic G-CSF (US$2,338, 95% 
CI: US$2,052-2,624) and the private wards (Class A (US$5,245, 95% CI: 
US$3,356-7,134) and Class B1 (US$3,749, 95% CI: US$2,914-4,584)). The 
main cost component identified in the out-of-pocket patient payments was the 
prescription charges (35.2%), followed by the ward charges (18.4%) and the 
laboratory cost (13.3%). Approximately one quarter of the total out-of-pocket 
patient payments was unclassified (29.4%) (Table 12). 
 
Table 12. Cost breakdown of the total out-of-pocket patient payments 
(n=367) 
 









       (145-504) 
432 
       (375-488) 18.4% 
Laboratory 
171 
       (120-260) 
314 
       (266-362) 13.3% 
Radiology 
17 
          (8-64) 
88 
       (66-110) 3.7% 
Prescription 
507 
       (319-891) 
829 
       (720-937) 35.2% 
Other/Unknown 
383 
       (226-661) 
692 
       (585-800) 29.4% 
Total 
1405 
      (901-2,442) 
2,230 
     (1,976-2,483) 100% 




3.3.4 Univariate analysis 
The association of cancer types with the total hospital cost was evaluated. 
Patients with lymphoma had a significantly higher cost (p < 0.001) than patients 
with other cancer types. Male patients had a significantly higher total hospital 
cost (p < 0.001) than female patients. Other factors associated with a 
significantly higher total hospital cost were inpatient referrals (p < 0.001), 
severe sepsis (p < 0.001), and a low MASCC risk index (p < 0.001) (Tables 11 
and 13). In the correlation analysis, a higher total hospital cost was also 
significantly associated with a longer length of stay (r = 0.86, p < 0.01), a lower 
ANC at presentation (r = 0.17, p < 0.01), and a longer time to recover the ANC 
(r = 0.16, p < 0.01).  
 
The association of cancer types with the out-of-pocket patient payments was 
also evaluated. The lymphoma group again had a significant higher cost (p < 
0.001) than the other cancer types. The patients in the 18-40 years age group (p 
< 0.01) and male patients (p < 0.01) also had a significantly higher cost than 
older patients and female patients, respectively. Other predictive factors 
associated with higher out-of-pocket patient payments were treatment with 
therapeutic G-CSF (p < 0.01), inpatient referrals (p < 0.01), severe sepsis (p < 
0.001), and a lower MASCC risk index (p < 0.05). Patients staying in private 
wards (Class A/B1) were associated with a significantly higher out-of-pocket 
patient payments (p < 0.001) than those in the subsided wards (Class B2/C) 
(Tables 11 and 13). The correlation analysis revealed that the out-of-pocket 
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patient payments was positively correlated with a longer length of stay (r = 0.63, 
p < 0.01), a lower ANC at presentation (r = 0.11, p < 0.05), and a longer time 











Out-of-pocket patient payments a Total hospital cost a 




Breast CA 1,822 < 0.001* 3,662 < 0.001* 
Gastrointestinal CA 1,462 0.411 2,415 0.634 
Head & Neck CA 887 0.999 1,995 0.94 
Lung CA 1,528 0.098 3,207 0.072 
Sarcoma 1,058 1 2,703 0.988 
Genitourinary CA 760 0.952 1,662 0.804 
Gynecologic CA 512 1 1,945 1 





NCCS clinic 1,501 0.002* 3,567 < 0.001* 




41-60 years 926 0.002* 
    




B1 1,496 0.763     
B2 3,549 < 0.001*     
C 3,645 < 0.001*     
B1 
A1 -1,496 0.763     
B2 2,053 < 0.001*     
C 2,149 < 0.001*     
ED = emergency department; NCCS = National Cancer Centre Singapore; CA = cancer; * significant at α = 0.05; @ Conducted 
by using Scheffe's Test; a 2012 US$
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3.3.5 Multivariate analysis 
Table 14 shows the factors that were found to be significantly associated with a 
higher total hospital cost. The factors were the length of stay (coefficient=0.061, 
95% CI: 0.056~0.065, p<0.001), lymphoma (coefficient=0.105, 95% CI: 0.064-
0.146, p<0.001), and severe sepsis (coefficient=-0.131, 95% CI: 0.086-0.176, 
p<0.001). This multivariate model for the total hospital cost had an adjusted R2 
























Length of stay 0.061 0.056 0.065 0.002 0.763 < 0.001 
Time to ANC recovery 0.003 -0.003 0.009 0.003 0.024 0.363 
ANC at presentation 0.008 -0.054 0.070 0.031 0.007 0.797 
MASCC risk index < 21 -0.013 -0.052 0.026 0.020 -0.017 0.513 
Lymphoma 0.105 0.064 0.146 0.021 0.141 < 0.001 
Male gender 0.026 -0.006 0.059 0.016 0.042 0.110 
Severe sepsis 0.131 0.086 0.176 0.023 0.154 < 0.001 
Inpatient referral 0.038 -0.008 0.083 0.023 0.043 0.107 
a. Adjusted R² = 0.782, p < 0.001; b. Only clinically relevant variables that were statistically significant at p value of 
0.05 in the univariate analysis were included in the regression model; c. Bolded p values are statistically significant; 




A separate multivariate model was used to identify the significant predictors for 
higher out-of-pocket patient payments, which are shown in Table 15. The 
factors were the length of stay (coefficient=0.054, 95% CI: 0.049-0.060, 
p<0.001), lymphoma (coefficient=0.067, 95% CI: 0.012-0.121, p=0.017), 
severe sepsis (coefficient=0.081, 95% CI: 0.020-0.142, p=0.009), 18-40 years 
age group (coefficient=0.082, 95% CI: 0.019-0.144, p=0.011), treatment with 
therapeutic G-CSF (coefficient=0.101, 95% CI: 0.041-0.161, p=0.001), and 
staying on a private ward (coefficient=0.408, 95% CI: 0.359-0.457, p<0.001). 






























Length of stay 0.054 0.049 0.060 0.003 0.614 < 0.001 
Time to ANC recovery 0.004 -0.004 0.013 0.004 0.031 0.320 
ANC at presentation -0.003 -0.085 0.080 0.042 -0.002 0.948 
MASCC risk index < 21 0.019 -0.033 0.072 0.027 0.022 0.473 
Lymphoma 0.067 0.012 0.121 0.028 0.080 0.017 
Male gender 0.017 -0.027 0.060 0.022 0.024 0.452 
Severe sepsis 0.081 0.020 0.142 0.031 0.085 0.009 
Inpatient referral 0.013 -0.048 0.074 0.031 0.013 0.683 
18-40 year age group 0.082 0.019 0.144 0.032 0.078 0.011 
Therapeutic G-CSF treatment 0.101 0.041 0.161 0.030 0.100 0.001 
Private Ward (Class A or B1) 0.408 0.359 0.457 0.025 0.499 < 0.001 
a. Adjusted R² = 0.691, p < 0.001; b. Only clinically relevant variables that were statistically significant at p value of 0.05 in 
the univariate analysis were included in the regression model; c. Bolded p values are statistically significant; ANC = 
absolute neutrophil count; G-CSF = granulocyte colony-stimulating factor; MASCC = Multinational Association of 
Supportive Care in Cancer 
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3.4 Discussion 
In this study, we described the total hospital cost and out-of-pocket patient 
payments among solid tumor and lymphoma patients who received inpatient 
management of chemotherapy-induced FN in Singapore. The clinical factors 
associated with the total hospital cost and out-of-pocket patient payments were 
also identified. The factors that were found to be associated with a higher total 
hospital cost for FN treatment were a longer length of stay, severe sepsis, and 
lymphoma. The factors associated with a higher out-of-pocket patient payments 
were a longer length of stay, severe sepsis, lymphoma, the age group 18-40 
years, treatment with therapeutic G-CSF during admission, and staying on a 
private ward (Class A or B1).  
 
When analyzed by cancer type, the mean total hospital cost was US$6,560 for 
lymphoma patients, US$2,898 for breast cancer patients, and ranged from 
US$3,353 to US$4,898 for patients with other identified cancers. A similar 
pattern was found in previous studies [77,78,87]. Among cancer patients who 
received inpatient care, the Bennett study [77] estimated that the mean direct 
cost was US$21,601 for lymphoma patients, which was much more costly than 
that of breast cancer (US$13,186) or other cancers (US$12,150). A recently 
published Spanish retrospective study [75] reported that the cost was highest 
when lymphoma was the underlying cancer (€4,514), followed by breast cancer 
(€3,518) and lung cancer (€3,310). This difference was probably related to a 
longer length of stay due to lymphoma patients suffering FN episodes [73]. One 
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study [73] showed that lymphoma patients had the longest length of stay (10.1 
days) and patients with female breast cancer had the shortest mean length of 
stay (5.9 days). The length of stay result was consistent with the cost, as 
lymphoma had the highest mean total hospital cost (US$24,218) and female 
breast cancer had the lowest mean cost (US$11,132). As the length of stay was 
directly associated with the total hospital cost, interventions to improve FN 
management in future should focus on promoting the outpatient management 
among those low-risk FN patients.  
 
A lower out-of-pocket patient payment was associated with the Class B2 and C 
wards. The majority of the patients were citizens or residents and they received 
more subsidies in these wards than in the other ward classes. The government 
only subsidizes 0% to 20% of the total hospital bill for Singapore citizens and 
permanent residents in the private Class A and Class B wards [91]. In contrast, 
citizens and permanent residents in the Class B2 and Class C wards can receive 
a subsidy of up to 80% of their total bill [91]. As the patients’ choice of ward 
class may reflect their preference or values as well as their socioeconomic 
status, which are an important determinant in clinical decision-making, future 
cost-effective analysis or cost-utility analysis studies should collect the 
willingness to pay value separately, based on the different ward classes.    
 
Prescription charges were the largest component of the overall out-of-pocket 
patient payments of FN, followed by the ward charges, and the laboratory cost. 
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The medication costs and ward costs were therefore probably the main cost 
drivers in the inpatient management of FN. A micro-costing method can be used 
to account for the cost of the ward and medication, if a more accurate estimate 
of the direct medical cost of FN is required. Prescription charges were identified 
as the largest component in the out-of-pocket patient payments because the 
reimbursement of healthcare resources in Singapore differs from other 
countries. The government subsidy for cancer patients mainly focuses on the 
hospitalization charges and the chemotherapy charges [93]. Certain costly 
supportive care medications that are frequently used in the management of FN, 
such as G-CSF, are not fully covered for reimbursement. Therefore, cost-
effective analysis on those medications may be useful to formulate the strategies 
to reduce patients’ out-of-pocket payments. In addition, it has been 
demonstrated that medication errors (such as inappropriate medication dosing) 
in the management of infectious diseases may contribute to higher medication 
costs among patients [94]. Future studies should aim to lower the cost burden 
of FN by focusing on interventions that can improve medication management, 
such as having a clinical pharmacist review the prescribed medications to 
reduce potential medication errors, and to optimize the medication management 
strategies [94]. 
 
There are a number of limitations to this study. A large proportion of the 
expenses in the total out-of-pocket patient payments could not be classified. 
This may introduce some variability in identifying the main cost drivers of the 
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cost of FN. We did not capture patients’ comorbidities in detail, hence we were 
unable to analyze the contribution of comorbidities to the cost burden of FN. 
Our inclusion criteria were stricter than other studies, which makes comparisons 
of the cost estimates difficult [8,73,86,95]. The cost was calculated from the 
start date of an FN episode until the discharge date. Additional costs due to 
comorbidity or cancer-related morbidity and mortality were not considered. 
Those patients whose discharge date was more than 10 days after both their 
fever and ANC recovered were excluded from the analysis. These criteria were 
applied so that we only studied the cost of the management of FN, not the other 
costs that are associated with the management of comorbidities or cancer due to 
an extended hospital stay. Due to the unavailability of data breakdown, micro-
costing on the total hospital cost was not feasible. However, the average cost-




In conclusion, the total hospital cost and out-of-pocket patient payments of FN 
management in lymphoma cases were substantially greater than in other solid 
tumor cases. A longer length of stay and severe sepsis were associated with a 
higher total hospital cost for FN management. The cost of FN identified in this 
study could be useful for further economic evaluations on the FN management 











Chapter 4. Cost-effectiveness analysis of granulocyte 
colony-stimulating factor prophylaxis strategies for 











Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. 
The first-line treatment for DLBCL includes combination chemotherapy with 
cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-
CHOP) [96]. The current guidelines suggest that patients who are undergoing 
R-CHOP chemotherapy are at intermediate risk (10% to 20%) for FN and it is 
recommended that the prophylactic use of G-CSF should be considered among 
patients with risk factors for FN, such as old age, previous chemotherapy or 
radiotherapy, and poor performance status [2,17]. 
 
In Singapore, two types of G-CSF are commercially available, filgrastim and 
pegfilgrastim (a second-generation filgrastim with a sustained duration of 
action). Globally, the patent for filgrastim is recently expired, and a number of 
biosimilars of filgrastim are currently under development and evaluation. 
Nivestim, a biosimilar filgrastim, was recently approved for clinical use in 
Singapore. In a phase III clinical trial, the efficacy and safety of nivestim were 
demonstrated to be similar to those of filgrastim [97]. Because the price of 
biosimilar filgrastim (nivestim) has the potential to be lower than that of its 
reference product (filgrastim), there is an opportunity for nivestim to improve 
the cost-effectiveness of the prophylaxis strategies for FN. 
 
Although several cost-effectiveness analyses of the prophylactic use of G-CSF 
among lymphoma patients who are undergoing CHOP-based chemotherapy 
 81 
have been published in the past few years [18,98-100], the results have been 
varied. Recently, one study from the European G5 countries showed that the 
prophylactic use of biosimilar filgrastim was more cost-efficient for the 
reduction of FN under all possible prophylaxis strategies evaluated than 
filgrastim and pegfilgrastim [101]. However, to the best of our knowledge, 
publications regarding the cost-effectiveness of FN prophylaxis with biosimilar 
G-CSF among lymphoma patients who are undergoing R-CHOP chemotherapy 
are limited, particularly in the Asian population. Therefore, the primary 
objective of this study was to evaluate the cost-effectiveness of PP and SP with 
biosimilar filgrastim (nivestim), pegfilgrastim, or NP to reduce the risk of FN 
in patients with NHL who were undergoing R-CHOP chemotherapy with 




4.2.1 Model overview  
A Markov model was constructed with TreeAge Pro 2013 (TreeAge Software, 
Inc, MA) to compare seven prophylaxis strategies for FN: 1) PP with nivestim 
through all cycles of chemotherapy; 2) PP with nivestim during the first two 
cycles of chemotherapy; 3) SP with nivestim; 4) PP with pegfilgrastim through 
all cycles of chemotherapy; 5) PP with pegfilgrastim during the first two cycles 
of chemotherapy; 6) SP with pegfilgrastim; and 7) NP. PP is defined as the 
routine administration of G-CSF with each cycle of chemotherapy, regardless 
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whether a patient had previously experienced an episode of FN. SP is defined 
as the initiation of G-CSF in subsequent cycles of chemotherapy after a patient 
experienced a FN episode. For both SP strategies (strategies 3 and 6) and those 
that included PP at the first two cycles of chemotherapy (strategies 2 and 5), 
secondary G-CSF prophylaxis was initiated and continued during the 
subsequent cycles once the patient experienced an episode of FN. 
 
The model target population was a hypothetical cohort of patients with NHL 
(mean age, 55 years) with R-CHOP as a curative treatment. The time horizon 
of this model was 18 weeks, which was the period of six chemotherapy cycles. 
The Markov model was used with a cycle length of 1 week (7 days). 
 
4.2.2 Model structure 
This Markov model included five health states (mutually exclusive): 1) no FN 
or history of FN; 2) FN with severe complications; 3) FN without 
complications; 4) no FN, but a history of FN; and 5) death of FN (Figure 5). 




Figure 5. Structure of Markov state transition model 
 
In this model, all patients began in health state 1 (no FN or history of FN). 
Health states 2 and 3 were temporary states that individuals had to exit after 1 
week. To integrate the memory of FN history into the Markov model, health 
state 4 was added. Health state 5 was set as the absorbing state. The transitions 
from state 1 to states 2 and 3, and from state 4 to states 2 and 3 only occurred in 
week 2 of each chemotherapy cycle (Figure 6). The face validity of this model 
has been discussed and confirmed with local experts and clinicians. This study 
was approved by the SingHealth Institutional Review Board. Informed consent 
was waived, and patient records/information was anonymized and de-identified 
prior to analysis. 
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Figure 6. Markov trace of the cohort simulation for the first two cycles of 
chemotherapy 
 
4.2.3 Model inputs 
4.2.3.1 Cost  
The cost data on nivestim and pegfilgrastim were obtained from NCCS. The 
cost of medication administration was not included because the patients self-







Table 16. Model inputs 
Parameters Value Reference PSA distribution 
Costs, 2013 US$    
Pegfilgrastim 6 mg (per injection) 532 US$ NCCS NA  
Nivestim 300 μg (7 days of injections) 352 US$ NCCS, [102] NA  
Hospitalization cost for FN with complications 22,135 US$ NCCS, [84] Gamma (α = 29.23, λ = 0.0013) 
Hospitalization cost for FN without complications 9,588 US$ NCCS, [84] Gamma (α = 98.72, λ = 0.010) 
 
Utilities 
   
NHL with chemotherapy (without FN) 0.80 NCCS, [103] Beta (α = 92.70, ß = 23.17) 
FN without complications 0.77 NCCS, [103] Beta (α = 61.33, ß = 18.42) 
FN with severe complications 0.43 NCCS, [103] Beta (α = 4.43, ß = 5.78) 
 
Probabilities and efficacy 
   
RR of FN (versus no G-CSF); pegfilgrastim 0.55 [102,104] Log-normal (mean = -0.60, SD = 0.22) 
RR of FN (versus no G-CSF); nivestim 0.62 [104,105] Log-normal (mean = -0.48, SD = 0.13) 




FN risk in cycle 1; no prophylaxis 0.17 [104] Beta (α = 84, ß = 410) 
FN risk in cycles 2 to 6; no prophylaxis 0.03 [104] Beta (α = 61, ß = 349) 
Risk of severe complications in cases of FN 0.14 NCCS, [84] Beta (α = 13, ß = 83) 
FN with complications case fatality rate  0.025 [88] Beta α = 4, ß = 154) 
FN without complications case fatality rate 0.0063 [88] Beta (α = 1, ß = 157) 
US$ = US dollars; NA = not applicable; NCCS = National Cancer Centre Singapore; PSA = probabilistic sensitivity analysis; 
G-CSF = granulocyte colony-stimulating factor; FN = febrile neutropenia; SD = standard deviation; NHL = non Hodgkin’s 










Although episodes of FN may lead to a dose reduction or a delay in 
chemotherapy that may affect the patient’s treatment cost, for this study, the 
variation on treatment costs was limited because the simulated cohort of patients 
were undergoing curative-intent chemotherapy. It was therefore assumed that 
the costs of chemotherapy were the same across all arms of the model, so these 
costs were not included in our analysis. 
 
The costs of hospitalization for FN among lymphoma patients with and without 
serious complications were obtained through an observational study conducted 
at the NCCS [84] [Note: this observational study [84] is the same as the study 
that was introduced in Chapter 3]. A previous study in Singapore reported that 
more than 95% of cases of FN were managed in an inpatient setting [7]. To 
simplify the model, all FN events in this study were assumed to require 
hospitalization. 
 
All costs were first adjusted to 2013 Singapore dollars by the Singapore CPI 
(health care component) [106]. The cost data were then converted to US dollars 
using the 2013 PPP conversion rate of 1 SG$ = 0.88 US$ [107], obtained from 
the World Bank. 
 
4.2.3.2 Utilities 
Utility estimates were generated from a local study in Singapore [103] [Note: 
this study [103] is the same as the study that will be introduced in Chapter 7]. 
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In that study, there are a total of 67 hospitalized patients with lymphoma who 
were undergoing chemotherapy. Twenty-eight out of 67 patients (41.8%) 
developed FN within the past 7 days from the interview date, among which 7 
patients (25%) experienced severe complications. The EuroQol 5-Dimensions 
questionnaire (EQ-5D) was administered to each patient, and the average utility 
index score was calculated to estimate the utility value for each health state. 
EQ-5D utility index scores were calculated using a Japanese value set, which 
offers the closest approximation to Singapore’s population [108]. 
 
4.2.3.3 Probabilities and efficacy 
Table 16 shows the efficacy of pegfilgrastim in the prevention of FN in patients 
with NHL estimated with data from a local retrospective study [102]. We 
assumed that nivestim had an efficacy equivalent to that of filgrastim [97] and 
estimated its efficacy on the basis of a randomized trial in lymphoma patients 
[105]. Nivestim was assumed to be given for 7 days per cycle of chemotherapy 
[102]. 
 
The RR of FN with and without a history of FN within each chemotherapy cycle 
was based on an observational study that was conducted by the NCCS [102]. 
The risk of severe complications in cases of FN was estimated in a study 
conducted in Singapore [84] [Note: this study [84] is the same as the study that 
was introduced in Chapter 3]. 
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In addition, the risks of the development of FN without PP with G-CSF were 
obtained from Lyman et al. [104]. It was assumed that R-CHOP had a risk of 
FN equivalent to that of the CHOP regimen [109]. The risks of the development 
of FN in cycles 2 to 6 were assumed to be equivalent [104]. 
 
The case-fatality rates for FN with and without severe complications in patients 
with NHL were based on a prospective observational study [88] from 
Singapore.  
 
4.2.4 Model analyses 
The model outputs included the total costs, the number of FN episodes 
prevented, and the quality-adjusted life year (QALY) gained for each of the 
seven prophylaxis strategies. The primary outcome of this economic evaluation 
was the incremental cost per episode of FN prevented. If a strategy was more 
costly and did not provide any additional benefit (i.e., both more costly and less 
effective), it was considered to be “dominated.”  
 
A probabilistic sensitivity analysis was performed and a beta distribution was 
used to reflect the uncertainty in the risks. The cost parameters were assumed 
to follow a gamma distribution. A log-normal distribution was used for the RR. 
The parameters of these distributions were derived from published literature 
when available [84,88,102,104,105]. The Monte Carlo simulation was 
conducted for 10,000 iterations for each comparison. The cost-effectiveness 
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acceptability curves were generated on the basis of the results of the 
probabilistic sensitivity analysis. 
 
Scenario analyses were performed. The cost per QALY gained was chosen as 
the outcome for each individual prophylactic strategies. A cost-effectiveness 
threshold of US$ 50,000 per QALY gained was employed. 
 
4.3 Results 
4.3.1 Base-case analysis 
Table 17 shows the total and incremental health outcomes and costs associated 
with all seven FN management strategies (cost per FN episode prevented as the 
main outcome). NP, SP with nivestim, and SP with pegfilgrastim were 
dominated by PP with pegfilgrastim (cycles 1 and 2). The costs associated with 
PP with nivestim (cycles 1 and 2), PP with pegfilgrastim (cycles 1 and 2), PP 
with nivestim (all cycles), and PP with pegfilgrastim (all cycles) were 
US$3,813, US$4,056, US$4,545, and US$5,331, respectively. The number of 
FN episodes per patient throughout all six cycles of chemotherapy were 0.25, 
0.24, 0.21, and 0.19, respectively. 
 
The incremental cost-effectiveness ratio (ICER) for PP with pegfilgrastim 
(cycles 1 and 2) compared with PP with nivestim (cycles 1 and 2) was 
US$13,532 per episode of FN prevented; for PP with nivestim (all cycles) 
compared with PP with pegfilgrastim (cycles 1 and 2), the ICER was 
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US$22,565 per episode of FN prevented; and for PP with pegfilgrastim (all 
cycles) compared with PP with nivestim (all cycles), the ICER was US$30,452 






Table 17. Results of the costs and effectiveness of the prophylaxis strategies (cost per FN episode prevented) 
Strategy Cost, 2013 
US$ 
Episode of FN 
per patient @ 
Incremental 






PP with nivestim (cycles 1 & 2) 3,813 0.25 reference reference reference 
PP with pegfilgrastim (cycles 1 & 2) 4,056 0.24 243 0.02 13,532 
PP with nivestim (all cycles) 4,545 0.21 489 0.02 22,565 
PP with pegfilgrastim (all cycles) 5,331 0.19 786 0.03 30,452 
No prophylaxis * 4,101 0.36 -- -- Dominated 
SP with nivestim  * 4,162 0.33 -- -- Dominated 
SP with pegfilgrastim * 4,297 0.33 -- -- Dominated 
@ Throughout all six cycles of chemotherapy; * Dominated by PP with pegfilgrastim (cycles 1 and 2); PP = primary 
prophylaxis; SP = secondary prophylaxis; FN = febrile neutropenia; US$ = US dollars; ICER = incremental cost-






4.3.2 Probabilistic sensitivity analysis 
The cost-effectiveness acceptability curve from the probabilistic sensitivity 
analysis (Figure 7) revealed that PP with nivestim (cycles 1 and 2) has the 
highest probability to be cost-effective (ranged from 48% to 60%) when the 
willingness to pay (WTP) threshold is lower than US$10,000 per FN episode 
prevented. In contrast, if the WTP threshold is higher than US$20,000 per FN 
episode prevented, PP with G-CSF (nivestim or pegfilgrastim) for all cycles 








4.3.3 Scenario analysis 
Table 18 shows the total and incremental health outcomes and costs associated 
with all seven FN management strategies (cost per QALY gained as the main 
outcome). NP, SP with nivestim, and SP with pegfilgrastim were dominated by 
PP with pegfilgrastim (cycles 1 and 2). PP with nivestim (all cycles) was 
extended dominated by the mixed strategy of PP with pegfilgrastim (cycles 1 






Table 18. Results of the costs and effectiveness of the prophylaxis strategies (cost per QALY gained) 
Strategy Cost, 2013 
US$ 
QALYs Incremental 





PP with nivestim (cycles 1 & 2) 3,813 0.2754 reference reference reference 
PP with pegfilgrastim (cycles 1 & 2) 4,056 0.2755 243 0.0001 4,058,623 
PP with pegfilgrastim (all cycles) 5,331 0.2756 1,275 0.0001 11,928,289 
PP with nivestim (all cycles) ^ 4,545 0.2755 -- -- Dominated 
No prophylaxis * 4,101 0.2751 -- -- Dominated 
SP with nivestim  * 4,162 0.2733 -- -- Dominated 
SP with pegfilgrastim * 4,297 0.2752 -- -- Dominated 
@ Throughout all six cycles of chemotherapy; * Dominated by PP with pegfilgrastim (cycles 1 and 2); ^ 
Extended dominated by a mixed strategy of PP with pegfilgrastim (cycle 1&2) and PP with pegfilgrastim (all 
cycles); PP = primary prophylaxis; SP = secondary prophylaxis; FN = febrile neutropenia; QALYs = quality-






In our study, we found that NP, SP with nivestim, and SP with pegfilgrastim 
were dominated by PP with pegfilgrastim (cycles 1 and 2) in the base case 
analysis. This advocates for a routine PP strategy to prevent FN among all 
patients with NHL who undergo R-CHOP chemotherapy. In Chapter 3, we 
identified that inpatient management cost of FN was US$4,193 per episode, and 
the management cost of FN in lymphoma cases (US$6,560) was the highest 
among the cancer types. Hence, this emphasizes the importance to routinely PP 
patients with G-CSF (nivestim or pegfilgrastim) who are undergoing R-CHOP 
in Singapore in order to prevent the occurrence of FN, as this strategy is cost 
effective and it reduces patients’ risks of FN risks for hospitalization and 
infection-related complications.  
 
Considering the short time horizon (18 weeks) in our proposed model, it is not 
suitable to use QALY as the primary outcome for this study, because the benefit 
of reducing the FN-related mortality rate using G-CSF cannot be fully captured 
within a relative short time horizon (during the chemotherapy cycles). 
Therefore, we have chosen the ICER involving natural health units (episodes of 
FN prevented) as the main outcome for this study. However, we have also 
conducted our analysis using the cost per QALY gained approach, in order to 
ensure our study findings are comparable to other cost-effectiveness studies 
[18,98-100]. It should be noticed that when the cost per QALY gained approach 
was used, multiple strategies (NP, SP with nivestim, and SP with pegfilgrastim) 
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are still dominated by PP with pegfilgrastim (cycles 1 and 2) in the base case 
analysis. This demonstrates robustness of our main finding that a routine PP 
strategy to prevent FN should be advocated among all patients with NHL 
receiving R-CHOP chemotherapy. 
 
A recent US study evaluated the cost-effectiveness of G-CSF prophylaxis 
among patients with NHL who were undergoing CHOP-based chemotherapy 
[98]. In that study, a time horizon of life was used and the cost-effectiveness 
was assessed by the ICER involving QALY. PP with G-CSF was found to be 
cost-effective when compared with SP with G-CSF at a WTP threshold of 
US$50,000 per QALY. This is consistent with the findings in our study. A 
Canadian study [18] assessed the cost-effectiveness of PP with G-CSF among 
patients with DLBCL who underwent R-CHOP during six cycles of 
chemotherapy. It was reported that PP with G-CSF was not cost-effective when 
compared with NP at a WTP threshold of US$50,000 per QALY. The main 
reason why this study presents different results from the current study [98] could 
be due to the relatively short time horizon they have chosen and they have 
included the NP strategy as the reference (assuming NP strategy is the standard 
care in their settings). We believe that the assessment of the cost-effectiveness 
of G-CSF prophylaxis within a shorter time horizon (during the chemotherapy 
cycles) is more appropriate because FN is an acute illness and there is little 
evidence to support the long-term benefits of G-CSF prophylaxis. However, it 
was identified in our study that the NP strategy was dominated by the PP with 
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G-CSF (nivestim or pegfilgrastim) for the first two cycles of chemotherapy. To 
our knowledge, this is the first study that has evaluated the value of PP with G-
CSF during the first two cycles of chemotherapy among lymphoma patients. 
One previous study [19] concluded that G-CSF prophylaxis for all cycles of 
chemotherapy is more effective in patients with breast cancer, but associated 
with higher cost, when compared to the administration of prophylaxis solely for 
the first two cycles of chemotherapy. However, the cost-effectiveness of PP 
with G-CSF limited to the first two cycles has not been determined. The results 
in our study demonstrated that this strategy is cost-effective when compared to 
the PP with G-CSF for all cycles as this strategy generates a sizable cost-saving 
with a slight loss on the health benefits that may not be clinically significant. 
However, further studies are required to refine and optimize a dosing regimen 
that requires less G-CSF.  
 
Our study has several limitations. First, the efficacy of nivestim was assumed 
to be equivalent to that of filgrastim. Although it is safe for us to assume that 
their efficacies are similar, this uncertainty may have affected our results. 
Second, we presented all-cause mortality in our model, as we were unable to 
segregate the mortality of other causes during chemotherapy. This could 
potentially lead to an overestimation on both costs and effectiveness. However, 
given the short time horizon in this model (18 weeks) and most mortality during 




In conclusion, routine PP with G-CSF (nivestim or pegfilgrastim) is cost-
effective in Singapore for reducing the risk of FN in patients receiving R-CHOP 
than other strategies including SP or not offering prophylaxis. The findings in 
this study have provided evidence to advocate the routine use of G-CSF as 





























Chapter 5. Cost-effectiveness analysis of therapeutic 
use of filgrastim for established febrile neutropenia 













In Chapter 3, we have reported that the cost of inpatient FN management was 
around US$4,193 per episode in Singapore, and FN patients who had developed 
severe sepsis were associated with a significantly higher economic burden. 
Hence, we have concluded that FN is associated with a significant economic 
burden on patients. 
 
Patients manifesting FN often receive filgrastim support as an adjunct therapy. 
However, the therapeutic use of G-CSF for established FN is not routinely 
recommended among low-risk FN patients, such as patients with solid tumors 
or lymphomas [5,110,111]. One recent meta-analysis of randomized control 
trails (RCT) suggested that patients receiving G-CSF plus antibiotics had 
shorter duration of FN and antibiotics use compared with patients receiving 
antibiotics alone [39]. Therefore, the therapeutic use of filgrastim is expected to 
reduce patient’s hospital length of stay and provide benefits on cost savings 
associated with reduced hospitalization and antibiotics use.  
 
With the emergence of biosimilar filgrastim to the market, there is a gradual 
decrease in the listed price of the originator product of filgrastim over the years, 
and this could have an impact on the cost-effectiveness of filgrastim in the 
treatment of FN [112]. To our knowledge, there is a lack of robust cost-
effectiveness studies that focus on the therapeutic use of filgrastim for 
established FN among patients with solid tumors and lymphomas. Therefore, 
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we designed this study with the primary objective to evaluate the cost-
effectiveness of therapeutic filgrastim in the treatment of FN among adult 
patients with solid tumors and lymphomas.   
 
5.2 Methods 
A decision-tree model was constructed by using TreeAge Pro 2013 (TreeAge 
Software, Inc, MA) to compare two treatment options for FN: (i) antibiotics 
alone (standard care), and (ii) antibiotics with therapeutic filgrastim 
(comparator) (Figure 8) [Note: Markov model was used in Chapter 4 because 
of the repeated occurrence of FN during the six cycles of chemotherapy. 
However, in Chapter 5, a decision-tree model is used because FN that occurs 
within only one FN episode is being examined]. The time horizon of this model 
was set as 21 days to represent the interval between each chemotherapy cycle. 
No discounting was applied due to the short time horizon in this model. The 
perspective was taken from a societal perspective, but only direct medical cost 
was considered in this study. The face validity of this model was endorsed by 

















FN was defined as a single episode of fever ≥ 38.3°C or fever ≥ 38.0°C for at 
least 1 hour and an ANC of less than 0.5 × 109/L [1]. Grade IV neutropenia was 
set as having an ANC of less than 0.5 × 109/L [113]. The duration of grade IV 
neutropenia was the number of days with ANC less than 0.5 x 109/L. Time to 
ANC recovery was the duration from FN onset date till patient’s ANC increased 
to 2.0×109/L. In this study, serious complication was defined as the occurrence 
of severe sepsis during the hospitalization. Length of stay was the overall 
duration from FN onset date till patient got discharged from the hospital. 
 
5.2.2 Model inputs 
5.2.2.1 Probabilities 
Table 19 shows the model inputs used in this study. Probability estimates 
needed for the analysis were mainly obtained from a database consisting of 305 
adult cancer patients diagnosed with solid tumors or lymphomas at NCCS with 
documented FN-related hospitalizations between 2009 and 2012 [88]. Due to a 
lack of relevant data in Singapore, the probabilities of grade IV neutropenia over 
3 days (with or without therapeutic filgrastim) were generated based on a 








Table 19. Model inputs 
Parameters Value (mean) Range (95% CI) PSA distribution Reference 
Costs (US$, 2014) 
Filgrastim 300μg (per injection) 37 29 to 44 (+/- 20%) Normal SGH 
Inpatient treatment cost; without 
complications (per day) * 
1100 858 to 1342 
Gamma (α = 79.98;  
 = 0.073) 
NCCS, [84]  
Inpatient treatment cost; with 
complications (per day) * 
1115 903 to 1326 
Gamma (α = 117.19; 
 = 0.11) 
NCCS, [84]  
 
Time parameter (day) 
Time horizon 21 NA NA Assumed 
Time to ANC recovery; Grade IV 
neutropenia > 3 days (antibiotics with 
filgrastim) 
5.30 4.91 to 5.68 
Gamma (α = 761.99; 
 = 143.77) 
NCCS, [88] 
Time to ANC recovery; Grade IV 
neutropenia ≤ 3 days (antibiotics with 
filgrastim) 
2.56 2.41 to 2.72 
Gamma (α = 10.24; 
 = 4.00) 
NCCS, [88] 
Time to ANC recovery; Grade IV 
neutropenia > 3 days (antibiotics 
alone) 
6.50 3.48 to 9.52 
Gamma (α = 30.55; 






Time to ANC recovery; Grade IV 
neutropenia ≤ 3 days (antibiotics 
alone) 
2.76 2.35 to 3.16 
Gamma (α = 192.36; 
 = 69.70) 
NCCS, [88] 
Length of stay; without complications 7.31 6.58 to 8.04 
Gamma (α = 388.23; 
 = 53.11) 
NCCS, [88] 
Length of stay; with complications 13.37 9.19 to 17.55 
Gamma (α = 42.29; 




    
Utility for adult cancer patients 
undergoing chemotherapy without FN 
0.85 0.82 to 0.88 
Beta (α = 422.49; β 
= 74.56) 
NCCS, [115] 
Utility for hospitalized patient with FN 
without serious complications 
0.73 0.66 to 0.80 
Beta (α = 131.40; β 
= 48.60) 
NCCS, [103] 
Utility for hospitalized patient with FN 
with serious complications 
0.43 0.20 to 0.67 




Probabilities and efficacy 
    
Probability of grade IV neutropenia > 
3 days (antibiotics alone) 
0.47 0.38 to 0.57 







Probability of grade IV neutropenia > 
3 days (antibiotics with filgrastim) 
0.26 0.18 to 0.34 
Beta (α = 26.74; β = 
76.26) 
[114] 
Probability of serious complications 
(grade IV neutropenia ≤ 3 days) 
0.10 0.05 to 0.14 
Beta (α = 20.31; β = 
182.77) 
NCCS, [88] 
Probability of serious complications 
(grade IV neutropenia > 3 days) 
0.26 0.16 to 0.37 
Beta (α = 16.28; β = 
46.33) 
NCCS, [88] 
Case fatality rate for FN without 
complications  
0.02  0.004 to 0.04 
Beta (α = 4.82; β = 
236.16) 
NCCS, [88] 
Case fatality rate for FN with 
complications 
0.26 0.11 to 0.40 
Beta (α = 8.88; β = 
25.26) 
NCCS, [88] 
CI = confidence interval; NCCS = National Cancer Centre Singapore; SGH = Singapore General Hospital; PSA = probabilistic 
sensitivity analysis; FN = febrile neutropenia; ANC = absolute neutrophil count; * Inpatient treatment cost per day was calculated 













Cost data were retrieved from a FN database at NCCS in 2014 [84]. The cost 
for each filgrastim injection (300 µg) was obtained from the Department of 
Pharmacy at SGH because patients with FN from NCCS were admitted to SGH 
for management. All costs were adjusted to 2014 SG$ using the healthcare 
component of the Singapore CPI [116]. The cost data were then converted to 
2014 US$ using PPP conversion rate obtained from the World Bank (2014; SG$ 
1 = US$ 0.86) [117].  
 
5.2.2.3 Utilities 
Two previous studies (both conducted in Singapore) were used to generate 
utility estimates [103,115]. The first consists of 521 adult solid tumors and 
lymphoma patients without FN [115] while the second consists of 102 FN 
patients hospitalized between 2014 to 2015 [103] [Note: this study [103] is the 
same as the study that will be introduced in Chapter 7]. Utilities were assessed 
using the EQ-5D and calculated using a Japanese value set [108]. Baseline 
health utility value was obtained from the first database by matching with the 
second database in terms of cancer type and stage as these were the factors that 
had been shown to affect HRQoL in cancer patients undergoing chemotherapy 
[118]. Utility values of each health states were computed based on the pooled 




5.2.3 Base-case analysis and sensitivity analyses 
Costs, QALY gained, and the ICER were calculated in the base-case analysis. 
One-way sensitivity analyses were conducted on all parameters by varying each 
variable within its plausible range, at a WTP threshold of US$50,000/QALY. 
A 10,000-iteration probabilistic sensitivity analysis (PSA) was also performed.  
 
5.2.4 Threshold analysis 
Threshold analysis for the cost of G-CSF was conducted based on a WTP 
threshold of US$50,000/QALY. The cost of filgrastim (per injection) was 
varied upwards from US$0 until the ICER of comparator (antibiotics with 
filgrastim) vs. standard care (antibiotics alone) was equal to US$50,000/QALY.  
 
5.2.5 Key assumptions 
There were several assumptions made in this study: 1) Duration of FN and 
duration of therapeutic use of filgrastim were assumed to be equivalent to the 
duration of ANC recovery; 2) Duration of serious complication was assumed to 
be equivalent to the length of stay after recovery from FN; 3) The therapeutic 
use of filgrastim did not affect the mortality rate [39]; 4) The utility for those 
patients who died remained the lowest value of their health state throughout 
their hospitalization; 5) Patients returned to their baseline utility value once they 




5.3.1 Base-case analysis 
Costs associated with comparator group and standard care group were 
US$9,110 and US$9,235, respectively (Table 20). The QALY associated with 
these two groups were 0.0450 and 0.0443, respectively. A cost-saving of 
US$125 and an additional 0.0007 QALYs gained were generated with the 
comparator, compared to the standard care. The treatment strategy of antibiotics 
with therapeutic filgrastim was a dominant choice for managing FN when 
compared with antibiotics alone. 
 












Standard care  
(antibiotics 
alone) 






9,110 0.0450 -125 0.0007 Dominant 
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness 
ratio; Eff = effectiveness; IC = incremental cost; IE = incremental 
effectiveness; a adjusted in 2014 US$ 
 
 
5.3.2 Sensitivity analyses 
In one-way sensitivity analyses (Figure 9), variations in all the variables except 
for probability of grade IV neutropenia over 3 days and length of stay for 
patients with serious complications yielded an ICER lesser than 
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US$50,000/QALY. The use of filgrastim remained cost-effective as long as the 
length of stay in patients with serious complications is not shorter than 9.5 days. 
Similarly, when the risk of developing serious complications in patients with 
grade IV neutropenia over 3 days is more than 16.3%, the strategy of antibiotics 






Figure 9. Tornado diagram for one-way sensitivity analyses 
 113 
The PSA has shown that the strategy of antibiotics with therapeutic filgrastim 
was the dominant choice in 76.9% of the model iterations (Figure 10). In 
addition, the therapeutic use of filgrastim remains as a preferred strategy (either 
cost-effective or dominant) in 83.7% of the model iterations, when compared to 
the standard care (antibiotics alone), at a WTP of US$50,000/QALY.  
 
 
Figure 10. Scatter plots for probabilistic sensitivity analyses. This graph is 
divided into several regions: (1) comparator dominates standard care 
(76.9%); (2) comparator is more costly and effective, and its ICER is less 
than or equal to the WTP, so comparator is cost-effective (6.8%); (3) 
comparator is more costly and effective, but its ICER is greater than the 






5.3.3 Threshold analysis 
Threshold analysis showed that the therapeutic use of filgrastim remained cost-
effective at a threshold of US$50,000/QALY if the cost of filgrastim was below 
US$87 per injection.  
 
5.4 Discussion 
In view of the recent reduction on listed price of filgrastim, this study was timely 
conducted to evaluate the cost-effectiveness of therapeutic filgrastim in the 
treatment of FN among patients diagnosed with solid tumors and lymphomas. 
Results suggested that the therapeutic use of filgrastim is a dominant strategy 
(cost-saving and more QALY gained) and should be used in majority of patients 
for the treatment of FN. As shown in the one-way sensitivity analysis, treatment 
with therapeutic filgrastim would remain as the preferred strategy when 
patient’s risk of experiencing prolonged grade IV neutropenia (over 3 days) was 
more than 16.3% or the length of hospitalization for FN with serious 
complication was expected to be more than 9.5 days. The routine use of 
therapeutic filgrastim in FN patients with solid tumors and lymphomas appears 
reasonable on both clinical and economic grounds.  
 
Our suggestions on the routine use of filgrastim for treatment of FN differ from 
the recommendations provided by published guidelines and literature 
[5,110,111]. This is partly due to the reduction of its listed price over the years. 
The average mean cost of filgrastim in the early studies was about US$200 per 
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dose compared to the current US$37 per injection of filgrastim 300µg 
[114,119]. The recommendations from guidelines [5,110,111] were last updated 
in 2011 and they seemed acceptable at that time because the use of filgrastim 
for the treatment of FN may not be cost-effective in patients at a low risk of FN 
complications, as the cost exceed the threshold value of US$87 per injection of 
filgrastim 300µg. However, in view of the decrease in the cost of filgrastim, it 
may be prudent to review these recommendations. Furthermore, nivestim, a 
biosimilar filgrastim, was recently approved for clinical use in Singapore. This 
has major impact because the price of nivestim is lower than the current listed 
price of filgrastim, resulting in further cost-savings. However, the long-term 
safety and efficacy data of nivestim are still unknown. Additional cost-
effectiveness analyses are necessary to compare the cost-effectiveness of 
nivestim with its reference product (filgrastim). 
 
It has been well recognized that not all FN patients are at the same level of risk 
for developing serious complications, and outpatient management can be 
considered among patients who are at low-risk for FN complications, such as 
patients diagnosed with solid tumors and lymphomas [4]. However, due to a 
lack of high-level evidence, outpatient management among low-risk patients 
was not strongly recommended by the current guidelines [3,4], and the adoption 
of outpatient management among low-risk FN patients is still relatively poor in 
the current clinical grounds. In a recently published study involving solid 
tumors and lymphoma patients in the United States, over 80% of the FN 
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episodes among these low-risk patients were initially managed in an inpatient 
setting [120]. Hence, early discharge is a main goal for the hospitalized low-
risk patients with FN as prolonged hospitalization could lead to unnecessary 
medical cost, reduced quality-of-life, and increased risk of developing hospital-
acquired infections. Considering that therapeutic use of G-CSF (filgrastim) is 
cost-effective, as demonstrated in this study, and allows patients to become 
clinically stable in a shorter time frame [114], routine use of therapeutic 
filgrastim for managing FN should be considered in this group of patients as 
this could promote early discharge among the low-risk FN patients and provide 
tremendous benefits to them. 
 
There are a number of limitations in this study. Firstly, our model presumed 
daily filgrastim use till recovery of ANC (defined as more than 2.0×109/L), 
which may exceed current clinical practice. However, the duration of ANC 
recovery has little impact on the results as shown by one-way sensitivity 
analysis. Secondly, the adverse reactions associated with filgrastim, such as 
mild bone pain, were not included in the analysis. However, considering the 
relatively low cost of administrating non-opioid analgesics to manage these 
adverse reactions, it is not likely to have a significant impact on the results.  
 
5.5 Conclusion 
In conclusion, our study revealed that the therapeutic filgrastim, in conjunction 
with antibiotics, in the treatment of FN is more cost-effective, when compared 
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to using antibiotics alone. This provides evidence to support the routine use of 
filgrastim for the treatment of FN among adult cancer patients with solid tumors 


























Chapter 6. What is the role of biomarker in promoting 
febrile neutropenia management? The application of 
procalcitonin in differentiating between infectious and 











As a body vital sign, temperature is commonly assessed in patients with cancer. 
Fever is often manifested among patients diagnosed with lymphoma, and this 
often poses as a diagnostic challenge to clinicians. Patients with lymphoma may 
develop a fever as a result of a localized or bloodstream infection (BSI) 
especially when they are on immunosuppressive chemotherapy, or they may 
develop fever as a result of the lymphoma itself (termed as malignant fever or 
“B” symptom). To distinguish between infectious fever and NIF, a combination 
of clinical features and investigations are typically used [121]. Patients with 
fever due to infection typically present with spiking temperatures associated 
with chills, warmth and periodic sweating, tachycardia, hypotension and altered 
mentation. In contrast, patients with NIF, such as malignant fever, may 
experience warmth and sweating but infrequently manifest with constitutional 
symptoms such as chills, tachycardia, hypotension or mental state changes 
[121]. Patients with NIF are also less responsive to antibiotics treatment and 
exhibit a more dramatic fever response to non-steroidal anti-inflammatory 
agents [122]. Misdiagnosis of infections among patients with NIF could lead to 
a longer duration or inappropriate use of antibiotics and an increased risk of 
antibiotic resistance. 
 
PCT, the prohormone of calcitonin, is a protein composed of 116 amino acids 
and is produced by parafollicular cells of the thyroid in response to hormonal 
stimuli and by the neuroendocrine cells of the lung and the intestine in response 
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to inflammation or infection [123-125]. The PCT levels increase within 4 hours 
of the stimulus and peak at approximately 6 hours [53]. The elimination half-
life of PCT is around 25-30 hours [126]. The PCT levels are undetectable 
(below 0.05 ng/mL) in healthy individuals, but they can rise dramatically in 
patients with severe sepsis or septic shock [125,127], and higher PCT levels are 
generally associated with poorer prognosis [128].  
 
In a number of studies, PCT has been shown to predict for BSI among cancer 
patients [29,129,130]. In addition, several studies have evaluated the diagnostic 
value of PCT to discriminate between infectious fever and NIF in cancer 
patients [131-134], but results are inconsistent. While several studies suggested 
that PCT could discriminate between infectious fever and NIF [132-134], a 
recent prospective study among cancer patients showed that PCT levels were 
not significantly different between patients with BSI and those with tumor-
related fever [131].  
 
Patients with lymphoma may develop fevers due to infections especially if they 
are immunosuppressed while receiving chemotherapy, but they may also have 
fevers due to pneumonitis associated with their treatment or malignant fever due 
to uncontrolled lymphoma. We hypothesize that PCT will be higher among 
lymphoma patients with infectious fevers compared to those with NIF. 
Therefore, the primary objective of this study is to prospectively evaluate the 
role of PCT in distinguishing infectious fever from NIF among febrile 
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lymphoma patients. The secondary objectives are to (i) explore the usefulness 
of PCT for differentiating BSI, localized infections and no documented 
infections (LINDI) [Note: no documented infections is defined as infections 
with unknown source], and NIF, and (ii) compare the PCT levels at the first 24 
hours of fever onset and the PCT levels at 24 to 72 hours afterwards fever onset 
among febrile lymphoma patients. 
 
6.2 Methods 
6.2.1 Study design and participants 
This is a prospective, observational cohort study conducted at the NCCS and 
SGH between August 2014 and November 2015. Patients diagnosed with 
lymphoma who were seen in clinic or admitted to the inpatient ward with a 
documented fever (temperature ≥ 38°C for 2 readings an hour apart or ≥ 38.3°C) 
[1], had the ability to understand and willingness to sign a written informed 
consent document, and had an Eastern Cooperative Oncology Group (ECOG) 
performance status graded from 0 to 3 were included. Patients who were 
diagnosed with severe burns, severe trauma, recent major surgery, autoimmune 
conditions [135], and/or were unwilling to provide informed consent were 
excluded from this study. This study was approved by the Singhealth 
Centralized Institutional Review Board, and all the participants provided 




6.2.2 Data collection 
Among patients who provided informed consent, the demographic, clinical, 
microbiological, and radiological data were prospectively collected by 
investigators. Patients were followed from the onset until the resolution of the 
fever if they were seen in clinic or from admission until discharge if they were 
treated in the hospital. On the first day of fever onset, full history, physical 
examination, chest radiograph, urinalysis and cultures were performed for all 
recruited patients. In addition, BC (aerobic and anaerobic) were taken within 24 
hours of fever onset. If there is evident for bacteria growth in the blood, repeated 
BC would be taken within 4 to 7 days of starting antibiotics. Stool culture for 
bacteria and parasites was only conducted as clinically indicated. Computed 
tomography scan, 2D-echocardiogram, lumbar puncture, bronchoscopy and/or 
biopsy were investigated as directed by clinical presentations.  
 
In this study, patients were classified into three groups based on the diagnosis 
given to them by their treating physician or team of physicians: (i) BSI i.e., 
presence of bacteria or fungus in BC; (ii) LINDI (i.e., clinical evidence of 
infection without bacteria or fungus in BC or infections with unknown source); 
(iii) NIF i.e., absence of clinical or radiological evidence of infection and this 
category included patients with malignant fever and those with drug-induced 
pneumonitis. For cases of malignant fever, in addition to reviewing the 
diagnoses made by the patients treating physician(s), we have also reviewed the 
medical records to ensure the following criteria were met: absence of any 
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clinical or radiological evidence of infection, no bacteria or fungus growing in 
blood culture, positive naproxen test if performed. The same patient could be 
recruited for different fever events as long as the previous event had resolved 
completely.  
 
6.2.3 PCT measurement 
PCT levels were measured using the Elecsys BRAMHMS PCT kit on the Roche 
Cobas e602 analyser. The PCT assay was performed with a lower limit of 
quantitation of 0.06 ng/mL. The measurement of serum PCT was performed at 
three independent timings in this study: one was drawn within 24 hours of the 
onset of fever (PCT1), the second was drawn between 24 to 72 hours (PCT2) 
of the onset of fever, and the third was drawn after 96 hours of the onset of fever 
(PCT3). PCT3 was only performed among those patients who were not 
discharged within 96 hours since fever onset. PCT3 served as a reference to 
guide clinician’s decision, and was not used in the data analysis. In this study, 
we defined the higher PCT value between PCT1 and PCT2 as PCTmax. The 
higher value of the two was taken because PCT typically does not rise 
immediately after the onset of infection, and the peak PCT value can take more 
than 1 day to occur in infectious fever cases [132]. The combined information 
of PCT1 and PCT2 could improve the accuracy on differentiating between 




The primary endpoints of this study are (a) the difference of PCT levels (PCT1, 
PCT2, and PCTmax) between infectious fever (BSI and LINDI combined) and 
NIF, and (b) the sensitivity, specificity, and area under the receiver-operating 
characteristic curve (AUC) of PCT in predicting infectious fever. The secondary 
endpoints are (i) the difference of PCT levels (PCT1, PCT2, and PCTmax) among 
BSI, LINDI, and NIF, (ii) the sensitivity, specificity, and AUC of PCT in 
predicting BSI, (iii) the difference between PCT1 and PCT2 between patients 
with infectious fever and NIF, and (iv) the difference between PCT1 and PCT2 
among patients with BSI, LINDI, and NIF. 
 
6.2.5 Statistical analysis 
All statistical analyses were conducted using SPSS Statistics Version 22. 
Descriptive statistics were employed to describe patient’s demographic and 
clinical characteristics. Firstly, Mann-Whitney U tests were used to compare 
PCT levels (PCT1, PCT2, and PCTmax) between infectious fever group (BSI and 
LINDI combined) and NIF group. The receiver-operating characteristic (ROC) 
curve for predicting infectious fever was generated. Secondly, Kruskal-Wallis 
H tests were performed to compare PCT levels (PCT1, PCT2, and PCTmax) 
among three different groups of patients (BSI, LINDI, and NIF). The post hoc 
pairwise comparisons were further explored with a Bonferroni correction 
method to control type I error. The ROC curve was used to identify the optimal 
cut-off value for predicting BSI, and the sensitivity and specificity were 
calculated based on this value. In addition, PCT1 and PCT2 values were 
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compared by using Wilcoxon signed-rank tests. All the tests were 2-sided, and 
the significance level was 0.05. 
 
6.3 Results 
A total of 80 patients were recruited for this study, with 108 eligible cases of 
fever included for analysis. The demographic and clinical characteristics of the 
included cases were shown in Table 21. The median age of included cases was 
60 years (IQR = 26), and 78 included cases (72.2%) were males. The majority 
(74.1%) of included cases was Chinese. The most common lymphoma subtype 
was DLBCL (49.1%) (Table 21). Out of the 80 recruited patients, 55 (68.8%) 
were with single episode of fever, 22 (27.5%) had two separate fever episodes, 





Table 21. The demographic and clinical characteristics of included cases 
Characteristics Total (n=108) BSI (n=12) LINDI (n=83) NIF (n=13) 
Age, median (range) 60 (42-68) 58 (44-63) 62 (39-70) 58 (43-69) 
Male Gender, n (%) 78 (72.2) 9 (75.0) 58 (69.9) 11 (84.6) 
Race, n (%)     
Chinese 80 (74.1) 6 (50.0) 65 (78.3) 9 (69.2) 
Malay 8 (7.4) 2 (16.7) 6 (7.2) 0 (0.0) 
Indian 8 (7.4) 2 (16.7) 4 (4.8) 2 (15.4) 
Others 12 (11.1) 2 (16.7) 8 (9.6) 2 (15.4) 
Cancer Type, n (%)     
Diffuse Large B-Cell Lymphoma 53 (49.1) 9 (75.0) 37 (44.6) 7 (53.8) 
Peripheral T-Cell Lymphoma 15 (13.9) 1 (8.3) 13 (15.7) 1 (7.7) 
Hodgkin's Lymphoma 7 (6.5) 0 (0.0) 6 (7.2) 1 (7.7) 
Natural Killer T-Cell Lymphoma 7 (6.5) 0 (0.0) 3 (3.6) 4 (30.8) 
Burkitt’s Lymphoma 4 (3.7) 0 (0.0) 4 (4.8) 0 (0.0) 
Follicular Lymphoma 4 (3.7) 1 (8.3) 3 (3.6) 0 (0.0) 
Mantle Cell Lymphoma 4 (3.7) 0 (0.0) 4 (4.8) 0 (0.0) 
Marginal Zone Lymphoma 3 (2.8) 0 (0.0) 3 (3.6) 0 (0.0) 
Primary Central Nervous System Lymphoma 3 (2.8) 0 (0.0) 3 (3.6) 0 (0.0) 
Epitheliotrophic Intestinal T-Cell Lymphoma 2 (1.9) 0 (0.0) 2 (2.4) 0 (0.0) 
Others 6 (5.6) 1 (8.3) 5 (6.0) 0 (0.0) 
Neutropenia *, n (%) 34 (31.5) 7 (58.3) 27 (32.5) 0 (0.0) 
HIV, n (%) 8 (7.4) 1 (8.3) 7 (8.4) 0 (0.0) 
SD = standard deviation; BSI = bloodstream infections; LINDI = localized infections and no documented infections; 
NIF = non-infectious fever; HIV = human immunodeficiency virus; * Neutropenia is defined as an absolute neutrophil 
count < 500 cells/mm3.  
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There were 83 cases of LINDI (76.9%), 12 cases of BSI (11.1%), and 13 cases 
of NIF (12.0%). For the 83 cases of LINDI, unknown source of infection was 
most prevalent (n = 31), followed by pneumonia (n = 20), urinary tract infection 
(n = 9), gastrointestinal infection (n = 8), upper respiratory tract infection (n = 
4), cellulitis (n = 2), ear infection (n = 2), liver abscess (n = 2), central nervous 
system infection (n = 1), invasive fungal infection (n = 1), neck abscess (n = 1), 
prostate abscess (n = 1), and wound infection (n = 1). Among the 12 cases of 
BSI, pathogens included Burkholderia pseudomallei (n = 1), Candida 
parapsilosis (n = 1), Cryptococcus neoformans (n = 1), Penicillin-Resistant 
Escherichia coli (n = 1), Listeria Monocytogenes (n = 1), Citrobacter koseri (n 
= 1), Pseudomonas aerugionsa (n = 1), Penicillin-Sensitive Escherichia coli (n 
= 2), Methicillin-Sensitive Staphylococcus aureus (n = 1), Stenotrophomonas 
maltophilia (n = 1), and Streptococcus mitis Group (n = 1). Among the 13 cases 
of NIF, there were 11 cases with malignant fever (84.6%) and 2 cases with drug-
induced pneumonitis (15.4%). The measurements on PCT1 were conducted in 
all the 108 included cases and PCT2 measurements were performed in 90 cases 
(83.3%).  
 
6.3.1 PCT levels in infectious fever and NIF 
Among the 95 infectious fever cases (BSI and LINDI combined) and 13 NIF 
cases, the median PCT1 levels were 0.22 ng/mL (range, 0.15-0.55 ng/mL) and 
0.13 ng/mL (range, 0.075-0.68 ng/mL), respectively (P = 0.161) (Table 22). 
PCT2 levels were not significantly different between these two groups either (P 
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= 0.066). However, the median PCTmax level was higher in the infectious fever 
group compared to the NIF group (median PCTmax: 0.44 ng/mL versus 0.19 
ng/mL; P = 0.026).  
 
Table 22. Comparison of PCT levels between infectious fever 
(bloodstream infection combined with local infections and no documented 
infections) and non-infectious fever cases 
Value Group N (%) Median (IQR) P value 
PCT1 Infectious fever 95 (88.0) 0.22 (0.15-0.55) 0.161 
Non-Infectious 
fever 
13 (12.0) 0.13 (0.075-0.68) 
PCT2 Infectious fever 79 (87.8) 0.49 (0.20-1.50) 0.066 
Non-Infectious 
fever 
11 (12.2) 0.21 (0.11-0.53) 
PCTmax Infectious fever 
a 95 (88.0) 0.44 (0.19-1.70) 0.026 
Non-Infectious 
fever b 
13 (12.0) 0.19 (0.085-0.68) 
IQR = interquartile range; PCT1 = procalcitonin measurement within 24 hours 
of fever onset;  PCT2  = procalcitonin measurement within 24 to 72 hours after 
fever onset; PCTmax = the highest procalcitonin measurement within 72 hours 
of fever onset. Bolded value represents a p value significant at the 0.05 level. a 
Out of 95 PCTmax cases in the infectious fever group, 40 cases (42.1%) used 
PCT1 value and 55 cases (57.9%) used PCT2 value. b Out of 13 PCTmax cases 
in the non-infectious fever group, 7 cases (53.8%) used PCT1 value and 6 
cases (46.2%) used PCT2 value. 
 
Figure 11 shows that the AUC were 0.691 (95% CI, 0.536-0.847) for PCTmax, 
0.620 (95% CI, 0.435-0.805) for PCT1, and 0.671 (95% CI, 0.508-0.835) for 
PCT2. The AUC for PCTmax was better than that for PCT1 and PCT2 in the 
identification of infectious fever. The optimal PCTmax cut-off of ≥ 0.215 ng/mL 
was found for predicting infectious fever, with a sensitivity of 66.3% and a 
specificity of 61.5%. 
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Figure 11. Receiver-operating characteristic curve for identifying patients 
with infectious fever based on PCT1, PCT2, and PCTmax. The AUC for 
PCT1 (n=108), PCT2 (n=90), and PCTmax (n=108) is 0.620 (95% CI: 
0.435-0.805), 0.671(95% CI: 0.508-0.835), and 0.691 (95% CI: 0.536-
0.847), respectively. 
 
6.3.2 PCT levels among BSI, LINDI, and NIF 
The PCT levels (PCT1, PCT2, and PCTmax) were compared among patients 
with BSI, LINDI, and NIF (Table 23). No significant difference was found in 
PCT1 (P = 0.217) among these three groups. Patients with BSI had significantly 
higher PCT2 than did those with NIF (median PCT2: 0.98 ng/mL versus 0.21 
ng/mL; P = 0.026). PCTmax levels were also higher in the BSI group compared 
to the NIF group (median PCTmax: 1.60 ng/mL versus 0.19 ng/mL; P = 0.002). 
PCTmax levels were also significantly higher in the BSI group compared to the 
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LINDI group (median PCTmax: 1.60 ng/mL versus 0.35 ng/mL; P = 0.034).  The 
ability of PCT levels at the different time points to predict for BSI was further 
evaluated (Figure 12). Based on the ROC curve, PCTmax levels performed better 
than PCT1 and PCT2 levels for predicting BSI (AUC: 0.749 versus 0.608 and 
0.699, respectively). The optimal PCTmax cut-off level was ≥ 0.475 ng/mL, with 



















Table 23. Comparison of PCT levels among BSI, LINDI, and NIF cases 











PCT1 BSI 12 (11.1) 0.48 (0.18-0.98) 0.217 0.837 0.411 0.591 
LINDI 83 (76.9) 0.22 (0.14-0.48) 
NIF 13 (12.0) 0.13 (0.075-0.68) 
PCT2 BSI 11 (12.2) 0.98 (0.26-23.90) 0.031 0.177 0.026 0.360 
LINDI 68 (75.6) 0.43 (0.19-1.40) 
NIF 11 (12.2) 0.21 (0.11-0.53) 
PCTmax BSI 12 (11.1) 1.60 (0.50-20.33) 0.003 0.034 0.002 0.181 
LINDI 83 (76.9) 0.35 (0.16-1.40) 
NIF 13 (12.0) 0.19 (0.085-0.68) 
IQR = interquartile range; PCT1 = procalcitonin measurement within 24 hours of fever onset;  PCT2  = procalcitonin 
measurement within 24 to 72 hours thereafter fever onset; PCTmax = the higher PCT value between PCT1 and PCT2; 
BSI = bloodstream infections; LINDI = localized infections and no documented infections; NIF = non-infectious fever. 






Figure 12. Receiver-operating characteristic curve for identifying patients 
with BSI based on PCT1, PCT2, and PCTmax. The AUC for PCT1 
(n=108), PCT2 (n=90), and PCTmax (n=108) is 0.608 (95% CI: 0.439-
0.777), 0.699 (95% CI: 0.529-0.868), and 0.749 (95% CI: 0.613-0.885), 
respectively. 
 
6.3.3 Comparison between PCT1 and PCT2 among BSI, LINDI, and NIF 
cases 
The relationship between PCT1 levels and PCT2 levels in patients with 
infectious fever (BSI and LINDI combined) and NIF was evaluated (Figure 13). 
PCT2 levels were significantly higher than PCT1 levels in patients who 
experienced infectious fever (median PCT: 0.49 ng/mL versus 0.24 ng/mL; P = 
0.001). In contrast, there was no significant difference between PCT2 levels and 
PCT1 levels in patients with NIF (median PCT: 0.21 ng/mL versus 0.17 ng/mL; 
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P = 0.374). In addition, PCT1 levels and PCT2 levels were compared among 
patients with BSI, LINDI, and NIF (Figure 14). PCT2 levels were significantly 
higher than PCT1 levels in patients with BSI (median PCT: 0.98 ng/mL versus 
0.47 ng/mL; P = 0.045) and patients with LINDI (median PCT: 0.43 ng/mL 
versus 0.24 ng/mL; P = 0.004). However, PCT2 levels were not significantly 
different from PCT1 levels in patients with NIF (P = 0.374).  
 
 
Figure 13. Comparisons between PCT1 and PCT2 among patients 
diagnosed with infectious fever and non-infectious fever. Patients with 





Figure 14. Comparisons between PCT1 and PCT2 among patients 
diagnosed with NIF, BSI, and LINDI. Patients with complete 




To the best of our knowledge, this is the first prospective study assessing the 
diagnostic value of PCT for discriminating between infectious fever and NIF 
among a homogenous population of febrile lymphoma patients. We identified 
that the PCTmax within the first 72 hours of fever onset would allow us to 
differentiate fever due to infectious causes (BSI and LINDI combined) from 
fever due to non-infectious causes (malignant fever and drug-induced 
pneumonitis), which was consistent with the findings in Schüttrumpf et al. [133] 
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that PCT was a reliable marker to discriminate infectious fever from drug-
related and tumor related fever.  
 
In a prospective study investigating the role of PCT in distinguishing between 
infectious and malignant fever among cancer patients, PCT taken within the 
first 24 hours was not able to discriminate between fever due to BSI and 
malignant fever [131]. These results are similar to ours in that the PCT levels 
taken within the first 24 hours of the onset of fever was unable to discriminate 
between infectious fever and NIF or between BSI, LINDI and NIF. This is likely 
due to the fact that PCT does not rise immediately after the onset of infection 
and if the PCT levels were taken too early in the course of infection, it may 
result in a false negative finding. Another study also showed that PCT levels 
among haemato-oncologic patients with infectious fevers only peak at 24-48 
hours after the onset of infection [132]. In the previously mentioned prospective 
study, the patients with BSI and LINDI had a significant drop in PCT levels at 
follow-up, but this drop was not seen among those who had tumor-related fevers 
[131]. Similarly, others have also shown that a decrease in PCT levels four to 
seven days later in response to antibiotics could differentiate between BSI and 
malignant fever [54]. In our study, we showed that PCT2 was significantly 
higher than PCT1 among patients with BSI and LINDI but not those with NIF. 
Hence, in addition to watching for the response of fever to antibiotic treatment, 
we showed that using the PCTmax level and repeating the PCT levels between 
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24 to 72 hours of fever onset to look for a rise might be able to help differentiate 
between infectious fever and NIF. 
 
PCT has several advantages to serve as a biomarker to identify infections. First, 
PCT can be measured within 1 to 2 hours of fever onset, which gives the 
clinicians immediate and meaningful information to identify the infectious fever 
and initiate the antibiotics treatment in those infectious cases. Second, PCT 
possesses a relatively short half-life (24 hours). Therefore, a rapid decline in 
PCT levels normally represents that the the infection cases are under control. 
Looking into the trend change in PCT levels can help clinicians make decisions 
on the early cessation of the antibiotics treatment as well. These advantages 
make PCT a useful tool to optimize the antibiotics usage among febrile patients. 
A large RCT has evaluated the effectiveness of PCT-guided algorithm to reduce 
the antibiotic exposure [54]. Compared to the control group in which antibiotics 
usage was guided by the existing guidelines, less antibiotics were required in 
the PCT-guided group, and the difference on mortality was not statistically 
different between these two groups [54]. The predefined PCT cut-off point was 
set as 0.50 ng/mL for the recommendation on antibiotics usage [54], which is 
similar to the optimal PCT cut-off to predict BSI identified in our study (PCTmax 
> 0.475 ng/mL). Based on the findings in this study, a PCT-guided algorithm in 
local settings could be developed and evaluated in RCT for reducing the 
antibiotics exposure among febrile patients. 
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There are several limitations in this study. First, it was observed that some 
patients included in this study were quite ill and while we were able to 
consistently make PCT1 draws, patients’ deterioration and discomfort led to 
poor compliance with PCT2 draws. This caused a number of missing data on 
PCT2 in this study and potentially introduced selection bias. Second, PCT3 
draws were not taken in many of the included cases because some of the patients 
were discharged well and early after their initial assessment and were not keen 
to return for an additional blood draw then. Therefore, PCT3 data was not 
included in the data analysis due to the large amount of missing data.  
 
6.5 Conclusion 
In conclusion, two separate PCT measurements are useful to differentiate 
between infectious fever and NIF, and predict for BSI among lymphoma 
patients with fever. Looking into the rise in PCT levels may help to distinguish 
between infectious fever and NIF. If there is a clinical suspicion of infection 
among febrile lymphoma patients and the first PCT reading is low, a repeated 
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7.1 Introduction  
CIN is a serious and common toxicity of chemotherapy treatment and is 
associated with substantial morbidity, mortality, and costs [136]. CIN can lead 
to fever, hospitalization, increased risk of life-threatening infections, and 
chemotherapy dose reductions or delays that can compromise treatment 
effectiveness [61]. In addition, previous studies have demonstrated that CIN can 
lead to a significant decline in patients’ HRQoL [61,137-139]. 
 
HRQoL is a patient’s subjective evaluation of his/her health status [140]. It is a 
multi-dimensional construct that focuses on aspects of a patient’s life affected 
by disease or its treatment [140-142]. The assessment on patient’s HRQoL 
becomes increasingly important in the clinical practice because healthcare 
providers’ perception on patient’s HRQoL is a key determinant on whether to 
provide or withdraw an effective treatment for a life threatening condition (such 
as cancer) [143,144]. HRQoL assessments could be included as outcomes of 
interest alongside clinical endpoints in studies to weigh the costs and benefits 
of a particular therapy [141]. In terms of HRQoL associated with patients with 
CIN, both general and cancer-specific instruments have been used in past 
studies [138]. The FACT-N questionnaire distinguishes itself as an HRQoL 
instrument specifically developed for patients with neutropenia, providing a 
targeted assessment of HRQoL in patients manifesting CIN. Besides providing 
a self-reported assessment of physical well-being (PWB), emotional well-being 
(EWB), social/family well-being (SWB) and functional well-being (FWB), it 
 140 
also captures specific concerns associated with neutropenia [61]. In a study 
conducted in the United States, the FACT-N was demonstrated to be more 
sensitive in detecting subtle HRQoL declines associated with CIN, compared to 
general instruments that are not neutropenia-specific [138,139,145]. As such, 
the FACT-N may be more appropriate for evaluating HRQoL in patients with 
CIN. 
 
In order to function as an effective assessment tool of HRQoL, it is required for 
FACT-N to possess good psychometric properties. At present, there is limited 
data describing the psychometric properties of the FACT-N. The English 
version of the FACT-N has only been validated in a study conducted in the 
United States, where the FACT-N demonstrated satisfactory reliability, validity 
and sensitivity among Caucasian cancer patients aged 65 and above undergoing 
chemotherapy [61]. In view of multi-ethnic Asian population, a validation study 
is required to evaluate the psychometric properties of the FACT-N before 
utilizing the questionnaire in clinical research. Therefore, the primary objective 
of this study is to examine the psychometric properties of the FACT-N among 
multi-ethnic Asian cancer patients with neutropenia in Singapore. This 
validation study would allow the questionnaire results generated from FACT-N 
to be used with confidence in future research conducted among multi-ethnic 
Asian patients in Singapore. 
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7.2 Methods  
7.2.1 Study design and patient population 
This was a single-centre, cross-sectional study conducted among cancer patients 
admitted to the cancer wards at SGH between August 2014 and July 2015. 
Patients fulfilling the following inclusion criteria were recruited in this study: 
patients aged 16 and above who experienced an ANC ≤ 1.5 × 109/L within the 
past 7 days, received chemotherapy within the past one month at NCCS, had a 
confirmed cancer diagnosis, were English-speaking or Chinese-speaking, and 
were able to provide informed consent. Patients were excluded if they did not 
speak English or Chinese, had very poor performance status (ECOG 
performance status of 4), or were admitted to the intensive care unit. This study 
was approved by the Singhealth Centralized Institutional Review Board. All the 
participants provided informed consent prior to study enrollment. 
 
7.2.2 Data collection 
Two questionnaires were provided to eligible patients, in the following order: 
{1} the EQ-5D questionnaire, and {2} the FACT-N questionnaire. Participants 
chose to complete the English or Chinese version of the questionnaires based 
on their language preference. Demographic information and clinical 
information such as ECOG performance status, cancer type, cancer stage, 
neutropenia grade and presence of fever were collected from electronic medical 
records and patients’ case notes. The severity of neutropenia (neutropenia 
grade) was determined by the patient’s ANC nadir within the 7 days preceding 
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the interview, and was classified using the Common Terminology Criteria for 
Adverse Events version 4.0 [146]. Fever was defined as a single oral 
temperature measurement of more than 38.3°C or a temperature of more than 
38.0°C over a 1-hour period [1]. 
 
7.2.3 Tools  
7.2.3.1 EQ-5D 
The EQ-5D is a preference-based HRQoL tool that comprises a descriptive 
system measuring five dimensions of health (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression) with a visual analogue scale. 
The EQ-5D (three-level) was used, whereby each dimension is divided into 
three levels (no problems, some problems and extreme problems). Participants 
would choose the level most applicable to their health state on the day of the 
interview. A higher rating on each EQ-5D dimension indicated a worse HRQoL. 
Responses to the EQ-5D dimension scales were computed into an utility index, 
where a higher score indicated a better HRQoL [147]. The EQ-5D has been 
previously validated in Singapore and measurement equivalence has been 
demonstrated for both English and Chinese versions [148].   
 
7.2.3.2 FACT-N 
The FACT-N is a profile-based instrument developed by the Functional 
Assessment of Chronic Illness Therapy (FACIT) organization. FACT-N 
consists of the Functional Assessment of Cancer Therapy – General (FACT-G) 
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questionnaire as a core module, supplemented by a 19-item neutropenia 
subscale (NS). The FACT-G comprises 4 general subscales: PWB, SWB, EWB, 
and FWB. The PWB, SWB and FWB subscales each contain 7 items, while the 
EWB subscale contains 6 items. Participants were asked to report their health 
state for the past 7 days by rating a series of statements using a Likert scale 
ranging from 0 to 4. A total score was computed for the FACT-N and each 
subscale; a higher score indicated better HRQoL. Malaise, Worry, and Flu-like 
symptoms were previously identified as the three subscales within the NS [61]. 
English and Chinese versions of the FACT-N were used in the study. The 
Chinese version was developed by investigators of this study who are fluent in 
both English and Chinese, using the translation and linguistic validation 
methodology provided by the FACIT organization. Initially, forward 
translations were conducted from English to Chinese by two independent 
translators, followed by a reconciliation of the two forward translations 
provided by a third translator. Subsequently, back translation into English was 
performed by a fourth translator, and a fifth translator reviewed and finalized 
the tested Chinese version. After proofreading of the tested questionnaire, a 
pilot study was conducted among 10 local cancer patients who were undergoing 
chemotherapy. These patients were asked to complete the tested Chinese 
version of the FACT-N and then answer questions from a cognitive debriefing 
script provided by FACIT organization. Based on patients’ feedback, the tested 
Chinese version was further revised to the present version used in this study. 
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7.2.4 Data analysis 
All the statistical analyses were conducted using SPSS Statistics Version 22. 
Missing values in the EQ-5D were coded as stipulated in the EQ-5D (three 
level) User Guide [147]. EQ-5D utility index scores were calculated according 
to the Japanese value set, which offered the closest approximation to 
Singapore’s population [108]. Missing values in the FACT-N were imputed by 
the half-rule; missing values were replaced by the mean of the non-missing 
items in the same scale if more than half the items in the scale were answered. 
Scores for the FACT-N and its subscales were calculated according to the 
FACT-N scoring guidelines [149]. Descriptive statistics were employed to 
describe patient’s demographic and clinical characteristics.  
 
7.2.4.1 Reliability 
Internal consistency of the FACT-N’s subscales was evaluated with Cronbach’s 
alpha coefficient (α). Internal consistency measures how well the items in a 
subscale measure the same underlying construct; α ≥0.70 was considered 
satisfactory and α ≥0.80 was considered as good [141]. Item-to-subscale 
correlation analysis was performed to examine the degree of convergence 
between each item and its subscale. Correction for overlap was performed when 
calculating each item’s correlation to its own subscale, by removing its 
contribution to the subscale score. The corrected correlation should have a 




Two-sample t tests were employed to compare FACT-N, the subscales in 
FACT-N (PWB, SWB, EWB, FWB, and NS), the subscales in NS (Malaise, 
Worry, and Flu-like Symptom), and EQ-5D utility index scores between known 
groups formed in accordance to ECOG performance status, neutropenia grade, 
or presence of fever within the past 7 days since the interview date. We 
hypothesized that patients with relatively good ECOG performance status 
(Grades 0 and 1), low grade of neutropenia (Grades 2 and 3), and absence of 
fever would report better HRQoL than those who had poor ECOG performance 
status (Grades 2 and 3), severe neutropenia (Grade 4), and presence of fever, 
respectively. Higher scores of FACT-N, FACT-N subscales (PWB, SWB, 
EWB, FWB, and NS), NS subscales (Malaise, Worry, and Flu-like Symptom), 
and EQ-5D utility index would reflect better HRQoL. 
 
Convergent validity analyses were conducted to determine whether the FACT-
N total score and its subscales scores correlated with their hypothesized related 
construct in EQ-5D. We hypothesized that FACT-N total score would correlate 
with the EQ-5D utility index score positively. By using the domain scores in 
EQ-5D, we hypothesized that a lower score in FACT-N’s PWB subscale, EWB 
subscale, and FWB subscale would correlate with a higher score in EQ-5D’s 
Pain/Discomfort domain, Anxiety/Depression domain, and Usual Activity 
domain, respectively. In addition, the FACT-N’s NS score was hypothesized to 
correlate with the Pain/Discomfort domain and Anxiety/Depression domain in 
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EQ-5D. The Malaise subscale in NS would correlate with the EQ-5D utility 
index score. The Worry subscale in NS was postulated to correlate with the EQ-
5D’s Anxiety/Depression dimension. Spearman’s correlation coefficient was 
used. Correlation was considered strong if the absolute value of the correlation 
coefficient r was 0.7 and above, moderate if between 0.4 to 0.7, and weak if 
between 0 to 0.4 [151]. 
 
7.2.4.3 Measurement equivalence 
Measurement equivalence was examined to evaluate whether score differences 
between the English and Chinese versions of FACT-N were clinically 
important. Multiple linear regression models were used to estimate score 
differences attributed to the influence of language alone, adjusting for age, 
gender, marital status (married vs. single/separated/divorced/widowed), 
employment status (employed vs. unemployed/retired), and education 
(university/polytechnic/secondary school vs. primary school/no formal 
education). Measurement equivalence was established if the 95% CI of the 




From August 2014 to July 2015, a total of 370 eligible patients were identified, 
out of which 276 patients completed the interview. The response rate was 
74.6%. The demographic and clinical characteristics of the included patients 
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were shown in Table 24. Among the 276 participants in this study, 200 (72.5%) 
completed the English-version questionnaires and 76 (27.5%) completed the 
Chinese-version questionnaires. Of all the patients, the mean age was 54.6 ± 
12.9 years. The majority of the patients were female (65.6%) and Chinese race 
(76.4%). Breast cancer (35.9%) and lymphoma (24.3%) were the most common 
cancer types among the participants.  
 
















Gender    
 Male 26 (34.2%) 69 (34.5%) 95 (34.4%) 
 Female 50 (65.8%) 131 (65.5%) 181 (65.6%) 
Age (mean ± SD) 61.5 ± 9.3 52.0 ± 13.1 54.6 ± 12.9 
Race    
 Chinese 75 (98.7%) 136 (68.0%) 211 (76.4%) 
 Malay 0 (0.0%) 35 (17.5%) 35 (12.7%) 
 Indian 0 (0.0%) 21 (10.5%) 21 (7.6%) 
 Others 1 (1.3%) 8 (4.0%) 9 (3.3%) 
Marital status    
 Married 61 (80.3%) 130 (65.0%) 191 (69.2%) 
 Single 7 (9.2%) 47 (23.5%) 54 (19.6%) 
 Separated/divorced 4 (5.3%) 13 (6.5%) 17 (6.2%) 
 Widowed 4 (5.3%) 10 (5.0%) 14 (5.1%) 
Employment status    
 Employed 16 (21.1%) 88 (44.0%) 104 (37.7%) 
 Unemployed 60 (78.9%) 112 (56.0%) 172 (62.3%) 
Education    
 No formal education 11 (14.5%) 3 (1.5%) 14 (5.1%) 
 Primary school 27 (35.5%) 26 (13.0%) 53 (19.2%) 
 Secondary school 30 (39.5%) 85 (42.5%) 115 (41.7%) 
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 Polytechnic/diploma 8 (10.5%) 49 (24.5%) 57 (20.7%) 
 University/postgraduate 0 (0.0%) 37 (18.5%) 37 (13.4%) 
Cancer types    
 Lymphoma 15 (19.7%) 52 (26.0%) 67 (24.3%) 
 Breast cancer 23 (30.3%) 76 (38.0%) 99 (35.9%) 
 Colorectal cancer 7 (9.2%) 19 (9.5%) 26 (9.4%) 
 Lung cancer 6 (7.9%) 5 (2.5%) 11 (4.0%) 
 Others 25 (32.9%) 48 (24.0%) 73 (26.4%) 
Cancer Stage    
 I 9 (11.8%) 23 (11.5%) 32 (11.6%) 
 II 13 (17.1%) 31 (15.5%) 44 (15.9%) 
 III 18 (23.7%) 56 (28.0%) 74 (26.8%) 
 IV 21 (27.6%) 63 (31.5%) 84 (30.4%) 
 Unknown 15 (19.7%) 27 (13.5%) 42 (15.2%) 
ECOG performance status    
 0 25 (32.9%) 126 (63.0%) 151 (54.7%) 
 1 28 (36.8%) 50 (25.0%) 78 (28.3%) 
 2 20 (26.3%) 19 (9.5%) 39 (14.1%) 
 3 3 (3.9%) 5 (2.5%) 8 (2.9%) 
Neutropenia grade at nadir    
 2 21 (27.6%) 49 (24.5%) 70 (25.4%) 
 3 18 (23.7%) 50 (25.0%) 68 (24.6%) 
 4 37 (48.7%) 101 (50.5%) 138 (50.0%) 
Presence of fever    
 Yes 48 (63.2%) 128 (64.0%) 176 (63.8%) 
 No 28 (36.8%) 72 (36.0%) 100 (36.2%) 
ECOG = Eastern Cooperative Oncology Group; SD = standard deviation. 
 
7.3.1 Reliability 
7.3.1.1 Chinese version of FACT-N 
The PWB, SWB, FWB and NS of the Chinese version of FACT-N demonstrated 
good internal consistency, indicated by Cronbach’s α that were above 0.80 
(Table 25). The EWB subscale showed acceptable internal consistency, with 
Cronbach’s α of 0.75. Item-to-subscale correlations were in the acceptable 
range for the SWB and FWB subscales (ranged from 0.31 to 0.81). Item-to-
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correlations were poor for GP3 in PWB (Because of my physical condition, I 
have trouble meeting the needs of my family; r = 0.08) and GE2 in EWB (I am 
satisfied with how I am coping with my illness; r = 0.26). Seventh out of 
nineteen items (89%) within the NS had acceptable item-to-subscale 
correlations, however, item-to-subscale correlations were poor for ES3 (I have 
night sweats; r = 0.06) and N6 (I have mouth sores; r = 0.24). Internal 
consistency was good for the Malaise subscale in NS (α = 0.81). However, the 
Worry subscale and the Flu-like Symptoms subscale in NS did not demonstrate 
satisfactory internal consistency (α = 0.68 and 0.62, respectively). For the Flu-
like Symptoms subscale in NS, the item ES3 (I have night sweats; r = 0.18) 
showed poor item-to-subscale correlation. 
 
Table 25. Cronbach’s α and corrected item-to-subscale correlation of the 








No of items with 
acceptable convergence 
/ Total (%) 
PWB 0.82 0.08-0.73 6/7 (86) 
SWB 0.84 0.43-0.81 7/7 (100) 
EWB 0.75 0.26-0.56 5/6 (83) 
FWB 0.83 0.31-0.70 7/7 (100) 
NS 0.85 0.06-0.59 17/19 (89) 
   Malaise 0.81 0.34-0.65 8/8 (100) 
   Worry 0.68 0.35-0.57 5/5 (100) 
   Flu-like 
Symptoms  
0.62 0.18-0.61 2/3 (67) 
EWB = Emotional Well-being; FWB = Functional Well-being; PWB = 




7.3.1.2 English version of FACT-N 
The SWB, EWB, FWB and NS of the English version of FACT-N demonstrated 
good internal consistency, indicated by Cronbach’s α that were above 0.80 
(Table 26). The PWB subscale showed acceptable internal consistency, with 
Cronbach’s α of 0.79. Item-to-subscale correlations were in the acceptable 
range for the PWB, SWB, EWB, and FWB subscales (ranged from 0.38 to 
0.75). Fifteen out of nineteen items (79%) within the NS had acceptable item-
to-subscale correlations. However, item-to-subscale correlations were poor for 
ES3 (I have night sweats; r = 0.22), An13 (I am motivated to do my usual 
activities; r = 0.19), N7 (My partner worries about me when my blood counts 
are low; r = 0.29), and N8 (My low blood counts interfere with my intimate 
relationships; r = 0.25). Internal consistency was good for the Malaise subscale 
in NS (α = 0.84), but the item-to-subscale correlation was poor for An13 (I am 
motivated to do my usual activities; r = 0.26). The internal consistency for the 
Worry subscale in NS was acceptable (α = 0.71). However, the Flu-like 
Symptoms subscale in NS did not demonstrate satisfactory internal consistency 





Table 26. Cronbach’s α and corrected item-to-subscale correlation of the 








No of items with 
acceptable convergence 
/ Total (%) 
PWB 0.79 0.42-0.66 7/7 (100) 
SWB 0.82 0.54-0.66 7/7 (100) 
EWB 0.82 0.43-0.71 6/6 (100) 
FWB 0.82 0.38-0.75 7/7 (100) 
NS 0.85 0.19-0.69 15/19 (79) 
   Malaise 0.84 0.26-0.76 7/8 (88) 
   Worry 0.71 0.30-0.67 5/5 (100) 
   Flu-like 
Symptoms  
0.68 0.29-0.66 2/3 (67) 
EWB = Emotional Well-being; FWB = Functional Well-being; PWB = 
Physical Well-being; SWB = Social Well-being; NS = Neutropenia Subscale. 
 
7.3.2 Known groups validity 
7.3.2.1 Chinese version of FACT-N 
Table 27 showed the results for known group validity of the Chinese version of 
FACT-N. For known groups by ECOG status and the presence of fever, NS and 
FACT-N scores were in line with the hypothesis. However, for the known group 
by neutropenia grade, none of the NS, FACT-N, and EQ-5D utility index scores 
were in line with the hypothesis. The EQ-5D and FACT-N were only able to 
differentiate patients on the basis of ECOG performance status (p < 0.001 and 
p = 0.002, respectively). There was no significant difference on NS scores on 
the basis of ECOG performance status, neutropenia grade, and the presence of 
fever.  
 
7.3.2.2 English version of FACT-N 
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Table 28 showed the results for known group validity of English version of 
FACT-N. For each known group, NS, FACT-N, and the EQ-5D utility index 
scores were in line with the hypothesis. The EQ-5D was able to differentiate 
patients on the basis of ECOG performance status (p < 0.001) and neutropenia 
grade (p = 0.009). Both NS score and FACT-N total score were statistically 
significantly different on the basis of neutropenia grade (p < 0.001 and p = 
0.009, respectively) and presence of fever (p < 0.001 and p = 0.001, 
respectively). In addition, patients with better performance status (ECOG 
Grades 1 and 2) reported significantly higher scores than those with poorer 






Table 27. Known group validity according to ECOG performance status, neutropenia grade, and presence of fever 
(Chinese version of FACT-N, N=76) 
 ECOG performance status Neutropenia grade Presence of fever 
 
0 & 1 
n = 53 
2 & 3 
n = 23 
p-value 
2 & 3 
n = 39 
4 
n = 37 
p-value 
No 
n = 28 
Yes 
n = 48 
p-value 
PWB 19.04 ± 5.84 14.09 ± 5.98 0.002 17.26 ± 6.60 17.84 ± 5.98 0.688 18.75 ± 6.15 16.83 ± 6.30 0.199 
SWB 21.73 ± 4.73 19.18 ± 8.61 0.192 21.49 ± 5.63 20.40 ± 6.82 0.451 21.25 ± 5.87 20.79 ± 6.47 0.753 
EWB 18.38 ± 4.75 18.04 ± 4.71 0.779 17.79 ± 5.02 18.78 ± 4.37 0.362 19.18 ± 4.30 17.75 ± 4.90 0.190 
FWB 13.62 ± 6.12 8.91 ± 4.59 0.001 12.44 ± 6.60 11.95 ± 5.56 0.727 13.04 ± 6.24 11.71 ± 5.99 0.368 















Malaise 17.92 ± 
13.30 
13.30 ± 4.93 0.002 16.13 ± 7.23 16.95 ± 6.02 0.593 17.14 ± 6.90 16.17 ± 6.52 0.546 
Worry 10.96 ± 4.82 10.22 ± 5.11 0.556 10.51 ± 5.10 10.97 ± 4.71 0.684 11.93 ± 4.40 10.04 ± 5.07 0.093 
FLS 9.38 ± 2.80 9.04 ± 2.55 0.613 9.41 ± 2.59 9.14 ± 2.87 0.663 10.64 ± 1.64 8.48 ± 2.91 <0.001 















EQ-5D 0.74 ± 0.17 0.38 ± 0.22 <0.001 0.58 ± 0.25 0.68 ± 0.24 0.062 0.62 ± 0.25 0.63 ± 0.25 0.827 
ECOG = Eastern Cooperative Oncology Group; EWB = Emotional Well-being; FWB = Functional Well-being; PWB = Physical 





Table 28. Known group validity according to ECOG performance status, neutropenia grade, and presence of fever 
(English version of FACT-N, N=200) 
 ECOG performance status Neutropenia grade Presence of fever 
 
0 & 1 
n = 176 
2 & 3 
n = 24 
p-value 
2 & 3 
n = 99 
4 
n = 101 
p-value 
No 
n = 72 
Yes 
n = 128 
p-value 
PWB 16.82 ± 6.51 12.08 ± 7.00 0.004 16.99 ± 6.62 15.53 ± 6.80 0.127 17.50 ± 6.49 15.55 ± 6.79 0.047 
SWB 23.00 ± 5.77 21.08 ± 5.19 0.105 22.53 ± 5.88 23.00 ± 5.59 0.559 22.66 ± 6.05 22.83 ± 5.56 0.844 
EWB 19.18 ± 5.35 15.58 ± 5.17 0.003 19.22 ± 5.24 18.28 ± 5.62 0.220 19.34 ± 5.48 18.41 ± 5.41 0.244 
FWB 16.96 ± 7.00 12.79 ± 6.78 0.008 17.23 ± 6.62 15.70 ± 7.47 0.127 16.43 ± 6.84 16.48 ± 7.25 0.964 















Malaise 17.17 ± 7.11 13.96 ± 7.53 0.058 17.82 ± 7.01 15.77 ± 7.30 0.044 18.20 ± 7.16 15.99 ± 7.15 0.038 
Worry 8.20 ± 4.74 8.96 ± 5.86 0.548 9.03 ± 4.76 7.56 ± 4.91 0.033 10.24 ± 4.98 7.20 ± 4.48 <0.001 
FLS 8.53 ± 3.19 6.79 ± 3.15 0.017 9.41 ± 2.80 7.26 ± 3.27 <0.001 10.81 ± 1.73 6.93 ± 3.03 <0.001 















EQ-5D 0.78 ± 0.23 0.45 ± 0.26 <0.001 0.79 ± 0.24 0.69 ± 0.26 0.009 0.77 ± 0.23 0.72 ± 0.27 0.241 
ECOG = Eastern Cooperative Oncology Group; EWB = Emotional Well-being; FWB = Functional Well-being; PWB = Physical 
Well-being; SD = standard deviation; SWB = Social Well-being; NS = Neutropenia Subscale; FLS = Flu-like Symptoms 
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7.3.3 Convergent validity 
7.3.3.1 Chinese version of FACT-N 
A moderate correlation between the FACT-N total score and the EQ-5D utility 
index score was observed (|r| = 0.43) (Table 29). The FACT-N’s PWB subscale 
score showed weak correlation with the EQ-5D’s Pain/Discomfort domain (|r| 
= 0.37). The FACT-N’s EWB subscale score was weakly correlated with the 
EQ-5D’s Anxiety/Depression domain (|r| = 0.35). A moderate correlation was 
also observed between the FACT-N’s FWB subscale score and the EQ-5D’s 
Usual Activity domain (|r| = 0.43). For the FACT-N’s NS score, no significant 
correlations were observed with EQ-5D’s Anxiety/Depression domain and 
Pain/Discomfort domain. In addition, the EQ-5D utility index score was found 
to moderately correlate with the Malaise subscale in NS (|r| = 0.43). The Worry 












7.3.3.2 English version of FACT-N 
A moderate correlation between the FACT-N total score and the EQ-5D utility 
index score was observed (|r| = 0.44) (Table 30). The FACT-N’s PWB subscale 
score showed weak correlation with the EQ-5D’s Pain/Discomfort domain (|r| 
= 0.37). The FACT-N’s EWB subscale score was moderately correlated with 
the EQ-5D’s Anxiety/Depression domain (|r| = 0.46). A weak correlation was 
also observed between the FACT-N’s FWB subscale score and the EQ-5D’s 
Usual Activity domain (|r| = 0.34). For the FACT-N’s NS score, it was 
moderately correlated with EQ-5D’s Anxiety/Depression domain (|r| = 0.41) 
and weakly correlated with Pain/Discomfort domain (|r| = 0.30). In addition, the 
EQ-5D utility index score was found to moderately correlate with the Malaise 
subscale in NS (|r| = 0.40). The Worry subscale in NS was weakly correlated 

















PWB -0.29a -0.33b -0.38b -0.37b -0.32b 0.48b 
SWB -0.15 -0.13 -0.26a -0.02b 0.16 0.15 
EWB -0.08 -0.10 -0.13 -0.38b -0.35b 0.25a 
FWB -0.32b -0.32b -0.43b -0.26a -0.18 0.44b 
NS -0.12 -0.26a -0.25a -0.12 -0.19 0.22 
   Malaise -0.30b -0.37b -0.39b -0.23a -0.25a 0.43b 
   Worry 0.05 -0.17 0.00 -0.00 -0.05 -0.02 
   Flu-like Symptoms 0.07 0.09 -0.13 -0.01 -0.14 0.00 
FACT-N (Total) -0.30b -0.35b -0.42b -0.26a -0.23 0.43b 
EWB = Emotional Well-being; FWB = Functional Well-being; PWB = Physical Well-being; SD = standard deviation; SWB 
= Social Well-being; NS = Neutropenia Subscale. a Correlation is significant at the 0.05 level (2-tailed); b Correlation is 
significant at the 0.01 level (2-tailed). Bolded values represent a Spearman’s correlation coefficient with an absolute value 


















PWB -0.30b -0.22b -0.21b -0.37b -0.25b 0.40b 
SWB -0.00 -0.02 -0.08 -0.23b -0.16a 0.18a 
EWB -0.13 -0.09 -0.24b -0.30b -0.46b 0.39b 
FWB -0.25b -0.15a -0.34b -0.28b -0.22b 0.37b 
NS -0.14a -0.10 -0.12 -0.30b -0.41b 0.30b 
   Malaise -0.32b -0.26b -0.25b -0.28b -0.31b 0.40b 
   Worry 0.04 -0.03 0.09 -0.10 -0.39b 0.08 
   Flu-like Symptoms -0.03 0.09 -0.11 -0.21b -0.19b 0.15a 
FACT-N (Total) -0.24b -0.17a -0.26b -0.40b -0.42b 0.44b 
EWB = Emotional Well-being; FWB = Functional Well-being; PWB = Physical Well-being; SD = standard deviation; SWB 
= Social Well-being; NS = Neutropenia Subscale. a Correlation is significant at the 0.05 level (2-tailed); b Correlation is 
significant at the 0.01 level (2-tailed). Bolded values represent a Spearman’s correlation coefficient with an absolute value 




7.3.4 Measurement equivalence  
For all subscales of the FACT-N, the unadjusted and adjusted results generated 
from the linear regression models were shown in Table 31. After adjusting for 
the covariates, the 95% CI for adjusted difference on FACT-N total scores and 
domain scores (PWB, SWB, EWB, and NS) between Chinese and English 
versions were within the 0.5 SD margin, suggesting an acceptable measurement 
equivalence between the two language versions. However, the 95% CI of the 
difference between the Chinese and English versions in FWB domain scores 
and the Worry subscale scores in NS were partially overlapped with the 
predefined equivalence margin of 0.5 SD. This revealed that the measurement 
equivalence between the Chinese and English versions was uncertain in the 














Table 31. Results and measurement equivalence between English and Chinese versions of the FACT-N 
 
Mean Score ± SD English vs. Chinese 
English & 
Chinese 
(n = 276) 
English 
(n = 200) 
Chinese 
(n = 76) 
Equivalence 
margin 









PWB 16.61 ± 6.63 16.26 ± 6.74 17.54 ± 6.27 ± 3.313 -1.284 (-3.040 to 0.470) -1.273 (-3.215 to 0.670) 
SWB 22.27 ± 5.91 22.77 ± 5.73 20.96 ± 6.22 ± 2.955 1.806 (0.250 to 3.362)c 1.234 (-0.427 to 2.896) 
EWB 18.62 ± 5.25 18.75 ± 5.44 18.28 ± 4.71 ± 2.623 0.469 (-0.924 to 1.861) 0.982 (-0.581 to 2.546) 
FWB 15.29 ± 7.07 16.46 ± 7.09 12.20 ± 6.08 ± 3.537 4.263 (2.452 to 6.073)c  4.696 (2.684 to 6.708)c 
NS 43.78 ± 13.33 43.01 ± 13.44 45.82 ± 12.92 ± 6.665 -2.813 (-6.340 to 0.714) -2.365 (-6.196 to 1.466) 
Malaise 16.72 ± 7.05 16.79 ± 7.22 16.53 ± 6.64 ± 3.525 0.262 (-1.612 to 2.135) 0.165 (-1.895 to 2.225) 
Worry 8.96 ± 5.00 8.29 ± 4.88 10.74 ± 4.89 ± 2.498 -2.447 (-3.742 to -1.152)c -2.341 (-3.757 to -0.925)c 
FLS 8.59 ± 3.12 8.33 ± 3.22 9.28 ± 2.72 ± 1.558 -0.951 (-1.772 to -0.131)c -0.574 (-1.477 to 0.330) 






± 13.762 2.440 (-4.869 to 9.749) 3.275 (-4.824 to 11.374) 
CI = confidence interval; EWB = Emotional Well-being; FWB = Functional Well-being; FLS = Flu-like Symptoms; PWB = 
Physical Well-being; SD = standard deviation; SWB = Social Well-being; NS = Neutropenia Subscale. 
a 
Linear regression was 
used, difference = the English version group – the Chinese version group (reference group); 
b 
Mean difference adjusted to 
demographic variables: age, gender (male vs. female), marital status (married vs. single/separated/divorced/widowed), employment 
status (employed vs. unemployed), education (university/polytechnic/secondary school vs. primary school/no formal education); 
c
The 95% CI exceeded the  0.5 SD equivalence margin threshold.  
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7.4 Discussion 
To the best of our knowledge, this is the first study that evaluated the 
psychometric properties of the FACT-N among multi-ethnic Asian patients of 
various types of cancer undergoing chemotherapy. It has been revealed that the 
English and Chinese versions of the FACT-N total scores are equivalent at the 
equivalence margin of 0.5 SD. In addition, our results suggest that the English 
version of FACT-N is a valid and reliable tool to measure the HRQoL among 
Asian cancer patients with CIN in Singapore. For the Chinese version of FACT-
N, its reliability has been demonstrated as satisfactory. However, the known-
group validity and convergent validity of Chinese version of FACT-N have not 
been fully demonstrated.  
 
In this study, both Chinese and English versions of FACT-N demonstrated good 
reliability to measure the HRQoL in patients with CIN. For English version of 
FACT-N, the internal consistency (Cronbach’s α) of all the FACT-N subscales, 
except for the Flu-like Symptoms subscale in NS, were within the acceptable to 
good range (α = 0.71-0.85). In addition, the item-to-subscale correlations have 
revealed that most of the items in English version of FACT-N correlated well 
with their subscales (r > 0.3), indicating a satisfactory construct validity of 
FACT-N. However, poor item-to-subscale correlations were observed with ES3 
(I have night sweats; r = 0.22), An13 (I am motivated to do my usual activities; 
r = 0.19), N7 (My partner worries about me when my blood counts are low; r = 
0.29), and N8 (My low blood counts interfere with my intimate relationships; r 
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= 0.25). Previously, a similar validation conducted in US identified that ES3 
had a poor item-total correlation within the subscale of NS (r < 0.20) [61]. This 
is consistent with the findings in our study. For item An13, the poor correlation 
could be due to the varying interpretation on the term “usual activities” [154]. 
For item N7, it could be affected by the patient’s marital status, as some patients 
who are single or divorced may find this question not applicable to themselves. 
In addition, for item N8, it has been observed during the interview that some of 
the patients were confused with the term “intimate relationships”. It was 
because patients normally perceived “intimate relationships” as the relationship 
between husband and wife. However, for those patients who are single or do 
not have a partner, we observed that some of them would consider this question 
as not applicable and have a trend to report “None of the time” for this question. 
Future study should consider refining this question to achieve better responses 
from patients. Similarly, for the Chinese version of FACT-N, the internal 
consistency of all the FACT-N subscales, except for the Worry subscale and 
Flu-like Symptoms subscale in NS, were within the acceptable to good range (α 
= 0.75-0.85). In addition, the item-to-subscale correlations have revealed that 
most of the items in Chinese version of FACT-N correlated well with their 
subscales (r > 0.3), indicating a satisfactory construct validity of FACT-N. 
However, poor item-to-subscale correlations were observed with GP3 in PWB 
(Because of my physical condition, I have trouble meeting the needs of my 
family; r = 0.08), GE2 in EWB (I am satisfied with how I am coping with my 
illness; r = 0.26), ES3 in NS (I have night sweats; r = 0.06), and N6 in NS (I 
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have mouth sores; r = 0.24). The poor item-to-subscale correlation on ES3 is 
consistent with the findings in the previous US study [61]. For GP3, GE2, and 
N6, the poor item-to-subscale correlations could be due to patient’s different 
perceptions on the items translated into Chinese version. However, considering 
the relatively small sample size included in the Chinese version of FACT-N 
(n=76), future study with larger sample size is needed to make robust 
conclusions. 
 
The English version of FACT-N had also demonstrated known group validity 
to differentiate patient groups based on clinical characteristics. For the English 
version of FACT-N total score or the NS score, it was revealed that the group 
differences were in the same direction as hypothesized and consistent with the 
findings derived from the EQ-5D. The English version of FACT-N total score 
could distinguish patients according to their ECOG status (p value = 0.002), 
neutropenia grade (p value = 0.009), and the experience of fever (p value = 
0.001). In contrast, EQ-5D was only able to differentiate patients based on the 
ECOG status and neutropenia grade (p value < 0.001 and p value = 0.009, 
respectively). This demonstrates that the English version of FACT-N total score 
could be more useful than generic instrument such as EQ-5D to measure the 
specific concerns related to fever. In addition, for the English version of FACT-
N total score, group differences according to the ECOG status, neutropenia 
grade, and the experience of fever were around or beyond the minimal clinically 
important differences defined in a previous FACT-N validation study (FACT-
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N = 8-11 points) [61]. Therefore, the differences between known groups on the 
English version of FACT-N total score were not only statically significant, but 
also clinically important in this study. From these results, we propose that the 
English version of FACT-N could serve as a tool to capture the health status 
and allow clinicians to assess the impact of chemotherapy on HRQoL, 
particularly among those patients who are at high risks for neutropenia-related 
complications. For example, in patients who suffer from neutropenic fever after 
chemotherapy, this tool may provide guidance to clinicians whether the patients 
suffer from poor HRQoL, hence requiring supportive care intervention such as 
the use of G-CSF to alleviate the impact of neutropenia-related toxicities. Future 
studies should evaluate this intervention strategy in a well-designed, robust 
clinical trial. However, for the Chinese version of FACT-N, the total score could 
only distinguish patients according to their ECOG status (p value = 0.002), and 
its known group validity on the basis of neutropenia grade and presence of fever 
is not satisfactory.  
 
The convergent validity of the English and Chinese versions of FACT-N were 
evaluated by contrasting with EQ-5D. As hypothesized, the English and 
Chinese versions of FACT-N total score correlate moderately with the EQ-5D 
utility index score (|r| = 0.44 and 0.43, respectively). This demonstrates the 
convergent validity of using the FACT-N total score to capture the HRQoL of 
patients with CIN. Specifically, most of the subscales in FACT-N correlate 
moderately or weakly with the EQ-5D domains as we hypothesized in priori. 
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The English version of FACT-N’s PWB subscale correlated weakly with the 
EQ-5D’s Pain/Discomfort domain (|r| = 0.37). However, compared to the other 
subscales in the English version of FACT-N, PWB showed the strongest 
correlation with the EQ-5D’s Pain/Discomfort domain. This is consistent with 
the findings in another similar validation study in Singapore [155]. Similarly, 
the FACT-N’s NS score demonstrated the strongest correlation with the 
Pain/Discomfort domain (|r| = 0.30) and Anxiety/Depression domain (|r| = 0.41) 
in EQ-5D, although they were weakly or moderately correlated. The main 
reason for this weak correlation could be due to the different measurement scope 
of these two instruments. The EQ-5D measures HRQoL on the day of the 
interview, whereas the FACT-N measures HRQoL in the preceding 7 days. 
Therefore, the results could be varied due to different measurement scope. For 
the Chinese version of FACT-N, its NS score was not significantly correlated 
with EQ-5D’s Anxiety/Depression domain and Pain/Discomfort domain, which 
was against the priori hypothesis. In addition, its Worry subscale in NS was not 
found significantly correlated with the EQ-5D’s Anxiety/Depression domain. 
These makes the convergent validity of Chinese version of FACT-N remain 
questionable, and future study with larger sample size is needed to demonstrate 
its convergent validity. 
 
There are a few limitations in our study. Firstly, in this study, the measurement 
equivalence between the Chinese and English versions was not established for 
the FWB domain and the Worry subscale in NS. Therefore, cautions need to be 
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taken when one interprets the FWB domain scores and the Worry subscale 
scores pooled from Chinese and English versions. Secondly, it should be noted 
that the measurement equivalence assessed in this study was only on the scale 
level. Measurement equivalence for each individual item was not evaluated as 
it would require a larger sample size. With a larger sample size, measurement 
equivalence between Chinese and English versions of FACT-N should be 
further evaluated using sophisticated psychometric methods such as the 
differential item functioning based on item response theory. Thirdly, it was 
difficult to evaluate the test-retest reliability in this cross-sectional study 
because the rapid fluctuations on ANC among those patients experiencing CIN 
would require the investigators to repeatedly administer the FACT-N 
questionnaire to patients within several days [61]. This was hard to practice in 
the rapidly changing clinical situations. Therefore, the test-retest reliability was 
not included in this validations study due to the lack of data on responsiveness. 
Furthermore, it should be noted that the validity of Chinese version of FACT-
N has not been fully demonstrated, which could be due to the relatively small 
sample size. Future study with larger sample size is needed to further evaluate 
the validity of Chinese version of FACT-N in local population. Lastly, it should 
be noted that among the samples included in this study, the majority were 
female, unemployed and diagnosed with breast cancer. Cautions need to be 
taken when our findings are generalized to other patient populations, as the 
difference on patients’ clinical and demographic characteristics might have an 




This study demonstrates that the English version of FACT-N is a valid and 
reliable instrument to be used in clinical practice to evaluate the HRQoL among 
multi-ethnic Asian patients with CIN in Singapore. The two language versions 
of FACT-N have demonstrated comparable measurement results, although 
measurement equivalence on the FWB subscales and the Worry subscales in 
NS between the English and Chinese versions needs to be further investigated. 
These findings support the English version of FACT-N to be used as an 
instrument to assess HRQoL instrument in future studies conducted among 
multi-ethnic Asian population in Singapore, and also highlighted a need to 





















Chapter 8. Development and validation of a prognostic 
model for risk stratification of cancer patients with 













Patients with FN constitute a heterogeneous population with varying risks of 
developing complications, and not all the patients manifesting FN require the 
standard intensity of treatment, including hospitalization and empiric treatment 
with antibiotics [3,32]. Alternative simpler treatment strategies, such as early 
hospital discharge or outpatient treatment with oral antibiotics, can be 
considered among low-risk patients with FN, which may lead to potential 
savings in resources, improvement in patients’ HRQoL, and lower the incidence 
of nosocomial-associated infections [3]. 
 
Over the years, several studies have sought to develop prognostic models to 
stratify the risk of developing serious complications among patients manifesting 
FN [31,156,157]. The Talcott model was first developed and validated to 
differentiate between low-risk patients with FN and high-risk patients with FN 
in 1988 [156,158]. As a further improvement on the Talcott model, the MASCC 
risk index was developed [31], and has been widely utilized as a prognostic 
model to identify patients with FN who are at low-risk of developing 
complications [159-163]. Although the MASCC risk index has been well 
accepted by the existing guidelines for identification on patients who are at low 
risk for complications of FN [1,3,32], its specificity is relatively low and still 
requires improvement [34]. In addition, it was reported that a proportion of low-
risk patients identified by the MASCC risk index, who is eligible for alternative 
early discharge and outpatient management, refused to get early discharged and 
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were still managed inpatient [59]. This reflects that the current MASCC risk 
index does not take into account on patients’ self-perception of their own health 
status. 
 
PRO describes a patient’s health status from patient’s perspective, and allow a 
patient to directly report their feeling, function, and perception on their HRQoL 
[60]. The measurement on PRO has shown its attractiveness in highlighting 
imperative issues, improving patient outcomes, and promoting patient-centered 
care [164,165]. In addition, the PRO measure can facilitate earlier detection of 
symptoms than other measures, and has demonstrated its prognostic 
significance for cancer survival [166,167]. One recent review reported that 
patient’s self-reported health status, including the symptoms and functional 
issues, could be prognostic for survival outcomes among a variety of cancer 
patients with solid tumors [168]. In other health conditions such as chronic 
obstructive pulmonary disease, PRO was revealed to be predictive for disease 
exacerbations and deterioration [169]. Considering the prognostic value of PRO 
on the adverse events, it is of interest to explore the use of PRO as a prognostic 
factor to improve the performance of the MASCC risk index on predicting the 
development of serious complications among patients with FN. Therefore, the 
primary objective of this study is to develop and validate a prognostic model by 
incorporating PRO and MASCC risk index (PROMASCC), for identifying 
patients with low-risk of developing serious complications of FN. The 
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secondary objective is to compare the performance of (i) MASCC risk index, 
and (ii) PROMASCC model. 
 
8.2 Methods 
8.2.1 Study design and patients 
This was a single-centre, cross-sectional observational study, conducted 
between August 2014 and April 2016 at SGH. This study was approved by 
Singhealth Centralised institutional Review Board. Written informed consent 
was obtained from all participants prior to study enrollment. 
 
Patients were included in the study if they fulfilled the following inclusion 
criteria: (1) age 16 years and older, (2) confirmed diagnosis of solid tumors or 
lymphomas, (3) experienced a single oral or tympanic temperature of >38.0°C, 
(4) an ANC of <0.5 x 109/L or a count with a predicted decrease to <0.5 x 109/L 
during next 48 hours, and (5) received chemotherapy within the past one month 
prior to the episode of FN. Patients were excluded if they are: (1) too ill to 
respond, (2) admitted to the intensive care unit (ICU), (3) unwilling to give 
informed consent, or (4) unable to understand English or Chinese. For patients 
who experienced multiple febrile episodes, only the first febrile episode 
occurred during the study period was considered. 
 
8.2.2 Measures  
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Patient’s socio-demographic characteristics and clinical information were 
collected from electronic databases and medical notes. The MASCC risk index 
was evaluated within the first 24-hour of fever onset. Patients with a MASCC 
risk index of ≥ 21 are regarded as low-risk of developing serious medical 
complications, while patients with a risk index of < 21 as high-risk. The FACT-
N questionnaire was administered by face-to-face interview to patients within 7 
days of their FN onset prior to discharge. Either English or Chinese version of 
the FACT-N was used, according to patient’s own language preference. The 
ECOG performance status was assessed during the interview.  
 
The FACT-N questionnaire was selected because it was the only HRQoL 
instrument that captured the neutropenia-specific concerns from different 
domains, and can provide a specific measurement on the HRQoL among cancer 
patient with neutropenia. In Chapter 7, the Chinese version of FACT-N was 
developed based on its English version, using the translation and linguistic 
validation method provided by the FACIT organization [103]. In addition, the 
psychometric properties and the measurement equivalence between the English 
and Chinese versions have already been established for most of the domain and 
total scores [103].  
 
8.2.3 Outcomes 
The outcome variable was the occurrence of a serious medical complication. 
Table 32 listed all the medical conditions that are defined as serious medical 
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complications in this study, which were derived based on the Klastersky study 
[31]. The observation period was from the FN onset date until fever resolution 
for 5 consecutive days. If patients were discharged prior to fever resolution for 
5 consecutive days, the observation would be continued, to check whether 
patients experienced readmission due to recurrent fever. Patients were then 
categorized as (1) without serious medical complication during the observation 
period (favorable outcome), or (2) with a serious medical complication during 
the observation period (poor outcome). 
 
Table 32. Medical complications considered serious 
 Arrhythmia or electrocardiogram changes requiring active treatment 
 Severe bleeding episode that requires transfusion 
 Confusion or altered mental state 
 Congestive cardiac failure seen on chest x-ray and requiring treatment 
 Death before fever resolution  
 Disseminated intravascular coagulation 
 Hypotension (defined as systolic blood pressure less than 90 mmHg or 
requiring pressor support to maintain blood pressure) 
 Intensive care unit admission 
 Persistence of positive blood cultures or breakthrough bacteremia 
 Proven invasive or superficial fungal infection  
 Allergic reaction 
 Hospital readmission before complete fever resolution (related to 
neutropenic episode) 
 Renal failure requiring investigation and/or treatment with IV fluids, 
dialysis, or any other intervention 
 Respiratory failure: arterial oxygen pressure less than 60 mmHg while 
breathing room air or need for mechanical ventilation 





8.2.4 Derivation and evaluation of the PROMASCC model 
Univariate analyses were performed to select a first set of statistically 
significant covariates for inclusion in a multivariate model, and all the 
covariates with a P value less than 0.05 for the null hypothesis of no effect were 
considered. The domain scores and total scores of FACT-N were tested in the 
univariate analyses, which include the PWB, FWB, SWB, EWB, FACT-G total 
score, FACT-N total score, NS, Malaise subscale, Worry subscale, and Flu-like 
symptom subscale. 
 
Continuous variables identified as significant in the univariate analyses were 
further categorized based on the minimum P-value approach [170]. The effect 
of taking various cut-off points was evaluated and the one that corresponds to 
the lowest P value relating the covariate to the outcome was selected [170]. 
After categorization of significant covariate identified in the univariate 
analyses, a multiple logistic regression model was performed by incorporating 
the categorized PRO covariates and categorized MASCC risk index (≥21). A 
backward selection procedure was used for the selection of covariates, and a 
two-sided P value greater than 0.05 results in removal from the model. 
Covariate coefficient and its odds ratio (OR) with 95% CI were calculated. 
 
Based on the coefficient estimates of included covariates in multivariate logistic 
model, a PROMASCC score was calculated for each patient. The nearest integer 
of each factor’s coefficient estimate in the logistic model was assigned as its 
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weight. The sum of these individual weights was the PROMASCC score. A 
higher PROMASCC score is associated with a greater likelihood of having 
favorable outcome, which is fever resolution without serious complications. 
Several prediction rules were generated based on the PROMASCC model, using 
each possible value of the score as a threshold. Patients were classified as low-
risk for serious complications if their PROMASCC scores were higher than the 
thresholds. The cut-off point associated with the lowest misclassification rate 
was identified as the optimal threshold for PROMASCC model. 
 
The sensitivity, specificity, positive predictive value (PPV), negative predictive 
value (NPV), AUC, and misclassification rate of the PROMASCC model (with 
the optimal threshold) were evaluated and compared with the MASCC risk 
index, in which true positive cases were those predicted as low-risk and indeed 
recovered from FN without developing serious complications. 
 
8.2.5 Internal validation of the PROMASCC model 
The c-statistic, which is equivalent to the AUC, was calculated to assess the 
model discrimination. Bootstrapping technique was used to validate the 
PROMASCC model (with the optimal threshold), because it was reported that 
the internal validity of a predictive logistic model could be best estimated by 
bootstrapping, when compared to other validation techniques, such as the cross-
validation and split-sample analyses [171]. Bootstrap samples were drawn 
repeatedly (repetition = 5,000) with replacement from the original sample, and 
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each bootstrap sample is of the same size as the original sample [172]. A 
prediction model was developed in each bootstrap sample, and its performance 
was evaluated separately both in the bootstrap sample and in the original sample 
[172]. The difference in performance (“bootstrap performance” minus “test 
performance in original sample”) represents the optimism, and the model 
optimism which was averaged across all the bootstrap iterations was then 
subtracted from the original model performance in the original sample to 
generate the optimism-corrected performance estimate [172]. All the statistical 




8.3.1 Overall patient characteristics 
Between August 2014 and April 2016, one hundred and twenty patients were 
included in the analysis from a total of 163 patients with FN recruited (response 
rate = 73.6%). Basic demographics and clinical information of included patients 
were summarized in Table 33. The mean (±SD) age was 54.8 (±12.6) years. 
Majority of patients were female (n = 82, 68.3%) and Chinese (n = 91, 75.8%). 
The population comprises a various group of cancer types, with breast cancer 
(n = 59, 49.2%) and lymphoma (n = 32, 26.7%) being the most common. Most 
of the patients were outpatient when the fever occurred (n = 90, 75.0%). The 
number of patients completed the Chinese and English versions of FACT-N 
questionnaires were 34 (28.3%) and 86 (71.7%), respectively. Ninety-nine 
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patients (82.5%) had a MASCC risk index ≥ 21 on the FN onset date. Complete 
resolution of fever without complications occurred in 78 patients (65.0%), and 
42 patients (35.0%) developed at least one serious complication.  
 
Table 33. Characteristics of patients (n=120) 
Characteristics  
Age, years, mean (SD) 54.8 (12.6) 
Gender, n (%)  
Male  38 (31.7) 
Female 82 (68.3) 
Ethnicity, n (%)  
Chinese 91 (75.8) 
Malay 16 (13.3) 
Indian  7 (5.8) 
Others  6 (5.0) 
Underlying cancer type, n (%)  
Lymphoma 32 (26.7) 
Breast cancer 59 (49.2) 
Colorectal cancer 6 (5.0) 
Prostate cancer 3 (2.5) 
Cervical cancer 2 (1.7) 
Lung cancer 2 (1.7) 
Others 16 (13.3) 
Cancer stage, n (%)  
I/II 31 (25.8) 
III/IV 59 (49.2) 
Unknown 30 (25.0) 
ECOG performance status, n (%)  
0-1 92 (76.7) 
2-4 28 (23.3) 
Hospitalization status at fever onset, n (%)  
Outpatient 90 (75.0) 
Inpatient 30 (25.0) 
Language version of questionnaire, n (%)  
Chinese 34 (28.3) 
English 86 (71.7) 
MASCC risk index ≥ 21, n (%)  
Yes 99 (82.5) 
No 21 (17.5) 
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Outcomes, n (%)  
Favorable 78 (65.0) 
Poor 42 (35.0) 
SD = standard deviation; ECOG = Eastern Cooperative Oncology Group; 
MASCC = Multinational Association of Supportive Care in Cancer 
 
8.3.2 Derivation and evaluation of the PROMASCC model 
In Table 34, it has shown the potential predictive factor tested in the univariate 
analyses, and its association with the favorable outcome (fever resolution 
without serious complications). Among all the FACT-N domains and total 
scores, the malaise subscale score has been significantly associated with the 
favorable outcome (P = 0.024). The malaise subscale was then categorized 
based on the “minimum P-value approach” [170], and the optimal cut-off point 
was found to be 11. Subsequently, the multivariate analysis was performed by 
incorporating the categorized MASCC risk index (threshold of 21) and 
categorized malaise subscale score (threshold of 11). The coefficient estimates 
of the included covariates in the multivariate model were shown in Table 35, 
together with its corresponding OR and 95% CI. The mean, median, and range 






Table 34. Descriptive statistics and univariate analysis of FACT-N elements for favorable outcomes (n=120) 
Scale Mean 
(SD) 
Median Range Coefficient SE OR 95% CI P-value 
FACT-G  71.3 
(18.7) 
72.5 26-107 0.02 0.01 1.02 1.00-1.04 0.098 
PWB  15.4 ( .0) 16.5 0-28 0.05 0.03 1.05 0.99-1.11 0.090 
FWB  14.9 (7.3) 15.0 2-28 0.05 0.03 1.05 1.00-1.11 0.058 
SWB  22.4 (6.2) 24.5 0-28 0.02 0.03 1.02 0.96-1.08 0.515 





40.0 9-71 0.02 0.01 1.02 0.99-1.05 0.162 
Mal ise  16.  (6.7) 16.5 2-31 0.07 0.03 1.07 1.01-1.14 0.024 
Worry  8.1 (5.2) 7.0 0-20 0.03 0.04 1.03 0.96-1.11 0.412 
Flu-like 
symptoms  
7.3 (3.3) 8.0 0-12 -0.01 0.06 0.99 0.88-1.11 0.846 
FACT-N  111.6 
(27.2) 
112.6 47.7-175 0.01 0.01 1.01 1.00-1.03 0.068 
SD = Standard deviation; PWB = Physical well-being; FWB = Functional well-being; SWB = Social/family well-being; EWB 
= Emotional well-being; FACT–G = Functional Assessment of Cancer Therapy–General; FACT-N = Functional Assessment 







Table 35. Multivariate prognostic model for favorable outcome (n=120) 
Risk Factor Coefficient SE OR 95% CI P-value 
MASCC risk 
index ≥ 21 
2.32 0.58 10.13 3.24-31.74 <0.001 
Malaise 
Subscale ≥ 11 
1.49 0.51 4.42 1.64-11.92 0.003 
OR = Odds ratio; SE = Standard error; CI = Confidence interval; MASCC = 
Multinational Association of Supportive Care in Cancer 
 
In the final PROMASCC model, the weights assigned to “MASCC risk index ≥ 
21” and “Malaise Subscale ≥ 11” were two points and one point, respectively. 
The risk score defined by the PROMASCC model was the sum up of the 
individual weights, which led to a score range from 0 to 3 for the PROMASCC 
model. Table 36 revealed the performance of different thresholds in 
PROMASCC model. It was observed that a threshold of “Score = 3” was 
associated with the lowest misclassification rate (24.2%). Therefore, the 
optimal threshold for PROMASCC model was identified as three points. 
 
Table 36 also showed the comparison of the prognostic performance between 
PROMASCC model (threshold of 3) and MASCC risk index (threshold of 21) 
on identifying low-risk patients for developing serious complications. 
Compared to the MASCC risk index, the PROMASCC model has shown 
advantages on the improved specificity (PROMASCC vs. MASCC: 64.3% vs. 
38.1%) and PPV (PROMASCC vs. MASCC: 81.0% vs. 73.7%), lower 
misclassification rate (PROMASCC vs. MASCC: 24.2% vs. 25.8%), and 
increased AUC (PROMASCC vs. MASCC: 0.732 vs. 0.658), while with 
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acceptable decreases in the sensitivity (PROMASCC vs. MASCC: 82.1% vs. 






Table 36. Performance of PROMASCC model with different thresholds (n=120) 
 TPN FPN TNN FNN Se Spe PPV NPV Miscal AUC 
Score = 3 
 











Score ≥ 2* 
 





76.2% 25.8% 0.658 
Score ≥ 1 77 38 4 1 98.7% 9.5% 67.0% 80.0% 32.5% 0.541 
Score ≥ 0 
 
78 42 0 0 100% 0% 65.0% NA 35.0% 0.500 
*There is only two factors in the PROMASCC model, the “MASCC risk index  21” (given 2 points) and “Malaise 
subscale  11” (given 1 point). Either the PROMASCC score = 2 or PROMASCC score = 3, it must be fulfilled that 
“MASCC risk index  21”. In this way, using “PROMASCC score  2” in the PROMASCC model will lead to the same 
results as using “MASCC risk index  21” in the MASCC risk index; TPN = Number of true positive cases (patients 
identified as low-risk and did not develop serious complications); FPN = Number of false positive cases (patients 
identified as low-risk but developed serious complications); TNN = Number of true negative cases (patients identified as 
high-risk and developed serious complications); FNN = Number of false negative cases (patients identified as high-risk 
but did not develop serious complications); Se = Sensitivity; Spe = Specificity; PPV = Positive predictive value; NPV = 
Negative predictive value; Miscal = Misclassification rate; AUC = Area under the receiver-operating characteristic curve; 






8.3.3 Internal validation of PROMASCC model 
The internal validation of the PROMASCC model (threshold of 3) was 
examined by bootstrapping technique. The bootstrapping procedure estimates 
the optimism for the c-statistic to be 0.0005, which corresponded to an 
optimism-corrected area of 0.731 (95% CI: 0.648 to 0.814). This demonstrated 
the PROMASCC model has no significant issues with over-optimism. 
 
8.4 Discussion 
To the best of our knowledge, this is the first study that has developed and 
validated a prognostic model by incorporating a neutropenia-specific PRO 
measure with the MASCC risk index to identify low-risk patients with FN for 
developing serious complications. The results of this study have demonstrated 
the newly developed PROMASCC model has a better performance than 
MASCC risk index, with a lower misclassification rate and an increased AUC. 
Specifically, the malaise subscale score in the FACT-N has shown strong 
prognostic value for predicting serious complications. Further, the 
PROMASCC model has a higher PPV, which is imperative for a risk assessment 
tool for low-risk prediction, as false positive low-risk predictions could be 
dangerous to patient care in terms of FN management. As we have effectively 
reduced the false positive rate (patients identified as low-risk but developed 
serious complications), an improved PPV on the risk assessment model can 
provide clinicians with more confidence in promoting simpler and cost-
effective management strategies among the identified low-risk patients. 
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In this study, the additional measurement of PRO by the malaise subscale in 
FACT-N has improved the identification of low-risk patients with FN. This 
finding is consistent with several studies which reported that patient’s self-
reported health status was predictive for the disease exacerbations [169] and 
adverse events [173,174]. This implies that patients could provide accurate 
judgement on their own health status, and could show some early indicators of 
disease progression that might not be captured by the traditional clinical and 
laboratory procedures [174]. Therefore, routine incorporation of PRO measures 
should be advocated in the FN management. In addition, one previously 
published review indicated that patient-reported HRQoL could add prognostic 
value beyond the clinical information on predicting disease progression and 
survival among cancer patients [166]. In that study, a total of 39 RCTs were 
reviewed, and various domains were reported to be prognostic for survival, 
which included the function scales (physical, emotional, social), symptom 
scales (fatigue, pain, nausea and vomiting), and patient-reported global health 
status [166]. However, one recent review revealed that the actual prognostic 
HRQoL domain could vary across different disease sites [175]. For example, 
the patient-reported physical functioning could be prognostic for several cancer 
sites (e.g. colorectal, esophageal, and lung), however failed to show its 
prognostic power in other cancer sites (e.g. prostate, breast, and ovarian) [175].  
In our study, a mixed group of cancer types were included, with a majority of 
patients were with lymphoma and breast cancer, and the malaise subscale in 
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FACT-N has shown the greatest prognostic value for predicting the serious 
complications. However, its generalizability might be limited when being 
applied to a specific cancer type group. Future study should consider 
investigating the use of PRO among patients with a specific cancer type, and 
explore the most powerful prognostic domain for that cancer type.  
 
The malaise subscale of FACT-N has been identified to be useful to improve 
the performance of MASCC risk index. Cancer patients often present with 
inflammation while experiencing cancer-related fatigue, and these symptoms 
are commonly among those who are experiencing sepsis and other serious 
complications. A systematic review, which included a total of 34 studies, has 
revealed an association between cancer-related fatigue level and the 
immune/inflammatory response markers, especially among those patients with 
early stages of breast cancer [176]. For those patients with terminal incurable 
cancer, the correlation between patient’s fatigue level and the inflammatory 
parameters was also observed in a recent prospective study [177]. Specifically, 
the inflammation was found to be associated with cancer patient’s physical 
fatigue, but not with other domains, such as the mental fatigue [178]. Therefore, 
physical fatigue levels may reflect a surrogate on the onset and manifestation of 
FN, as well as patients’ risks of developing serious complications. It would be 
interesting for future studies to further explore the use of other disease-specific 
instruments that are focused on measuring patient’s fatigue level, especially the 
physical fatigue, for risk stratification of patients with FN. 
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The applications of PRO in the clinical practice have been explored in a number 
of aspects [164], which include serving as a screening tool to alert clinicians on 
the undetected problems (such as depression and functional problems), 
monitoring the treatment outcomes, and promoting patient-centered care. 
However, it was also noted that the use of PRO in the clinical practice is only 
narrowed to the discussion and detection of HRQoL issues, while its impact on 
the disease management pattern is quite limited [164], because the clinician is 
more prone to a “watching and waiting” approach rather than change the 
treatment straight away [179]. Therefore, it is necessary to identify how to 
incorporate the PRO into the decision-making process in the routine care, and 
translate the PRO measurement into the actual impact on the pattern of care in 
the clinical practice. Nevertheless, the challenge of PRO applications in clinical 
practice was found to be the heterogeneity in various type of instrument used, 
different time points selected to collect the PRO, and how the questionnaire was 
administered to the patients [164]. Future modelling effort on integrating PRO 
into the prognostic model should consider to standardizing these variations, and 
promote the clarity of the developed model for a broad application in the clinical 
practice. 
 
The main limitation of this study is its small sample size, which may lead to 
inadequate statistical power to detect other domains in FACT-N that could have 
true effects on predicting the development of serious complications [180]. In 
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addition, a small sample size may lead to a risk of over-estimating the 
magnitude of an association and produce false-positive results [180]. Although 
the internal validity of the PROMASCC model has been evaluated and is well 
established in this study, further evaluation on its external validity in some 
prospective studies with larger sample size is needed before the PROMASCC 
model can be implemented clinically. Therefore, this study should be regarded 
as a pilot, and the findings in this study are exploratory. It should also be noted 
that the patients included in this study are cancer patients with solid tumors and 
lymphomas who are less likely to manifest immunosuppression and infective 
complications than those diagnosed with hematological malignancies such as 
leukemia. Further, those patients who are too ill to respond to the questionnaire 
or admitted to ICU were also excluded from this study. This would introduce 
selection bias and affect the generalizability of this study’s findings to other 
patients with more disease burden (such as patients with leukemia or those 
admitted to ICU). However, the goal of this risk assessment tool is to identify 
patients who are at low risk for complications for simpler and cost-effective 
management strategies. Patients who are at high risk for complications 
associated with FN should receive inpatient management, and the PROMASCC 
model would not to be appropriate to use in this population. In addition, we have 
also utilized the minimum P-value approach to categorize the continuous 
variable in the PROMASCC model. Categorization of variables can promote 
the acceptance of the developed model to clinicians due to its ease of use, but 
this is at an expense of throwing away information [170]. The cut-off point (11 
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for the malaise subscale score) obtained by the minimum P-value approach is 
highly dependent on the samples and could vary greatly between samples, 
which makes its generalizability limited [170]. However, this study has 
demonstrated the potential of malaise subscale from FACT-N in predicting 
serious complications. Future studies should consider developing a scoring 
system by using the prognostic factor as continuous variable, while keeping the 
ease of use merit of the model, when a larger sample size is available.  
 
8.5 Conclusion 
In conclusion, this study has developed and validated a PROMASCC model by 
combining the malaise subscale in FACT-N along with the MASCC risk index, 
and demonstrated that additional measurement on patient’s fatigue level could 
improve the risk stratification of patients with FN. This study provides evidence 
to support the need to collect patient’s self-reported fatigue routinely, together 
with the MASCC risk index, among patients with FN for stratifying their risk 
of developing serious complications. In the PROMASCC model developed in 
this study, patients with a PROMASCC score = 3 were considered as low-risk 
















Chapter 9. Concluding remarks and recommendations 













9.1 General information 
This thesis aimed to investigate directions for optimizing FN management 
among Asian cancer patients in Singapore, with an overarching aim to reduce 
the disease burden as well as the economic burden of FN in local settings. In 
this last chapter, the specific research questions raised at the beginning of this 
thesis would first be recapped, followed by the elaborations of the major 
findings made in this thesis and the explanations on how the studies performed 
answered each specific research question. After that, the main contributions and 
limitations of the studies will be further discussed. At last, we would provide 
some recommendations on future studies for further contributions to the 
optimization of FN management in Singapore. 
 
9.2 Major findings 
In the beginning of this thesis, the following questions were raised in the 
introduction chapter (Section 1.5): 
(i) What is the most cost-effective strategy to use G-CSF as prophylaxis and 
treatment for FN?  
(ii) Is biomarker useful in guiding antibiotics usage among patients diagnosed 
with FN? 
(iii) Can we integrate the PRO into risk assessment tool and improve the 
prognostic performance on identifying patients with FN who are at low risk of 
developing serious complications?  
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The following sections would elaborate the major findings from Chapter 2 to 
Chapter 8, in which studies were conducted to address each of the three specific 
questions mentioned above. 
 
The first aim of this thesis was to identify the most cost-effective strategy to use 
G-CSF as prophylaxis and treatment for FN. In Chapter 2, by conducting a 
systematic review on the existing COI studies of FN among lymphoma patients, 
it was observed that majority (70%) of the studies employed the perspective of 
healthcare provider, and only 20% of the studies considered long-term costs of 
FN. Estimated costs for FN adjusted to 2013 US dollars ranged from US$6,396 
to US$28,506. The large variance on the cost estimates of FN was mainly due 
to different healthcare systems, and it is necessary to conduct a country-specific 
study in Singapore to have an accurate estimation on the cost of FN in local 
settings. In addition, the main component of the economic burden of FN was 
identified as the direct medical cost in the inpatient care. Therefore, focus 
should be put on estimating the direct medical cost of FN in future COI study, 
 
After getting a general insight on the past COI studies on FN, a local COI study 
of FN in Singapore was conducted and presented in Chapter 3. It was found that 
the mean total hospital cost was US$4,193 (95% CI: US$3,779-4,607) and the 
mean out-of-pocket patient payment was US$2,230 (95% CI: US$1,976-2,484), 
per FN episode in Singapore.  
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Chapter 4 employed the cost estimation on FN identified in the local COI study 
on FN (presented in Chapter 3), and performed a cost-effectiveness analysis 
from a societal perspective to compare various prophylaxis strategies. The SP 
and NP were dominated by PP, and routine PP with G-CSF is cost-effective for 
preventing FN, when compared to SP and NP. 
 
In contrast to using G-CSF as prophylaxis, Chapter 5 investigated the cost-
effectiveness of adding G-CSF to antibiotics as a treatment for established FN 
from a societal perspective. In the base-case analysis, therapeutic use of G-CSF 
is a cost-saving choice when compared to using antibiotics alone. At a WTP 
threshold of US$50,000/QALY, the strategy of antibiotics with therapeutic G-
CSF remained as the preferred choice (either dominant or cost-effective) in 
83.7% of the model iterations. This demonstrated that the additional use of G-
CSF as a therapy for FN is cost-effective and should be advocated in the routine 
care. 
 
The second aim of this thesis was to investigate the usefulness of the biomarker 
in guiding antibiotics usage among FN patients. Chapter 6 conducted a 
prospective study to evaluate the role of PCT in differentiating between 
infectious fever and NIF. Compared to a single measure of PCT within 24 hours 
of fever onset date, an additional PCT measurement 24 to 72 hours thereafter 
was demonstrated to provide diagnostic value. Two separate PCT 
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measurements can improve the accuracy on discriminating between infectious 
fever and NIF, and predict for BSI. 
 
The third aim of this thesis was to explore the integration of PRO in risk 
assessment tool for identifying patients with FN who are at low risk of 
developing serious complications. Chapter 7 performed a cross-sectional study 
to validate a neutropenia-specific HRQoL questionnaire (FACT-N) in 
Singapore. The psychometric properties and the measurement equivalence 
between the English and Chinese versions of FACT-N were established for 
most of the domain and total scores. 
 
Subsequently, Chapter 8 developed and validated a prognostic model 
(PROMASCC model) by incorporating the malaise subscale in FACT-N and 
the MASCC risk index for identifying low-risk patients with FN for developing 
serious complications. It was found that compared to the MASCC risk index, 
the PROMASCC model has shown advantages on the improved specificity and 
PPV), lower misclassification rate, and increased AUC, while with acceptable 
decreases in the sensitivity and NPV. This demonstrated that the additional 
measurement on PRO, especially on patient’s fatigue level, could improve the 
performance of risk assessment tool for prognosticating the development of FN 
associated serious complications. 
 
9.3 Main contributions 
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The studies performed in this thesis has contributed new knowledge in the 
management of FN among Asian cancer patients in Singapore in several ways. 
 
First, the cost data generated from our study has demonstrated the substantial 
cost on FN management in Singapore. The estimation on the cost of FN has also 
provided useful and valuable information for further economic evaluations on 
the management strategies of FN, which can help healthcare provider and policy 
maker make a better decision on resource allocation in FN management. 
 
Second, our studies have identified the most cost-effective strategies to use G-
CSF in the prophylaxis and treatment of FN. This can inform the clinicians on 
the most cost-effective way of using G-CSF for managing FN. In addition, since 
our studies have identified that the routine use of G-CSF is cost-effective in 
both prophylaxis and therapeutic stage of FN management, policy makers can 
consider encouraging the broaden usage of G-CSF by including this agent into 
the national formulary and provide government subsidy on it. It should be noted 
that apart from cost-effectiveness analysis, policy makers also need to consider 
other factors, such as the budget impact, when making such decisions.  
 
Third, we have demonstrated the usefulness of PCT in differentiating between 
infectious fever and NIF. This has provided evidence for the further 
development of PCT-guided algorithm for rational antibiotic usage among 
patients with FN. 
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Fourth, in our study, the disease-specific instrument for CIN, FACT-N, has been 
validated among cancer patients with CIN in Singapore. This contributed to the 
HRQoL research in Singapore by providing a validated HRQoL instrument for 
future studies to evaluate the perception of patients with CIN on their own 
health status. Furthermore, this study has provided a translated and validated 
Chinese version of FACT-N for use among Chinese-speaking population as 
well. In addition, a risk assessment tool (PROMASCC) for identifying low risk 
patients with FN was developed and validated in Singapore population. This 
can promote the simpler management strategies to be implemented among low 
risk patients manifesting FN, and reduce the disease burden as well as the 
economic burden of FN in local settings. 
 
9.4 Limitations 
The specific limitations of each study have been discussed in detail in the 
individual chapters. A brief summary are provided as follow. First, due to the 
constraint of project timeline and limited resources, the sample size in most of 
the studies is not substantially large. Therefore, we recommended that our 
findings should be considered as preliminary, and further studies with larger 
sample size were still expected. Second, our studies have limited the 
participants to persons aged 16 and above due to the considerations on the 
difficulty to obtain the informed consent and a lack of appropriate instrument 
designed for children. As such, caution should be made when generalizing our 
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findings to patients younger than 16 of age. Third, it should be noted that the 
cost data, utility data, and clinical data used in our studies were chosen based 
on the population in Singapore and might not be completely applicable to other 
countries. Different healthcare system and cultures could lead to different 
outcomes. Therefore, further validation of our findings is needed before 
researchers generalized our study results into other countries. 
 
9.5 Recommendations for future studies 
The studies in this thesis have raised several research questions that need to be 
further investigated in the future studies. 
(i) A more comprehensive cost study for the management of FN is needed 
in the future, which accounted for the indirect cost from uncompensated 
care delivered by family members and volunteers, as well as the 
productivity loss due to FN. 
(ii) It will be ideal to perform a cost-effectiveness analysis alongside RCT 
to validate the findings identified in our studies on the G-CSF usage in 
prophylaxis and treatment of FN. 
(iii) Based on the findings on the performance of PCT to differentiate 
between infectious fever and NIF, future study should consider 
developing a PCT-guided algorithm to reduce the antibiotic exposure, 
and evaluate its effectiveness and cost-effectiveness in a large RCT. 
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(iv) External validation on the PROMASCC model developed in our study 
with a larger sample size is necessary before it could be implemented in 
clinical practice for identifying low risk patients with FN. 
 
We believe that the further investigation on the research question mentioned 
above could complement the findings in this thesis, and continue to contribute 
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